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ABSTRACT
Cardiovascular diseases are the leading cause of death worldwide. Blood vessel
replacement is a common treatment for vascular diseases such as atherosclerosis,
restenosis and aneurysm, with over 300,000 bypass procedures performed each year.
However, vein grafts are limited due to their availability. Although synthetic vascular
replacements have been successful for large diameter arteries, they have shown minimal
success in arteries with diameters <6mm. This is because most synthetic materials induce
thrombus formation which, within a few months of implantation, causes failure of the
vascular graft due to occlusion. Tissue engineering is a promising approach to the
fabrication of non-thrombogenic vascular grafts, but a reliable and expandable cell source
for tissue-engineered vascular graft (TEVG) has not been established.
The work presented here is motivated by the current unavailability of an ideal
tissue engineered blood vessel replacement. Our overall goal is to create a living tissue
engineered vascular graft that is biodegradable, non-thromobogenic, presents low
antigenicity and has mechanical properties that match the native arterial tissue. For this
purpose, we have created and characterized pure elastin (EL) tubes from porcine carotid
arteries as the scaffolds. We have shown that these elastin scaffolds obtained by our
technique are pure, have increased porosity (over decellularized arteries), are highly
biocompatible and possess an architecture that is similar to the native artery which may
help integration with the host tissue.
In order to repopulate the scaffold with vascular cells to make it a living,
responsive blood vessel replacement, we developed a novel in vivo cell recruitment
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technique. The local release of growth factors through an agarose gel delivery system
within the lumen of the scaffold attracted vascular cells into the scaffold when placed in
adipose tissue in a rabbit model. To reduce thrombogenicity, heparin was immobilized
onto the EL scaffolds. A significant improvement in in vitro blood compatibility was seen
with heparin immobilization. Platelet adhesion was reduced, thrombin inactivation was
elevated, and plasma clotting time was significantly prolonged. Endothelial cells seeded
on these heparin immobilized EL scaffolds maintained a quiescent profile with high
thrombomodulin and PECAM-1 expression and low ICAM-1 expression. A majority of
the cells were even able to resist detachment on exposure to physiological levels of shear
stress.
These studies provide a new strategy to engineer a small diameter blood vessel
with excellent antithrombogenicity, tissue compatibility and mechanics to integrate with
host tissue. The true test of function though, lies in future animal vascular implant
studies.
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CHAPTER 1
INTRODUCTION

Tissue engineering of small diameter vascular grafts involves the creation of a
replacement artery that matches the characteristics of the native tissue as closely as
possible [1]. This includes the matching of mechanical properties – with collagen
providing the strength and elastin providing the compliance and recoil during pulsation,
cellular components – fibroblasts in the adventitia synthesizing collagen, vasoactive
SMCs within the medial layer, and endothelial cells providing the natural nonthrombogenic interface in addition to various signals to prevent SMC proliferation, check
inflammation and maintain hemostasis.
In order to achieve all the above properties, the main components required are –
correct scaffold material, vascular cell source, scaffold cellularization technique, and the
maintenance of cell function within the living graft.
The obvious choice of cells is autologous cells since it would eliminate the
immune response problem. The difficulty to obtain large numbers of vessel derived
autologous cells for immediate transplantation (single stage seeding) or the need to grow
them in culture (two-stage seeding) while maintaining the functional properties and
preventing contamination inhibits their use. New sources of vascular cells such as bone
marrow or adipose derived stem cells represent a more accessible and regenerative source
[2, 3].
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Scaffold material choice and engineering is a very important aspect of tissue
engineering. Manipulation of cell function can be achieved by creating a scaffold that
provides the mechanical and biochemical environment that cells are familiar with.
Synthetic grafts of Dacron and ePTFE that have been successful in large diameter arterial
replacements have not shown the same success in small diameter applications. Beside the
thrombogenic blood contacting surface of these materials and the absence of recognizable
sequences on their surfaces for cells to attach, their other drawback was also the
mismatch of mechanical properties – especially the compliance with the adjacent native
tissue which led to hyperplasia of SMCs and eventual restenosis [4].
Biodegradable synthetic polymers such as PLGA have been used to create tissue
engineered arteries such that the seeded cells secrete extracellular matrix proteins
collagen and elastin, while the synthetic scaffolds degrades, eventually leaving behind a
completely biological graft [5]. This approach however, is limited by the amount of time
in culture it takes to grow the artery and also the possibility of small amounts of synthetic
material remaining behind which may initiate a strong inflammatory reaction that could
affect the graft’s long term function.
Biological scaffold materials not only express peptide sequences that allow cells
to recognize the surface and adhere to, but can also be remodeled by the cells to help
integration with the native tissue thus providing the ideal substrate for cell attachment
and signalling. Most biological scaffolds, especially those made from reconstituted
proteins like collagen/fibrin, do not possess the perfect mechanical properties to be able
to withstand hemodynamic forces [6]. This has been attributed to the lack of orientation

2

of protein fibers which in native tissue provides structural integrity and even signaling.
The use of mechanical and biochemical cues in vitro to improve scaffold properties has
met with some success [7, 8].
Acellular tissue based scaffolds have been widely investigated as they resemble
native tissue in terms of architecture, viscoelastic properties, cell recognizable basement
and most of all the potential for cellular remodeling and integration with native tissue [9,
10]. However, recruitment of cells into an acellular tissue scaffold is quite difficult.
In order to create a tissue engineered blood vessel that meets all the above
requirements, we propose to investigate the use of modified acellular tissue based
scaffolds with increased porosity to improve cellularization, autologous cell recruitment
by a novel in vivo technique, endothelial cell seeding for nonthrombogenic blood
interface and prevention of intimal hyperplasia, and heparin immobilization as a
additional anti-thrombotic layer as well as interaction with growth factors for improved
biological response.
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CHAPTER 2
LITERATURE REVIEW

2.1 Circulatory system
The circulatory system is composed of blood vessels that regulate blood flow by
varying their resistance. The main function of arteries is to carry blood into capillaries,
which provide the maximum resistance to blood flow, thereby allowing exchange of
nutrients to and waste from all body tissues. The metabolites from tissues are carried
back to the heart through the venous system.
2.1.1 Anatomy of a normal artery
A normal artery consists of three layers - the intima (tunica interna), the media
(tunica media) and the adventitia (tunica externa). The intima is the innermost, bloodcontacting layer of arteries and is composed of endothelial cells (ECs) that rest on a
basement membrane composed of laminin, collagen, heparin sulfate proteoglycan and
fibronectin [11].
Besides providing a barrier between blood and the surrounding tissue, ECs secrete
a number of factors responsible for regulating vascular tone, SMC hyper-proliferation
and thrombosis. ECs possess both thromboresistant as well as pro-thrombotic properties.
Unactivated ECs exhibit thromboresistance in various ways – by interfering with the
coagulation cascade, inhibiting platelet adhesion/aggregation as well as activating
fibrinolytic pathways. Heparin like molecules synthesized by ECs bind thrombin and
antithrombin III causing their inactivation [12]. Thrombin also interacts with
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thrombomodulin (expressed on ECs) and gets inactivated [13]. ECs synthesize
prostacyclin (PGI2) and nitric oxide (NO) - potent inhibitors of platelet aggregation [14,
15]. NO also mediates vasodilation, limits smooth muscle cell (SMC) proliferation and
inhibits leukocyte-EC interactions. ECs also synthesize fibrinolytic enzymes such as
tissue plasminogen activator (tPA) and urokinase plasminogen activator (uPA) [16].

Figure 2.1 Structure of an artery [17]
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However, when perturbed (mechanically/chemically), ECs promote coagulation
by synthesis of pro-coagulant factors such as tissue factor (thromboplastin) [18], von
Willebrand factor (vWf) , plasminogen activator inhibitor, platelet activating factor and
extracellular matrix (ECM) components . vWf is synthesized by ECs and secreted into
the ECM where its bound by the collagens. Platelet adhesion to ECM is mediated by vWf
and gpIIb/IIIa (a receptor on the surface of platelets) [19].
The middle layer of arteries is composed of SMCs arranged circumferentially
within a matrix consisting mainly elastin and collagen secreted by them. The elastin
within the media is responsible for maintaining the structure of the artery as it undergoes
continuous pulsations brought about by the contractions of the smooth muscle. This is the
layer that imparts mechanical characteristics to the artery. The adventitia is composed of
a collagenous matrix containing fibroblasts, blood vessels (vasa vasorum) to supply
nutrients to arterial tissue, and nervous innervation. The complex ECM of an artery, with
elastin, collagen and proteoglycans, is responsible for its’ unique, viscoelastic properties.

2.2 Vascular disease and pathology
Hypertension is a major risk factor for most symptomatic vascular diseases. It
causes muscular hypertrophy as well as intimal thickening (arteriosclerosis) in both large
and small arteries. This leads to progressive hardening of the arterial wall and loss of
elasticity which can result in ballooning of the artery (aneurysm) which could lead to
rupture, disturbed blood flow patterns and hence turbulence leading to endothelial cell
damage which causes thrombus formation and eventually occlusion of the artery [20].
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Pathologies affecting small and medium sized blood vessels are the major cause of death
worldwide [21].
Aneurysms are caused due to injury to the medial layer of the artery [22].
Degradation of elastic tissue within this layer causes the localized dilatation of the artery
causing turbulence of blood flow. This increases the chances of thrombus formation
and/or rupture of the artery. Aneurysms can also be caused due to trauma, congenital
defects as well as microbial attack.
Atherosclerotic arterial disease is the most common condition leading to a
failing artery. It is a systemic disease which begins with injury to the endothelial lining
causing endothelial dysfunction which causes changes in EC properties such as
permeability, interaction with inflammatory cells, and response to various stimulatory
agents. ECs become permeable to lipoproteins which accumulate in the sub-endothelial
intima [23].

Figure 2.2 Cut section of an artery showing features of an atherosclerotic plaque [24]
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This accumulation of oxidized LDL (low density lipoproteins) damages the
arterial wall by producing oxygen radicals and causes changes in platelet adherence to
ECs and activation of ECs to secrete various chemokines that cause proliferation of
SMCs and macrophages. Accumulation of lipid-filled macrophages (known as foam
cells) in the intima, particles of lipid and calcium, and eventually the buildup of fibrous
plaque that causes narrowing of the lumen and hence disturbed blood flow, is
characteristic of the progression of atherosclerotic disease [20].
Although atherosclerotic lesions may occur in arteries of all sizes, there are a few
areas such as the abdominal aorta, iliac, carotid and coronary arteries as well as vascular
bifurcations that are more prone [25].
2.2.1 Treatments currently used
The majority of research involving treatments has focused on nipping the problem
in the bud by treating risk factors. Dietary control, changes in lifestyle (exercise) and
reducing smoking are some such examples.
Thrombotic disease can be treated with anticoagulation or fibrinolytic therapy
however, progression of disease condition warrants surgical intervention. Balloon
angioplasty is a method that involves the insertion of a balloon into the stenosed artery
using a catheter. The balloon is inflated to dilate the artery and crack the plaque thus
restoring blood flow. Sometimes a metallic stent is used to hold the artery open and
prevent re-stenosis. New drug-eluting stents to reduce thrombosis are being evaluated.
The other surgical option is bypass or replacement of the diseased artery to restore
blood flow. The preferred replacement is the patient’s own blood vessel such as the
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internal mammary artery or the saphenous vein however in many patients these vessels
are unavailable either from being diseased themselves or from previous use. Also, the
need for multiple surgery to remove these vessels and causing donor site morbidity, make
these options less desirable. All these reasons prompted the search for an artificial blood
vessel replacement.

2.3 History of vascular conduits
As early as 1906, Carrel and Gutherie demonstrated the use of homologous and
heterologous arteries and veins for human arterial replacement however lack of immune
rejection knowledge prevented the success of these transplantations [26]. These attempts
were followed by the use of inert, impervious non-biologic materials such as paraffin
lined glass and aluminum and even ivory [27] as structural replacements. In the 1940’s,
Hufnagel developed polymethylmethacrylate tubes. This was followed by polyethylene
and siliconized rubber tubes [28] where it was hoped that their smooth and impermeable
surfaces might help to minimize the formation of thrombus. In the early 1950s, Vorhees
made an observation that a piece of silk thread lying in a dog’s ventricle was covered by
a smooth endothelium-like surface. Inspired by this observation, he hypothesized that a
woven rather than a smooth material, by stimulating the formation of this smooth layer,
would provide a non-thrombogenic surface suitable for an arterial prosthesis. In a
preliminary study, a hand-woven fabric made from Vinyon N (co-polymer of vinyl
chloride and acrylonitrile) was used successfully to bridge arterial defects in dogs [29]. In
a subsequent and more complete report, Blakemore and Vorhees described the first
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clinical use of this fabric as an arterial prosthesis and showed that leakage of blood
through the graft had ceased within 1 min after the prosthesis was filled with blood at
arterial pressure [30].
Once the idea of porous woven fabrics was introduced, a variety of materials
including Nylon (polyamide), Teflon (polytetrafluoroethylene), Orlon (acrylonitrile),
Dacron (polyethylene terephthalate), and polyurethane (PU) were tested. The first
commercial fabric graft was made from braided nylon (by Dr. Edwards in 1955) and
sealed with fibrin. It was quickly realized that a porous graft was necessary to allow
neotissue ingrowth thus allowing better healing. However, incomplete healing of the
inner surface of the nylon graft led to thrombosis and also, these tubes frayed causing
graft ruptures. Elastic nylon yarn (Helanca) was used in a canine model in which all the
implants remained patent in the 12 month implant period however, there was a loss in
tensile properties of about 80% which caused concern about success in longer implant
periods [31]. In order to avoid kinking when bent, crimped nylon grafts were used.
Crimping also reduced the loss in tensile strength to about 20-30% [32].
Ivalon sponge (PVA) was considered a suitable vascular prostheses material in
the 1950s due to its similarity in mechanical properties to normal arteries. It is obtained
as a rubbery foam which on boiling in water for several minutes and then drying
completely becomes a woody block that can be cut into slices of any thickness. On
wetting, these slices regain their softness and elasticity [33]. An animal study by Harrison
[34] showed that though the grafts were easy to insert, and had very good properties
before implantation, they became brittle soon after implantation and failure was seen due
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to loss in elasticity and rupture of grafts. The small diameter grafts in the same study,
occluded due to thrombosis. Shumway et al. [35] used PVA for aortic replacement and
showed some success, however, their method of preparing the scaffold was quite
cumbersome.
In 1957 Teflon was evaluated as a vascular graft material due to its known
inertness. Teflon has proved superior to all synthetic materials used as vascular
prostheses. It elicits minimal tissue reaction, healing is rapid and it has shown no loss in
tensile properties over two years of implant. Infact, Teflon seemed to gain strength after
implanting. Due to its unwettability, up to a certain pore size, it prevents blood leakage.
However, this same property has been cited as the reason for a non-adherent neointima
formation which is susceptible to detachment. A crimped tube of knitted Teflon was used
by Edwards et al. which was easy to suture and had all the other excellent properties of
Teflon [36, 37].
Wesolowski et al. [38] made grafts of Orlon mesh and showed patency in high
flow sites in a canine model at 6 months but also saw loss of strength on implantation..
DeBakey et al., introduced the Dacron graft in 1958 [27]. Dacron has good stability and
is seen to maintain structure for over 10 years without deterioration with 5 year patency
rates of 93% for aortic replacements but only 43% for smaller diameters (such as below
knee). Also, Dacron grafts tend to lose strength though not as rapidly as nylon and are
thus thought to be suitable only for old patients whose requirement is for ~10years.
In the late 1960s, a process was developed to create microporous, non-fabric
grafts from PTFE by heating, stretching and thus expanding it (ePTFE) to improve tissue
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adhesion [39]. It is a fluorocarbon polymer, formed into sheets by a paste extrusion
process, producing a porous material that has solid nodes inter connected by fine fibrils.
The intranodal distance can be varied to change the graft porosity. These prostheses were
first used clinically in 1972 and have thence been in use for medium sized vessel
reconstruction.
Dacron and ePTFE are the most common synthetic polymers used for large
diameter vessel replacement. All synthetic polymers show thrombosis and thus occlude
small diameter (< 6mm) vessels. It has been shown that the rate of occlusion due to
thrombosis is higher in tightly woven grafts in vessels smaller than the aorta, due to low
porosity. Velour grafts are superior to knitted or woven grafts in this respect. With a
number of studies it has been shown that synthetic grafts work well as high flow, large
diameter replacements.

2.4. Small diameter arterial replacements
Blood vessels with an internal diameter less than 6mm are known as small
diameter arteries. The majority of patients requiring arterial surgery or replacement
involve these small arteries (coronary and peripheral artery disease). Damage to arteries
of the legs and hands, especially in diabetic patients, may also lead to amputation if not
replaced in time [40].
Due to the success of ePTFE and Dacron in large diameter vascular replacements,
they were the obvious first choices of materials for replacement of small diameter arteries
with synthetic prostheses however their success was not replicated when used as smaller
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arteries [41, 42]. The biggest reason for the lack of success of biomaterials in small
diameter situations is the low blood velocity allowing more interaction between blood
and the biomaterial surface. Since no ideal replacement has yet been found, ePTFE is still
the most frequently used conduit for femoropopliteal reconstruction (when autologous
saphenous veins cannot be used), because it is smooth, can be handled easily, and does
not need preclotting [42, 43].
2.4.1 Causes of small diameter graft failure
Graft related complications such as dilatation, occlusion due to thrombosis,
intimal hyperplasia, pseudo-aneurysm formation at the suture line, and graft deterioration
are experienced clinically. Injury induced responses are exacerbated by vascular graft
materials because the contacting tissues are reacting to surgical injury as well as the
implanted foreign body (synthetic material).
Three distinct modes of failure (according to the times after implantation they
occur) have been identified. Within 30 days of surgery, failure mainly results from
technical or judgmental errors. The development of stenosis within the graft is the most
common cause of failure during the first year whereas after a year or more, the
progression of atherosclerosis is the most prominent failure method [44].
2.4.1.1. Short term modes of failure
Mechanisms causing failure of vascular prostheses within the first few days postoperatively are termed as short term modes. Surgical errors introduced during clamping
can cause graft failure within 1 month in as many as 20% cases [45]. Infection of grafts
is one of the most catastrophic forms of failure. Implantation site and graft material are
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the two major determinants of infection. Rigorous aseptic techniques need to be
maintained to prevent any infections.
Hematoma can result from leakage through the graft ends if suturing has been
incorrectly performed. It can also occur due to a puncture in the graft causing blood to
spread between the tissue and the graft wall, resulting in swelling and discoloration.
False aneurysms can result from the repeated puncture of the graft at a single site. This
results in a large hole in the wall of the graft and leads to loss of an area for puncture and
perhaps a hematoma. The chance of infection and clotting of the graft is also greater.
From the time of implantation, the graft is subjected to continuous pulsatile flow that
creates tension in the wall as well as exerts shear stress on it. The graft also faces strong
biochemical agents that lead to graft degradation. Dilatation can occur almost
immediately after surgery and continue to increase with time.
2.4.1.2 Occlusive (long term) failure
The two most common causes of occlusive failure of grafts are thrombosis and
intimal hyperplasia.
2.4.1.2.1 Thrombosis
Thrombosis involves the activation of three interconnected regulatory systems,
the coagulation cascade, the complement cascade and the cellular components of the
blood such as leukocytes and platelets which when activated, lead to the formation of a
clot within the blood vessel thereby obstructing blood flow. On normal, un-activated,
confluent endothelium, tissue factor (TF) expression is low or absent, and
thrombomodulin (TM) expression is high, prostacyclin (PGI2) secretion is low or absent,
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nitric oxide (NO) secretion is present but low, von Willebrand factor (vWF) is present
within the EC but not secreted, and the number of cell adhesion molecules expressed on
the EC surface is also low. Activation of ECs causes a reversal of this profile i.e.
increased secretion of NO, PGI2, vWF and increased expression of cell surface adhesion
molecules [46].
All materials that are clinically used today as vascular replacements are inherently
thrombogenic. When artificial biomaterials come into contact with blood, a number of
thrombotic and inflammatory reactions occur - similar to what occurs when blood is
exposed to the ECM of a disrupted vessel. On exposure to blood, adsorption of plasma
proteins occurs. The type and amount of protein adsorbed depends on the characteristics
of the biomaterial surface. Albumin adsorption is usually considered beneficial because it
induces an inhibition of the activation of the complement system and reduces platelet
aggregation [47] whereas adsorption of fibrinogen is detrimental [48] because platelet
membrane receptors recognize RGD sequences in fibrinogen [49]. Alpha granules on
platelets contain glycoproteins that cause increased platelet deposition on the surface. The
conformational change that occurs after platelet adhesion can cause the exposure of a
larger number of receptors to various aggregation factors thus increasing thrombosis [50].
It has been suggested that a minimum flow velocity of 6-8 ml/sec/cm2 (known as
the thrombotic threshold velocity - TTV) is required to maintain a thin, stable, fibrin layer
on the graft surface [48]. Since the blood velocity in small vessels is less than the TTV,
the effects of thrombosis are more pronounced.
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2.4.1.2.2 Intimal hyperplasia
Neointimal hyperplasia is a response to injury in vascular tissues which promotes
abnormal thickening of vascular walls with luminal narrowing. It involves the
proliferation and migration of vascular smooth muscle cells from the media to the intima,
with subsequent synthesis of matrix proteins and other extracellular material causing the
narrowing of the lumen. Cell proliferation in the media begins immediately after injury
and peaks at 2 days, then declines by 7 days. The intimal cells continue to divide and
intimal proliferation peaks at 1 week, then declines by 2 weeks [51]. The number of
SMCs in the intima remains fairly constant after 2 weeks, but intimal size continues to
increase up to 8 weeks presumably due to the accumulation of extracellular matrix.
Studies have shown a progressive increase in intimal thickening from 2 to 8 weeks after
balloon injury, without an increase in SMC number but with matrix accumulation [52].
In normal arteries it has been shown that a reduction in shear stress is associated
with intimal hyperplasia [53]. If the shear stress departs from the optimum value, a
complex series of events occur which include the release of vasoactive substances such as
nitric oxide (NO) and prostacyclin (PGI2), mitogens such as platelet derived growth
factor (PDGF) and basic fibroblast growth factor (bFGF), activation of vascular cell
transcription factors, protein synthesis and re-arrangement of the cytoskeleton, causing
changes in vessel stiffness. When the shear stress falls below the optimum value intimal
hyperplasia occurs, leading to a reduction in the diameter of the vessel lumen, causing the
mean flow velocity and consequently the shear stress to increase [53]. It is generally
accepted that mechanical factors are important in its genesis. These include disturbed
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flow at the anastomosis leading to fluctuations in shear stress at the endothelium, injury
due to suturing and stress concentration at the anastomosis. Intimal hyperplasia
commonly causes graft failure in the first 2 years after surgery.
Among the various factors influencing graft failure, compliance and size
mismatch between graft and native vessel are believed to be the most important physical
factors whereas wall shear stress is thought to be the most important hemodynamic
factor. Wall shear stress affects platelet aggregation [54]. Low shear rates promote
platelet aggregation. High shear rates do not prevent platelet adhesion to the wall but do
decrease the size of aggregates however, shear stress greater than 70 dynes/cm2 causes an
exponential increase in platelet activation [55, 56]. Studies have shown that shear stress is
the parameter determining arterial diameter. It has been shown that arterial diameter
increases or decreases in response to changes in blood flow in a manner that maintains a
constant shear force [57].
The effect of thrombosis contributes more to the failure in the short term as
compared to compliance mismatch induced hyperplasia which becomes pre-dominant
once a fairly thromboresistant flow surface has been established.
2.4.2 Characteristics of ideal small diameter replacements
After tremendous experience by a number of researchers, certain characteristics
have been deemed necessary for the success of a small diameter arterial replacement. The
properties essential for simple insertion and long-term success of a graft are given in
Table 2.1.
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flexibility and ease of suturing
ability to be stretched, and provide circumferential strength to sustain pulsatile flow,
while allowing nutrient transport
biocompatibility
mechanical properties that match those of the native vessel
lack of chemical reactivity
very low thrombogenicity
porosity that should allow the leakage of a small amount of blood to allow the creation
of a tightly adherent thrombus, and the ingrowth of fibrous tissue
resistance to infection
ability to be sterilized and stored for long periods before use
availability in a wide range of sizes
Table 2.1 Requirements for a sucessful small diameter vascular graft

2.5 Tissue engineering of small diameter grafts - from bioinert to biointeractive
vascular prostheses
Vascular replacements are no longer passive conduits that provide structural
replacement but are looked at as functional devices. Initially materials that did not react
at all with the body were selected (bio-inert), followed by materials that allowed
preferential reaction such as albumin adsorption instead of fibrinogen adsorption
(bioactive) and now materials that react with a specific mechanism to allow healing (biointeractive) eg. heparin binding to reduce thrombogenicity are being investigated.
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Tissue engineering approaches which involve the colonization of a biomaterial
with the required cell types to achieve a living prostheses as a functional replacement
[58] have shown potential to create biocompatible, strong and compliant grafts that have
the capability of remaining patent.
2.5.1 Modification of traditional materials
Since the required mechanical properties such as suture strength, ease of suture,
vessel wall thickness, were available in existing commercial materials, the first attempts
to manipulate body responses were aimed at surface modification of these materials with
the aim of achieving the ideal healing response.
2.5.1.1. Anti-thrombogenic coatings
Thrombosis prevention has been attempted by creating surfaces that prevent
protein adsorption (non-fouling surfaces), those that inhibit the activity of thrombin and
those that prevent platelet adhesion and aggregation. Various synthetic and natural
materials have been investigated.
Early studies of the electrochemistry occurring at the blood-graft interface and in
normal blood vessels established that the inner surface of blood vessels are
electronegative when compared with their outer surfaces [59]. Also, it is known that
platelets are negatively charged. These results prompted the theory that a negative surface
charge prevents thrombosis by causing electrostatic repulsion of the negatively charged
cells involved in thrombosis while a positive surface charge promotes it.
Carbon is one such electronegative material that was used to coat the surfaces of
grafts to act as a thrombosis deterrent. Early animal studies of carbon-coated vascular
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prostheses demonstrated improved patency rates compared with uncoated controls. Arabi
et al. [60] showed that a homogeneous and stable coating of graphite on polyester
vascular grafts (GPVG) reduced the number of adherent platelets and prevented platelet
activation and spreading on the surface in comparison with non-coated and control
(collagen sealed polyester) grafts however suturing of GPVG was more difficult in
comparison with the other types. Aebischer et al. [61] also showed lesser thrombosis and
thinner fibrin capsule on turbostratic, high-density carbon coated Dacron grafts compared
to control non-coated grafts. However, surface irregularities on carbon-lined ePTFE
grafts have contributed to poor performance in other investigations [62].
Salicylic acid and its derivatives have been used as pharmaceutical agents for a
very long time. Aspirin was developed years later as a more palatable form of salicylate.
It is now known that the mechanism of action of aspirin is through the inhibition of
prostaglandin biosynthesis which further blocks thromboxane formation in blood
platelets [63]. This anti-aggregatory property of salicylic acid derived drugs has been
used by a number of researchers to create non-thrombogenic luminal surfaces of vascular
grafts.
San Roman et al. [64], created hydrophilic acrylic polymer coatings bearing
salicylic

acid

residues

for

Dacron

vascular

grafts

and

showed

improved

antithrombogenicity with respect to the uncoated prosthesis. Rodriguez et al. [65], created
resorbable

coatings

of

a

polyacrylic

derivative

of

Triflusal

(2-acetyloxy-4-

trifluoromethyl)benzoic acid (a derivative of salicylic acid with a well-established platelet
aggregation inhibitory profile [66]) on vascular grafts. The system allowed the slow
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release of Triflusan improving anti-aggregating properties without the use of any other
anti-thrombogenic drugs. A biodegradable coating of polylactic acid (PLA) containing a
microparticulate suspension of aspirin was applied to the luminal surface of small
diameter vascular prostheses to reduce platelet deposition on canine implanted arterial
grafts. Less platelet deposition was observed on the coated grafts when compared to
controls 2 and 24 hr post implant however there was no significant difference in platelet
deposition on coated and control grafts at 2 weeks or 1 month post implant [67].
Tissue factor (TF), a protein present in platelets and leukocytes, is involved in
coagulation by converting prothrombin to thrombin. St Pierre et al. [68] showed that the
intravenous administration of recombinant tissue factor pathway inhibitor (rTFPI) for
24 hours showed reduced platelet accumulation, fibrin deposition, and factor Xa activity
in an arterial injury animal model. The same group also showed that pre-clotted Dacron
grafts incubated in rTFPI and implanted in pig femoral arteries showed reduced
thrombogenicity (although the results were not statistically significant) [69].
Hirudin is another substance that is used for its anti-thrombotic properties. It is
secreted by the buccal glands of leeches and is capable of preventing coagulation by
inactivating thrombin. It has been used in medicine as an anticoagulant coating. Dacron
surfaces with covalently bound indium-labeled recombinant hirudin (25I-rHir) had no
gross thrombus and a thin pseudointima of platelets and plasma proteins whereas the
control patches had a thick pseudointima composed of fibrin-rich thrombus. rHir,
covalently bound to Dacron patches, maintained its biologic activity as well as prevented
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thrombus formation on the graft surface [70]. Although these results are encouraging, this
study was performed ex vivo for only 2hr thus limiting the results to short-term success.
Heparin is a sulfate-containing polysaccharide most commonly used as an anticoagulant. It has the highest negative charge of all known biologic molecules. This
negative charge is thought to be the first reason for reduced platelet interaction due to
electrostatic repulsion. Also, the action of antithrombin (AT) inhibiting thrombin through
the formation of a covalent complex is catalyzed by heparin or heparin analogs present in
the endothelial tissue [47]. The first attempt to immobilize heparin onto biomaterials was
carried out in 1963 [71]. These researchers used electrostatic binding of heparin to the
biomaterial through its anionic groups. Due to the weak binding, the heparin was lost
very quickly on establishment of flow. This initiated covalent binding of heparin to
biomaterials. Although covalent binding improved short term thrombogenicity, loss of
bound heparin over time still occurred.
One innovative idea explored the coupling of heparin to prostaglandins coated on
polymers. These heparin-prostaglandin materials exhibited low fibrin formation and
platelet aggregation, both in vitro and in vivo [47]. Heparin analogs were also
synthesized, since the AT-binding sequence was identified as a pentasaccharide segment,
to mimic the natural catalytic sites known to confer anticoagulant and antithrombotic
properties to heparin [72, 73]. These synthetic heparin-like polymers were shown to
exhibit anticoagulant properties similar to heparin. The in vivo antithrombotic activity is
more complex than that explained above, as not only activation of AT is important but
also other mechanisms, such as release of Tissue Factor Pathway Inhibitor (TFPI)
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contribute to the antithrombotic effect. Long-term clinical studies with heparinized grafts
need to be performed before this methods’ efficacy is known.
As part of the vascular wall, elastin is thought to have minimal platelet adhesion
and aggregation however due to difficulty in isolating elastin due to its insolubility, the
focus has been on creating elastin-mimetic materials. The repeating peptide sequence
VPGVG in elastin is the primary feature of most animal elastins (including humans) and
exhibits a unique property known as coacervation. Poly(VPGVG) have been shown to be
easy to produce and unreactive to macrophages and other cell types making them less
thrombogenic [74].
2.5.1.2 Endothelialization
Early failure due to thrombosis is greater in prosthetic grafts than in vein grafts.
This has been attributed to the lining of endothelial cells in vein grafts which is absent in
artificial materials. In contrast to animals, the flow surface of synthetic vascular grafts in
humans remains unhealed. Growth of endothelium from the adjacent vessel is limited to 1
cm from the anastomosis [75] whereas in young pigs complete endothelialization occurs
in 1 month and in dogs in 4 months. Also, the graft surface is covered with compact,
crosslinked fibrin matrix which is though to be the reason for reduced cellular ingrowth
[76]. Canine models have been identified as the closest to humans in terms of their
healing pattern [47].
Malcolm Herring, in 1978 introduced the concept of autogenous endothelial cell
transplantation to improve patency of small diameter vascular grafts [77]. His hypothesis
was that providing the natural, biological lining of blood vessels would provide
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antithrombotic properties and have an antiproliferative effect on SMCs hence preventing
failure of small diameter vascular grafts by both thrombosis as well as hyperplasia. A
monolayer of ECs line the vasculature and through the expression and secretion of a
spectrum of molecules regulate vascular tone and permeability, inflammation,
thrombosis, and fibrinolysis. When artificial biomaterials come into contact with blood, a
number of thrombotic and inflammatory reactions occur similar to what occurs when
blood is exposed to the ECM of a disrupted vessel. To prevent these reactions, EC are
being combined with biomaterials as a strategy to create an interface that covers the
underlying biomaterial, enabling blood contact without significant inflammation and
thrombosis, and maintenance of graft patency [46]. A number of investigators have
attempted to coat the entire surface of their biomaterials with ECs. However, to date, this
technique has not proven clinically successful due to a number of reasons – technical
complications that need to be overcome in order to isolate (in large enough numbers) and
seed (such that they do not detach) in a short time frame (less than 2 hrs is acceptable) all
under sterile conditions. Also, the success of this method seen in animal models has not
been translated in humans because the endothelium in humans does not regenerate as it
does in animals. The source of the neo-endothelium is not clear, however, studies indicate
proliferation from adjacent arteries (pannus ingrowth), through vascular ingrowth in
prostheses pores, and even circulating progenitor cells. Also, molecular studies suggest
that confluent ECs display a non-thrombogenic profile of molecules on the majority of
biomaterials tested however at sub-confluent densities, EC appeared to be more
thrombogenic [46].
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2.5.1.2.1 EC sources and harvesting
Jaffe et al., in 1973 [78], were the first to describe the isolation and culture of ECs
from human umbilical veins. The two primary sources of ECs are (i) non-essential
vessels and (ii) adipose tissue (omental or subcutaneous fat). Mechanical scraping [79]
and enzymatic digestion [80] are the two methods used to isolate ECs from blood vessels.
Mechanical scraping tends to damage the cells. Also, the maximum efficiency obtained
with this method has been 75%. Enzymatic digestion of basal lamina proteins also causes
some damage to ECs. The main disadvantage of isolating ECs from blood vessels is the
limited quantity obtained. In in vitro cell culture techniques have been used to overcome
this, however that prevents the use of these cells in emergency cases. Also, the possibility
of morphological and genotypic changes occurring in culture and the possibility of
contamination still remain.
Jarrell et al. [81], in 1986, isolated microvascular endothelial cells (MVECs) from
adipose tissue capillaries. This alternative source was pursued due to the large number of
cells obtained. Large enough numbers of pure MVECs are obtained by this procedure
within 2hrs with a maximum efficiency of 84%. There has been debate about whether
these MVECs are actually ECs or mesothelial cells and whether they will function as ECs
[82] however, several studies have shown that these cells express characteristic
ECmarkers such as vWF, CD31, CD34 [83, 84] and remain adherent on biomaterial
surfaces in spite of their rounded morphology.
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2.5.1.2.2 EC seeding techniques
Three methods have commonly been used for the seeding of ECs on the luminal
surface of grafts. The gravitational technique [85, 86] involves filling the graft lumen
with the cell suspension and rotating the graft periodically to allow attachment of cells to
the entire surface. It has been shown that the majority of cells transplanted by this method
are lost on exposure to flow [87]. In the hydrostatic technique, a pressure difference is
used to force the EC suspension through the interstices of the prostheses. Just as in the
gravitational method, a minimum of 2 hr culture time is required to prevent cell loss on
exposure to flow. The third technique, electrostatic seeding, utilizes the knowledge that
ECs are negatively charged [88-90]. A temporary positive charge is induced on the
material surface thus attracting ECs to it. In vitro evaluations of this method have shown
complete coverage of ePTFE grafts in 16 minutes indicating that this method is superior
to the other methods employed earlier.
2.5.1.2.3 Improving cell adherence to surface/ Surface modification for EC attachment
EC adherence to untreated traditional graft materials (ePTFE, Dacron) is very
poor [91] and even if they attach during culture, are usually lost on exposure to flow. This
has prompted the search for an appropriate coating that will increase the number of ECs
attached as well as improve their morphology (flattened). Various basement membrane
proteins such as fibronectin [92], arginine-glycine-aspartate (RGD)–containing peptide
(the active component of fibronectin) [93], gelatin [94, 95], collagen [96], or laminin [95,
97] when coated on traditional graft materials have shown to improved EC adhesion over
untreated graft materials. The disadvantage of coating basement membrane proteins is
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that exposure of any of these biocomponents to blood either due to inadequate
endothelialization or the loss of ECs due to shear, initiates a thrombotic reaction [87].
Krijgsman et al. [98], showed that bonding of RGD, heparin, and both RGD and heparin
accelerates and enhanced EC retention onto PU grafts whereas simple coating of
basement membrane proteins conferred no advantage over native PU grafts. Sipehia et al.
[99], applied ammonia plasma treatment to traditional materials and showed increased
EC densities on treated surfaces.
2.5.2 Scaffold engineering
The most important aspect of tissue engineering is the construction of a scaffold
that takes into consideration all the lessons learnt from failures with traditional materials.
The scaffold needs to match the natural tissue in structure as well as function while being
easy to manufacture on a large scale, sterilize and store for extended periods of time.
Three main aspects of tissue engineering that have been investigated most
extensively are the creation of porous scaffolds, scaffolds to match artery mechanics
(compliant materials) and design of biodegradable materials (to stimulate native tissue
regeneration).
2.5.2.1 Porous scaffolds
On contact with blood, all arterial prostheses develop a luminal coating of fibrin.
In non-porous grafts, this layer remains disorganized and prevents adherent endothelial
growth whereas in porous grafts, (in certain animal models), the thin fibrin layer is
replaced by endothelial cells spreading from the anastomotic region. However, this type
of healing is not seen in humans. The pattern of healing in dogs is seen to best mimic that
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of humans. Inspite of these differences in animal models, it has been seen that porosity
increases the patency rates of grafts across all species. Unfortunately, there is a maximum
porosity level beyond which the graft fails due to excessive hemorrhage.
2.5.2.1.1 Leak-proofing porous prostheses
Porosity is an important aspect of vascular prostheses healing and long term
patency. Porosity is required for the transfer of nutrients and for the ingrowth of tissue to
allow better integration. The major disadvantage of porous grafts, however, is their
permeability to blood during implantation. This contradictory need indicates that the graft
needs to have low initial, implantation porosity but high healing porosity to allow
fibroblastic growth. Pre-clotting the graft with the patient’s blood prior to implantation
was used as a means to make it leak-proof however a number of difficulties arose with
this technique. Studies have thus focused on producing a coating such as a biodegradable
component that will provide the initial seal but will degrade over time to produce a
porous graft.
A few research groups reported the complete sealing of grafts using fibrin glue.
However, surface thrombogenicity and calcification (on subdermal implantation) was
higher than non-treated grafts [100, 101].
The deposition of albumin on implant surfaces has been known to be
advantageous. It is shown to passivate the surface thus preventing thrombosis. Numerous
in vitro and animal studies proved this by providing leak-proof grafts that healed better.
The albumin coated prostheses is now commercially available in Canada and Europe and
are undergoing clinical trials in U.S. [47].
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Gelatin exhibits very poor antigenicity in humans and was thus used for graft
impregnation under the trade name Gelseal Triaxial graft. It promoted healing and
cellular growth and tissue integration without increase in thrombogenicity or patency
[102, 103].
Collagen was used to coat as well as impregnate porous grafts. Various studies
showed faster healing as well as endothelial layer formation in collagen treated grafts.
The three major grafts to have undergone animal and clinical studies are Dacron-collagen
coated – Hemashield in which the collagen (bovine type I) is impregnated and lightly
crosslinked with formaldehyde, and Hemaguard and Tascon grafts in which the sealant is
more heavily crosslinked with glutaraldehyde. Questions about the immunogenicity of
the collagen as well as thrombogenicity have been raised but a number of studies have
shown that crosslinking reduced thrombosis [104]. The collagen impregnated grafts are
the most widely used impervious grafts to date.
Other biodegradable materials such as alginate, chitosan, agar, PGA, PLA and
their co-polymers are also being studied.
2.5.2.2 Compliance matching
The most commonly used graft materials (Dacron and ePTFE) are rigid at the
time of implantation and this difference in compliance increases over time due to the
formation of a neointima which in porous grafts is further alleviated by the infiltration of
fibrous tissue within the interstices. This plays a very important role in graft
complications – especially at the anastomosis [76, 105].
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Compliance is defined as the ability of a vessel to dilate under pressure and is
defined by the mathematical formula
C=

∆R
×100
(R × ∆P )

Compliance mismatch between the host artery and the prostheses has been cited
as a reason for intimal hyperplasia. The abrupt changes in elasticity at the anastomosis
puts a stress on the natural vessel, which causes hyperplasia of smooth muscle [48].
Tissue hyperplasia is thought to be a means of compensating for lack of tissue
compliance and contractility [106]. Also, in rigid grafts, the flow velocity profile is
different from a compliant tube [107]. Since rigid synthetic grafts cannot adapt their
diameter to maintain constant wall shear stress (WSS), optimal WSS levels will not be
maintained. Increased shear stress damages endothelial cells and reduced shear stress
creates areas of relative stasis which are prone to platelet activation and deposition as
well as turbulent flow profiles. The aim of matching compliance is to minimise these
disruptive flow characteristics [108]. To reduce ill effects of compliance mismatch,
investigators have shown that stresses can be minimized when the ratio of diameter of
rigid graft to compliant artery is about 1.4 [109, 110].
Patency results of the human femoral artery were compared with grafts currently
in use [105] - human saphenous vein (HSV), knitted Dacron (DAC), glutaraldehydetreated umbilical cord vein (DBM), bovine heterograft, and ePTFE and correlated to the
compliance. After two years, patency rates of the more compliant materials (HSV, DBM)
exceeded 80%, while less than 45% of the incompliant grafts (DAC, PTFE) remained
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patent. These studies show that the clinical performance of synthetic grafts might be
improved by use of prostheses in which the viscoelastic characteristics match those of
arteries more closely. The mechanical properties of grafts need to match the
physiological characteristics, replicating elasticity, to withstand continuous pulsation, and
have high tensile strength for large pressures.
Van der lei et al. [111] demonstrated the necessity of both compliance and
biodegradability in regenerating a neo-artery that microscopically and functionally
matches the native tissue. In an elegant study evaluating three groups: I) compliant,
biodegradable, II) complant, biostable and III) non-compliant, biodegradable grafts
implanted in rat abdominal aortas for 6 weeks, they observed pulsations only in group I.
Histologically, SMCs were present in all samples however, elastic laminae were present
almost throughout the neomedia only in group I, restricted to the luminal layers of the
neomedia in group II, and totally absent in the neomedia of group III. They concluded
that the compliance of the grafts allowed smooth muscle cells to be mechanically
stimulated by the arterial pulsations to produce elastin and due to the biodegradation of
these grafts, compliance was maintained (which in other porous stable materials is lost
due to fibrous ingrowth).
2.5.2.3 Biodegradable scaffolds
Biodegradable materials can provide a temporary scaffold on whose support a
completely biological vessel can develop. These materials allow the gradual shift of
mechanical properties from the biomaterial to the healing tissue. This temporal response
can be modulated either by varying the crosslinking density or making co-polymers to
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achieve ideal mechanical properties over time. A successful result with biodegradable
materials requires guided tissue regeneration which can withstand arterial pressures. This
would depend upon the mechanical properties, degradation characteristics of the scaffold.
The concept of biodegradable prostheses started with Vorhees et al., when they
implanted porous Vinyon-N fabric tubes that allowed tissue ingrowth. Although these
materials leaked, the concept of biodegradable materials emerged – so that the graft
would have low porosity at implantation and then become more porous due to component
degradation. Biodegradable materials have been used in a variety of ways – as standalone
materials, in combination with non degradable materials, or as a coating.
2.5.2.3.1 Synthetic biodegradable materials
Polylactic, polyglycolic acid and co-polymers
The most widely investigated bioresorbable polymers are polylactic acid (PLA)
and polyglycolic acid (PGA). PGA is a highly crystalline, hydrophilic polymer which
undergoes rapid hydrolysis. L-PLA is semi-crystalline, less hydrophilic (hence degrades
slower) than PGA, and produces a physiologic degradation product (L-lactic acid). These
reasons make it a more common biomaterial than PGA. Also, co-polymers of glycolic
and lactic acid are commonly used.
The concept of a resorbable vascular graft was introduced in the 1960s, and the
first fully-resorbable graft was reported in 1979 [112]. These grafts ruptured and dilated.
In 1982, Greisler et al. implanted 3.5mm woven PGA grafts in rabbit abdominal aortas
[113]. The grafts were resorbed and replaced by tissue that resembled native aorta
histologically with a luminal coating of factor VIII positive cells, sub-endothelial region
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of smooth muscle-like myofibroblasts and an outer layer of vascularized connective
tissue. These replacements also remained patent at 7.5 months. The success of this study
raised a number of questions - Was this response due to porosity of the material? Was it
due to the material degradation or the interaction of the material with inflammatory cells
such that the release of growth factors by macrophages caused EC and myofibroblast
recruitment?
Comparison of this PGA graft with a Dacron graft with similar porosity (but non
degradable) concluded that porosity alone was not responsible for improved healing.
Several studies that followed strengthened the belief that factors related to macrophage
mediated degradation of the material enhanced arterial regeneration. The main factor,
released by macrophages, responsible for the mitosis of SMCs, was identified to be
bFGF.
Aneurysmal dilatation has been the biggest obstacle with resorbable grafts. In
order to prevent dilatation, the important aspect in resorbable grafts is that they must
encourage regeneration of tissue of sufficient strength before the loss of prosthetic
material strength occurs. Attempts to reduce dilatation have been made by slower
degradation rate compositions eg. copolymers of pg910 Vicryl-polydioxanone (PDS)
[114], Vicryl-polypropylene [115], enhancing tissue regeneration with growth factors
such as the heparin- FGF complex, and polymer blends of stable and degradables such as
Dacron-Vicryl grafts.
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Polyurethane and co-polymers
Polyurethanes (PUs) are composed of a soft segment that provides flexibility and
a hard segment that provides strength. PUs with a variety of mechanical properties can be
made by using different monomers for these segments [39]. PUs have been tested as
arterial substitutes since the 60s due to their superior elastic and compliant mechanical
properties and their acceptable biocompatibility [116]. Polyester PUs were the first ones
used for vascular applications; however, they underwent deterioration since they are
susceptible to hydrolysis, and majority occluded in the first year of grafting [117].
Polyether based PUs were then created which underwent drastic biodegradation and were
thus abandoned [118]. The Vectra graft (polyetherurethaneurea vascular access graft)
received FDA approval in 2000 [39].A small diameter coronary bypass graft made of the
same material is undergoing clinical trials. A variety of reinforcements (internal as well
as external) have been researched to improve the mechanical properties of PU grafts
however, due to differences in the mechanical properties(such as extensibility) of these
materials, there is fear of delamination. Combining PU with PLLA improved suturability
and allowed complete coverage with endothelial cells [119]. Animal trials with PUs have
been very successful [120] though clinical trials showed disappointing results [121] since
PUs are quite unstable in vivo. Also, there is concern over their degradation products
being carcinogenic [19].
Polycarbonate based PUs resistant to hydrolytic as well as oxidative degradation
have been synthesized [122, 123]. This graft is also undergoing clinical trials.
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2.5.2.3.2 Biological scaffolds
After years of studying synthetic polymers, it was thought that the body’s
response to natural/physiological materials might be better since they can be remodeled
by cells and thus research on natural materials as vascular substitutes began. Natural
materials have receptors for cell attachment and proliferation [124]. The first attempt to
create entirely biologic vascular structures in vitro, using collagen and cultured vascular
cells, was reported in 1982 [125].
Acellular ECM tubes
Allograft rejection is a well known phenomenon. Studies conducted in 1970s
showed that the main components causing an immune reaction in allografts were cells,
and to some extent proteoglycans. Removal of these components proved the success of
acellular dermal substitutes and inspired the use of this technique to prepare arterial
substitutes. Small diameter arteries (porcine, canine, ovine) have been treated with a
variety of chemicals to remove the cells and crosslinked by aldehydes, thereby reducing
its antigenecity, while conserving all the material properties of the original tissue.
Detergents such as sodium dodecyl sulfate (SDS), Triton X-100, enzymes such as trypsin
and a combination of hyper and hypotonic buffers are the common methods of
decellularization. Advantages of using decellularized arteries as vascular grafts are, ready
availability, ease of procurement from donors (mostly xenogeneic), the avoidance of
significant immunogenic issues usually associated with xenograft tissues and
preservation of extracellular matrix important for strength and cell attachment [126].
Glutaraldehyde (which is the most common tissue fixative) however, is shown to be
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cytotoxic and increases the material’s susceptibility to calcification [127]. Also,
repopulation by host cells is seen to be incomplete.
Modified human umbilical vein graft
The unmodified human umbilical vein (HUV allograft) proved unsuccessful as an
arterial replacement and hence was modified by glutaraldehyde treatment. Although early
reports were positive, long term results indicated a high incidence of aneurysms (upto
57% after 2yrs) [128].
Bovine carotid artery graft (xenograft)
Studies involving heterologous tissue began as early as 1954 with the idea that the
enzymatic removal of antigenic material such as cells could provide a xenogeneic (easy
to obtain) non-immunogenic tissue substitute. However, clinical experience with these
grafts was similar to HUV grafts in that short term results were promising but incidence
of aneurysms were very high within 4 yrs [129]. Also, some studies found that these
grafts got stiffer after a few years and also had high late occlusion rates [130, 131].
Bovine ureter
A product based on bovine ureter (FloNova) consisting of the ureters covered in
polyester mesh are being marketed. Though they have not been tested in humans, animal
studies have shown good patency and resistance to dilatation after 17 months of
implantation [132].
Small intestinal submucosa (SIS)
Various forms of intestinal tubes were employed as vascular substitutes but they
were subject to thrombosis and aneurysms. The most investigated form was the small
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intestinal submucosa (SIS). Although they exhibited good patency, aneurysms were still
noted and in small diameter replacements, thrombosis was also observed.
The failure of non-vascular tubes is attributed to the intrinsic difference in
structure of arteries and these tubes. The intestinal collagen layer (ICL) derived from the
submucosa of the small intestine which is primarily composed of type I collagen, was
proposed as a vascular substitute over 30 years ago. It showed good patency as a largediameter (10 mm) graft [133]. As a small-diameter (4–5 mm) graft, the construct
maintained sufficient mechanical strength, a non-thrombogenic surface, and long-term
resistance to hyperplasia and aneurysm formation while acting as a scaffold for
infiltration by host cells [134].
2.5.3 Creation of living grafts
After the initial attempts to implant scaffolds and allow tissue ingrowth to occur,
cell seeding in vitro was investigated to initiate functional tissue regeneration. For the
complete functionality of a tissue engineered small diameter blood vessel to be realized,
it was seen that cells would play an important role.
2.5.3.1 In vitro cell seeding on scaffolds
2.5.3.1.1 Synthetic materials
PGA/PLA and co-polymers
Niklason et al. [5] cultured bovine aortic SMCs onto tubular biodegradable
polyglycolic acid (PGA) scaffolds and placed them in pulsatile flow bioreactors. The
surface of the PGA scaffolds was chemically modified with sodium hydroxide, which
caused ester hydrolysis on the surface of the fibers, leading to increased hydrophilicity,

37

increased adsorption of serum proteins, and hence improved SMC attachment. After 8
weeks of pulsatile stretch in the bioreactor, ECs were seeded in the luminal surface of the
grafts. These grafts were implanted in cows and remained patent in vivo up to 1 month.
However, attempts to translate this approach to adult human cells initially failed.
Hoerstrup et al. prepared tissue engineered grafts from nonwoven polyglycolicacid (PGA) mesh coated with a thin layer of poly-4-hydroxybutyrate (P4HB) that were
seeded with vascular cells. The seeded constructs were grown in vitro for 21days using
biomimetic conditions and were then implanted as pulmonary artery replacements in
lambs and were follwed up for 100 weeks. There was no evidence of thrombus formation,
calcification, or aneurysm. Histology revealed cellularity and proteoglycans and
increased collagen contents in all of the groups. The mechanical profiles of the grafts
showed stronger but less elastic tissue properties than native pulmonary arteries [135].
Poly(diol citrate)
Novel biphasic scaffolds of concentric nonporous and porous layers of poly(diol
citrate) were fabricated by Yang et al. [136]. The nonporous phase was expected to
provide a continuous surface for EC adhesion, proliferation, and differentiation and
mechanical strength to the scaffold. The porous phase was to facilitate the infiltration and
differentiation SMCs. Human aortic smooth muscle cells (HASMCs) and endothelial
cells (HAECs) were seeded on these scaffolds where these cells demonstrated survival
and differentiation. When implanted subcutaneously, these scaffolds produced a thin
fibrous capsule and allowed tissue ingrowth.
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Poly(ethylene glycol) (PEG)
Hahn et al. [137] designed poly(ethylene glycol) based hydrogels containing an
adhesive ligand (RGDS) and a collagenase degradable sequence. They encapsulated
mouse smooth muscle progenitor cells within these scaffolds and subjected them to
biomechanical conditioning for 7 weeks. The conditioned scaffolds had significantly
higher collagen levels and improved moduli relative to those grown under static
conditions.
Poly(caprolactone) (PCL) and copolymers
A number of researchers [138, 139]are investigating elastic, poly(L-lactide-coepsilon-caprolactone) (PLCL) for vascular applications. Jeong et al. [140] seeded
vascular SMCs on PLCL scaffolds. Cell adhesion and proliferation was seen to increase
with increasing pore size.
Shin’oka et al. prepared tubular scaffolds of PLCL with a PGA fabric
reinforcement. These scaffolds were seeded them with autologous bone marrow cells and
implanted in young patients for ~1-1.5 years. There were no complications such as
thrombosis, stenosis, aneurysm formation or calcification [141].
PU and copolymers
Van der li et al., prepared microporous, compliant, biodegradable, grafts from a
mixture of polyurethane (95 weight %) and poly-L-lactic acid (5 weight %). When
implanted in rat abdominal aortas for 12 weeks, the implants remained patent with no
signs of dilatation or stenosis. ECs and SMCs grew in from the adjacent arterial tissue
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[142, 143]. Also, elastic laminae were regenerated and this was attributed to the
compliance and biodegradation of the material [111].
Williamson et al. [144] prepared composite scaffolds of PCL fibres to form the
luminal surface, then electrospinning porous PU onto the back of the PCL fibres to form
the vessel wall substitute. Human endothelial cells demonstrated strong attachment to
these composite PCL-PU scaffolds and proliferated to form a monolayer with strong
differentiation markers such as vWf and PECAM.
2.5.3.1.2 Natural materials
Reconstituted collagen
Collagen from various sources is easily available in powder or solubilized form.
Collagen gels have also been used because collagen is a major component of the
extracellular matrix of blood vessels and a natural cell substrate. On gelation, soluble
collagen assembles into linear filaments which aggregate to form fibers. This form is
conducive to cell mediated remodeling and can be resorbed over time as the cells lay
down their own matrix. However, these gels are found to have inadequate mechanical
properties to withstand hemodynamic pressures and shear stresses. Conditioning of the
gels with pulsatile flow has been explored as a means of stimulating matrix production
and fiber alignment in order to strengthen them. While this conditioning has shown about
200 % increase in tensile strengths, these values are still not sufficient for implantation
[145, 146].
Crosslinking has also been utilized to increase strength and stability of collagenbased vascular constructs however most crosslinking agents like glutaraldehyde,
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carbodiimides are cytotoxic. Several groups have also used various non-degradable
support structures to reinforce their collagen-based constructs, the most common being
Dacron [147, 148]. This method however, moves away from the completely biological
scaffold idea that drove the use of collagen in the first place. Berglund et al. [149] used a
dehydrated, crosslinked collagen sleeve as a temporary support. They used
dehydrothermal treatment and UV irradiation for crosslinking in order to eliminate the ill
effects of glutaraldehyde crosslinking. This reduced the cytotoxicity due to crosslinking
and provided ease of remodeling since lightly crosslinked matrices remodel better than
highly crosslinked ones. However, delamination of the actual graft and support sleeve is
an important concern in this method of reinforcement. Also, the rate of sleeve
degradation and the level of integration between the layers are important.
Tranquillo et al. [150] used magnetic force to orient collagen fibrils
circumferentially during their formation in order to mimic the natural vessel architecture
thus improving mechanics as well as causing SMCs to orient circumferentially as well.
Hyaluronic acid
Esterified hyaluronic acid, Hyaff-11, is a hyaluronan-based biodegradable
polymer developed for tissue-engineering applications [151, 152]. Turner et al. [153]
examined the attachment and proliferation of human ECs on Hyaff-11. They observed
that a specific type of Hyaff (pressed) supported cell growth the best. It allowed the
formation of a complete monolayer by 20 days and the deposition of basement membrane
components such as laminin, fibronectin, type IV and type VIII collagen. Lepidi et al.
[154] implanted HYAFF-11 tubes (2 mm diameter, 1 cm length) in the abdominal aortas
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of rats as temporary absorbable guides to promote regeneration of vascular structures and
observed that at 15 days, the luminal surface was completely endothelialized and by 21
days matrix components such as elastin and collagen were synthesized [155].
Elastin
Model polymers such as poly (GVGVP), the highly conserved, core sequence of
elastin, were prepared and exhibited an elastic modulus similar to the femoral artery
[156]. However, these polymers do not support cell adhesion very well. Nicol et al. [157]
showed that the incorporation of RGD into these sequences can improve cell adhesion
while maintaining the mechanical properties.
A number of researchers are investigating electrospinning of biopolymers to
create tubular scaffolds with nanoscale fibres. Daamen et al. [158] prepared a variety of
biological scaffolds with defined biochemical, biomechanical, and morphological
characteristics using different ratios of elastin, collagen and chondroitin sulfate. Li et al.
[126] compared the properties of electrospun fibers made of gelatin, collagen, solubilized
alpha-elastin, and as a first, recombinant human tropoelastin. In contrast to collagen and
gelatin, which could be spun into fibers in the nanometer scale, the diameter of
alphaelastin and tropoelastin fibers was always in the range of microns. At an optimum
delivery rate of 1.5 ml/h, fibers made of alpha-elastin and tropoelastin were elastic and
had a wavy pattern, which mimic the wavy topology of elastin in natural tissues such as
elastic arteries.
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Fibrin
Fibrin is the natural regenerative biomaterial of the body. It can be formed by the
crosslinking of autologous fibrinogen by thrombin, and the degradation rate of fibrin gels
can be controlled by addition of fibrinolytic inhibitors such as aprotinin or αaminocaproic acid [159]. Fibrin stimulates synthesis of collagen and elastin and yields
tissue engineered constructs with improved mechanical properties [160]. Fibrin also
promotes angiogenesis through attachment and proliferation of endothelial cells but does
not support platelet adhesion, suggesting that fibrin may be less thrombogenic than other
biomaterial substrates [159]. Long et al. [161] also noticed organized elastic fibers within
fibrin gels when neonatal SMC were cultured in fibrin gels. Also, the quantity of
crosslinked elastic fibers was enhanced by treatment with TGF-beta1 and insulin.
The advantage of gel systems are that scaffolds can be created in any shape and
dimension and cells can be encapsulated within the liquid before gelation thus
eliminating the problem of inadequate cell infiltration. Although a few researchers [159]
have shown that fibrin-based small-diameter tissue-engineered blood vessels exhibited
enough mechanical strength to withstand implantation in the jugular veins of lambs,
where they remained patent for 15 weeks, all gel-based systems have been unable to
function well under arterial pressures.
2.5.3.2 In vitro cell ECM synthesis - Cell sheets
In order to eliminate the effects of the biomaterial, some groups developed a
strategy to produce a completely biological blood vessel engineered by the self-assembly
method whereby sheets of fibroblasts, smooth muscle cells and endothelial cells are
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wrapped around mandrels and then cultured under pulsatile flow to bring about matrix
production [162]. The monolayer of endothelial cells rests on a decellularized biologic
extracellular matrix, named the inner membrane, which is composed of a scaffold of
extracellular matrix components produced by human dermal fibroblasts in culture [163].
The major disadvantage with this method is the amount of time required to grow these
vessels to obtain a mechanically strong vessel. Also the possibility of aneurysm
formation is questioned.
2.5.3.3 In vivo cell assembly - Fibro-collagenous tubes
Taking advantage of fibrous tissue formation during wound healing, Eiken [164],
Schilling et al. [165, 166], and most well known, Sparks [167, 168] first suggested the
subcutaneous implantation of a mandril to allow a fibrocollagenous capsule to grow
around it in 3–4 weeks. The mandril was removed and the tube that formed around it was
used for vascular replacements. Though this method provided a completely autologous
vessel, a follow up study by Hallin et al. [169] showed that the tubes occluded very
quickly due to thrombus formation mainly due to the exposure of collagen fibers to
blood. More recently, this idea of growing a blood vessel in the body was revived by
Campbell et al. [170, 171] when they implanted polymer tubing into the peritoneal and
pleural cavities of animals to grow vessels similar to natural arteries. The collagenous
capsule mainly contained myofibroblasts and was covered by a confluent layer of
mesothelial cells. Before implantation as carotid interposition grafts in rabbits, the tubes
were everted so that the mesothelium lined the lumen. This allowed the grafts to remain
patent for at least 4 months. Although all these methods eliminated immunogenic
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problems (and later, thrombogenicity), two main questions arise. First, since the
formation of a capsule is the body’s way of sealing off a foreign body, these
fibrocollagenous tubes that form in vivo are relatively avascular and thus may reduce
exchange between cells and blood when implanted intravascularly. Second, these
‘‘biotubes’’ are rich only in collagen. Collagen provides tensile strength to arteries
however, in order to sustain continual pulsatile flow and prevent dilatation (aneurysm
formation), elastin is a necessary component [25]. Unfortunately, elastogenesis in tissue
engineered constructs has been very limited [161, 172].
2.5.4 Environmental cues to improve graft properties
In order to control and manipulate cell function, mechanical and biochemical cues
are required.
2.5.4.1 Mechanical conditioning
Different mechanical stimuli such as strain, pulsation and even flow have been
used as a means to organize and hence strengthen, condition, and even culture tissue
engineered constructs (TECs).
Seliktar et al applied a 10% radial cyclic strain to human aortic smooth muscle
cell-embedded collagen constructs for 4 or 8 days [173]. They showed that the 4-day
strained constructs exhibited an enhancement of mechanical properties whereas after 8
days of straining the mechanical properties deteriorated. On further investigation [174]
they observed that MMP (specifically MMP-2) expression was significantly upregulated
in the strained samples and the inhibition of this enzyme prevented the enhancement of
mechanical properties. Since MMP-2 is known to degrade type I collagen as a normal
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part of the process of matrix remodeling, they explained the observed changes in
mechanical properties by hypothesizing that cyclic strain results in an upregulation and
activation of MMP-2, leading to the local degradation of collagen fibrils as the cells
reorganize the network. As more active MMP-2 accumulates in the constructs, matrix
degradation far exceeds the reconstruction and organization by cells thus decreasing the
ultimate stress and modulus of the constructs (at 8 days vs. 4 days). Kim et al. [175]
performed short and long term (10 and 20 week) studies and observed that at both time
scales SMC proliferation and expression of collagen and elastin increased in strained
samples.
Baguneid et al. [176] preconditioned their TECs in an in vitro pulsatile flow
circuit to determine the effect of pre-conditioning on EC adherence and retention on the
establishment of physiologic flow and observed that retention was significantly enhanced
by a period of preconditioning.
Niklason et al. [5] cultured constructs made of SMCs and ECs on biodegradable
scaffolds in specially designed pulsatile bioreactors. After 8 weeks of culture they were
able to create vessels with rupture strengths greater than 2000 mmHg, collagen contents
of up to 50 percent and differentiated SMCs.
2.5.4.2 Chemical conditioning
Chemical agents, especially aldehydes, have been used extensively to improve
properties of TECs. Glutaraldehyde has been used by a number of researchers to
crosslink and reduce the antigenicity of collagenous structures [149, 177] however it is
seen to be cytotoxic and induces calcification thus leading to implant failure [178]. Other
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crosslinkers such as epoxy compounds [179] and carbodiiamide based compounds [180]
have also been investigated.
Girton et al. [181] used a novel nonenzymatic crosslinking (glycation) of proteins
to stiffen and strengthen tissue equivalents and to increase their resistance to
collagenolytic degradation, without loss of cell viability. They added glucose and ribose
to cell culture medium to increase glycation of tissue constructs and also showed that
glycated tissue equivalents did not elicit inflammation or induce calcification upon
subcutaneous implantation.
Other researchers have added various chemicals such as PDGF to increase SMC
proliferation and TGFβ to increase smooth muscle alpha-actin expression [182], 20%
FBS, ascorbic acid, copper sulfate, praline, alanine and glycine to provide building blocks
for protein synthesis as well as increase crosslinking of these proteins [5] and sodium
ascorbate to improve mechanical properties [183].
2.5.4.3 Genetic engineering
In an artificial blood vessel the most important functions of ECs are preventing
thrombus formation, elimination of fibrin layer if formed (clot removal) and preventing
hyper-proliferation of SMCs (and hence hyperplasia). Genetic manipulation of ECs is an
avenue being pursued to achieve these functions however due to the number of
complications concerning the transfection agent, behavior (adherence, proliferation) of
transfected cells, and testing for tranfection, limited in vivo studies with relevant genes
have been performed.
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Canine jugular ECs were transfected with human tissue plasminogen activator
(tPA) using a retroviral vector [184]. Human tPA was detected by immunohistochemical
staining in ~ 61% of the transduced cells and no significant difference in the rates of
adherence or proliferation was seen in vitro between the transduced and non-transduced
ECs. However, adherence of the transduced ECs in vivo was significantly lower than that
of nontransduced ECs which the authors hypothesize to be due to reduced adherence after
exposure to hemodynamic forces. Dunn et al. [185] also observed the same trend
(reduced adherence of transduced cells on exposure to flow) however they also noticed
that transduction with another gene (such as β-gal) did not affect adherence. They thus
hypothesized that the cell loss may be due to proteolytic activity of tPA. On the addition
of a protease inhibitor cell adherence improved, confirming this hypothesis. Kimura et al.
[186] however observed no significant difference in retention between tPA transduced
and control (lacZ transduced) cells. Their use of an adenovirus for transfection may be a
possible cause for better retention.
Rat smooth muscle cells (SMCs) stably transfected with the gene for the
phenotype regulating protein cyclic guanosine monophosphate-dependent protein kinase
(PKG) were used as a cell source in the preparation of three-dimensional (3D) collagen
type I vascular constructs. PKG-transfected cells expressed severalfold higher levels of
the contractile protein smooth muscle alpha-actin (SMA), relative to untransfected SMCs
[187].
In conclusion, a number of strategies are being investigated to create a fully
functional small diameter arterial replacement. New techniques and a number of
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investigations are required to fully “engineer” an ideal blood vessel that matches every
aspect of the native tissue.
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CHAPTER 3
PROJECT RATIONALE

3.1 Hypothesis
An ideal tissue engineered blood vessel has not yet been created. Although cryopreserved
allografts have been used quite successfully as vascular grafts in animal models [188,
189], their limited shelf life, complications associated with the process of
cryopreservations and most of all their availability still hamper the widespread use [190].
Xenogeneic arteries do not have the problem of unavailability but cannot be used as is
due to immune problems. Decellularization has been widely used to eliminate this
problem since it maintains the extracellular tissue architecture quite well. However,
decellularized arteries cannot be repopulated by host cells completely [10, 191]. We
hypothesize that this is due to the dense collagen-elastin network. Also, the collagen
within these scaffolds is highly thrombogenic and antigenic. We thus came up with the
idea that removal of collagen in addition to cells leaving behind a pure elastin matrix will
increase porosity of the scaffold hence improving host cell infiltration while reducing
thrombogenicity as elastin is known to be non-thrombogenic [192, 193]. The long term
objective of our research is to create ideal tissue engineered grafts. Consistent with the
trends of tissue engineering, we aim to use a natural material – purified elastin - as our
scaffold. Since our scaffold possesses natural tissue architecture, we hypothesize that it
will integrate better with the native tissue. Also, since it is derived from a native artery,
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the EL scaffold will have mechanical properties similar to the host tissue which will lead
to lesser compliance mismatch at the anastomosis and hence better healing.

3.2 Specific Aims
Aim I: To create and characterize tubular pure elastin scaffolds for small diameter
blood vessel tissue engineering
Earlier studies have shown the complete removal of cells and collagen from porcine
aortic tissue by treatment with cyanogen bromide. However this method of elastin
scaffold formation caused a high degree of calcification in vivo. We will thus prepare
tubular elastin scaffolds from porcine carotid arteries using the same method but will
attempt to alleviate the calcification of these scaffolds by ethanol treatment which has
been shown to reduce the calcification of tissue scaffolds [194].The scaffolds will be
characterized for purity by histology and DNA analysis, mechanics by tensile test and
burst pressure measurement and biodegradability by incubation in enzyme solution.
Aim II: To repopulate the scaffold with vascular cells
Since a tissue engineered graft must function immediately upon implantation, it must
contain all the vascular cells that will provide all the signals necessary for proper
functioning. Earlier studies have shown that cells do not infiltrate the scaffold in static in
vitro culture. Thus dynamic culture using a pulsatile flow bioreactor and in vivo cell
recruitment techniques will be used to repopulate the scaffold with all the vascular cells
(fibroblasts, smooth muscle cells (SMCs) and endothelial cells (ECs)).
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Aim III: To reduce the thrombogenicity of the tubular elastin scaffolds
Although elastin is inherently non-thrombogenic, we have seen platelet adhesion on our
elastin scaffolds. In order to reduce this adhesion and hence improve the overall blood
compatibility of our scaffolds, we intend to use a two pronged approach: 1) heparin
immobilization and 2) endothelial cell culture on luminal surface. Heparin is a known
anticoagulant that reduces platelet adhesion and activation and brings about the
inactivation of thrombin by binding to antithrombin III. We aim to covalently bind
heparin to elastin using EDC-NHS chemistry and testing the thrombogenicity of these
crosslinked scaffolds (EL-Hep) in vitro with platelet adhesion assays, clotting time
assays, and the ability of heparin to bind antithrombin and hence inactivate thrombin.
Endothelium forms the natural anti-thrombogenic blood interface in arteries. We intend
to mimic that by culturing endothelial cells on EL-Hep scaffolds. Endothelial cell culture
on biomaterials has been investigated as a means to reduce thrombogenicity; however,
two main problems remain. The cells get activated just by culture on biomaterials or if
they remain quiescent, they detach on establishment of flow. We will thus test both the
profile of cells seeded on EL-Hep scaffolds as well as measure their retention on
exposure to shear.

3.3 Clinical Significance
Cardiovascular diseases are the leading cause of death worldwide. Blood vessel
replacement is a common treatment for vascular diseases such as atherosclerosis,
restenosis and aneurysm, with over 300,000 bypass procedures performed each year.
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Vein autografts are limited due to their availability. Although synthetic vascular
replacements have been successful for large diameter arteries, they have shown minimal
success in arteries with diameters < 6mm. This is because most synthetic materials induce
thrombus formation which, within a few months of implantation, causes failure of the
vascular graft due to occlusion. Tissue engineering enables the development of fully
biological vascular substitutes that restore, maintain and improve tissue function in a
manner identical to natural host tissue; however, a reliable and expandable cell source for
tissue-engineered vascular graft (TEVG) has not been established. Our long term goal is
to create a living tissue engineered vascular graft that is biodegradable, nonthromobogenic, non-immunogenic and has mechanical properties that match the native
arterial tissue. We propose to create pure elastin scaffolds from porcine carotid arteries,
repopulate these scaffolds with vascular cells to make a living, responsive blood vessel
replacement and also make these scaffolds nonthrombogenic by covalently binding
heparin on the luminal surface of EL scaffolds and also culturing endothelial cells on the
surface to provide a natural non-thrombogenic surface. The systematic approach
proposed above could bring about a new development in the tissue engineering of
vascular grafts.
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CHAPTER 4
CHARACTERIZATION OF TUBULAR PURE ELASTIN SCAFFOLDS AND
DESIGN OF PULSATILE FLOW BIOREATOR FOR IN VITRO SCAFFOLD
REPOPULATION

4.1 Introduction
Tissue engineered blood vessels represent the new era of small diameter vascular
replacements that are ready to use, resemble native arterial tissue in mechanics, structure
and function and above all, can provide a completely regenerated artery. Most tissue
engineering approaches rely on a scaffold material to provide a temporary support for
cells to attach to, grow on and synthesize their natural extracellular matrix. Synthetic
polymers such as polyglycolic [195] or polylactic acid [196],

polyurethanes [197],

naturally derived materials such as collagen [88], fibrin [159], and even combinations of
natural and synthetic materials [139] have been investigated for tissue engineered
arteries. Some researchers have even created completely autologous tissues either in vitro
by culturing sheets of vascular cells that they rolled to create tubes from [198] or in vivo
by implanting polymeric tubes subcutaneously [199] or in body cavities [171] to create a
tubular collagenous capsule as a graft.
Decellularized tissues have also been investigated since they provide a natural
structure for tissue engineering purposes. They match the host tissue properties very
closely, provide a familiar matrix organization for cells to attach and grow on, and allow
for true replacement and regeneration [200-202]. However, decellularized tissues have
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shown limited repopulation [126]. We hypothesized that this may be due to the dense
collagen – elastin network preventing cell infiltration [203]. In order to circumvent this
problem, we have created tubular pure elastin scaffolds by selectively removing cells and
collagen from porcine carotid arteries. This maintains the native arterial structure while
increasing the porosity of the scaffold to allow repopulation in vitro or with host cells in
vivo.
Earlier studies in the lab showed that these scaffolds support vascular cell
adhesion and proliferation; however, repopulation was still limited in static cultures even
with the supply of exogenous growth factors, enzymes to help degrade the matrix, and
even co-culture of fibroblasts with macrophages [204].
In this study, we wanted to evaluate the effect of mechanical stimulus on the
repopulation of the elastin scaffolds. We designed a pulsatile flow bioreactor to mimic
the in vivo arterial flow conditions and hence enhance scaffold cellularization. Pulsatile
bioreactors have been used in the repopulation of decellularized heart valves [205],
creation of functional blood vessels from biodegradable synthetic polymers [5, 206], and
the pre-conditioning of engineered grafts before vascular implantation [176].

4.2 Methods
4.2.1 Preparation of tubular elastin scaffolds
Porcine carotid arteries (5-7mm diameter) were harvested at a local
slaughterhouse, rinsed in cold phosphate buffered saline (PBS) and transported to the
laboratory on ice. They were then cleaned of adherent tissue and fat and rinsed in cold
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PBS. Vessels were treated with cyanogen bromide (CNBr) [207] to remove cells,
collagen and other ECM components, leaving behind pure elastin tubes. Briefly, fresh
tubular carotid artery samples were treated with 50 mg/ml CNBr (Acros Organics; Morris
Plains, NJ) in 70% formic acid (Acros Organics; Morris Plains, NJ ) (8 ml/cm2) for 19 h
at 20° C with gentle stirring, followed by 1 h at 60° C and boiling for 5 min to inactivate
CNBr. The scaffolds were then stored in 70% ethanol as a disinfectant.
4.2.2 Characterization of scaffolds
4.2.2.1 Histology
Elastin tubes were rinsed with phosphate buffered saline (PBS), embedded in
Tissue Tek OCT compound (Sakura Finetek, U.S.A. Inc., Torrance, CA), and frozen at 80°C after which 6 µm thick sections were cut using a cryostat (Microm HM 505 N,
Mikron Instruments, Inc.) and collected on glass slides. The samples were evaluated
using hematoxylin and eosin (H&E) staining for general morphology, Masson’s
trichrome stain to verify removal of collagen from the matrix and Verhoff-Van Gieson
stain (VVG) to evaluate the integrity of elastic fibers.
4.2.2.2 DNA assay
Quantitative DNA analysis for the scaffolds was done using the DNeasy® tissue
kit (Qiagen Inc. Valencia, CA). The protocol for DNA purification from rodent tails was
used as described in the kit since the expected yield was 1 – 4µg DNA/mg wet tissue.
Absorption was measured and the quantity of DNA calculated.
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4.2.2.3 In vitro biodegradability
Elastin scaffolds, 5–10 mg lyophilized samples (n = 3) were incubated in 1 mL of
0.1 U/mL ultra-pure elastase (dissolved in 100 mM Tris, 1 mM CaCl2, 0.02% NaN3, pH
7.8) for a total of 12 days on a shaker at 37°C. At day 1, 2, 3, 7, 8, 10 and 11, samples
were retrieved, rinsed three times with distilled water and lyophilized. The percentage of
mass remaining after digestion was calculated from the dry weight before and after
enzyme digestion.
4.2.2.4 Mechanical testing - Uniaxial tensile testing of rings
2-3 mm wide rings of fresh porcine carotid arteries and tubular elastin scaffolds
(n = 6 each) were subjected to radial tensile testing at a strain rate of 5 mm/s until failure
on an MTS (Synergie 100) machine. Stress strain characteristics were plotted and the
ultimate stress and engineering strain values were calculated. Young’s modulus was
calculated between 10 and 20% strain on the stress strain curve since this is the maximum
strain usually experienced by arteries.
4.2.2.5 Mechanical testing - Burst pressure
Burst testing of the scaffolds was performed by the delivery of distilled water
through a peristaltic pump. The maximum (burst) pressure of the scaffold was determined
using a pressure transducer connected to a data acquisition program on a laptop. Thirtymillimeter long scaffolds were attached via tapered adapters directly onto the transducer
on one side and the pressurized water on the other. The system was progressively
pressurized until vessel failure.
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4.2.3 Repopulation of scaffolds
4.2.3.1 Design of pulsatile flow bioreactor
The flow chart of the bioreactor system developed for mechanical conditioning of
the constructs and stimulation of in vitro scaffold repopulation is shown in Figure 4.1. A
Masterflex L/S variable speed digital peristaltic pump fitted with an L/S multichannel
pump head (Cole-Parmer, Vernon Hills, IL) was used with platinum-cured silicone
tubing (Cole Parmer) to create the flow loop of the cell culture media. The flow from the
peristaltic pump was passed through a pressure unit controlled by a timer circuit (an IC
555 pulse generator circuit with variable resistors and capacitor shown in Figure 4.2) to
provide the required beats/min pulse rate by adjusting the opening and closing of a
solenoid valve to allow air flow onto the polyurethane balloon through which the media
flowed. Check valves at the inlet and exit of the pump and pressure unit prevented
backflow of the media. Pulse rate could be adjusted by changing the resistor/capacitor
components of the timer circuit. Gas exchange in the construct chamber and media
reservoir occurred through 0.2 µm filters that were fitted to ports created in the vessels.
The gas permeable platinum-cured silicone tubing interconnecting system components
also provided an additional means of gas exchange. System components were sterilized
(autoclave or ethylene oxide) prior to assembly in a laminar-flow hood, and all
components except the peristaltic pump digital controller and bioreactor circuitry were
housed in a 5%CO2/37°C tissue culture incubator for studies.
Vessel-wall shear stress was computed using the Hagen–Poiseuille formula:
shear stress=4 µQ/πR3,
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with µ being fluid viscosity (N-s/m2) , Q being the volumetric flow (m3/s), and R being
the radius of the graft (m).
Flow rate was adjusted using the digital pump controller to achieve the required
shear stress.

Figure 4.1 Flow chart of pulsatile flow bioreactor connection. The pressure unit contains
a polyurethane balloon that is inflated and deflated with the help of air let in and out by
the solenoid valves which are controlled by a timing circuit that determines the rate of
pulsation (beats/min)
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Figure 4.2 IC 555 pulse generator circuit.

4.2.3.2 Cell culture

Figure 4.3 Solidworks designs of (A) construct chamber and (B) pulley system for
rotation during seeding
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Rat aortic vascular cells (fibroblasts/SMCs) were seeded onto the EL scaffolds
either on the adventitial side or on the luminal side and allowed to culture under static
conditions for 1-7 days before being subjected to pulsatile flow in the bioreactor system.
Table 4.1 gives the descriptions of experiments. With all the different cell culture
methods used, flow rate was changed in different experiments (to change wall shear
stress) as another variable for cell infiltration. Even for the static culture period, the
scaffolds were connected in the construct chamber (Figure 4.3 A) before seeding. When
cells were seeded on the adventitial side, the cell suspension was pipetted onto one side
of the scaffold and allowed to sit for 30 mins before being turned around to expose the
other half onto which cells were then suspended. However when cells were seeded onto
the luminal side, a cell suspension was pipetted directly into the lumen of the scaffold and
the pulley arrangement (shown in Figure 4.3 B) was used to slowly rotate the scaffolds to
allow the cells to attach throughout the inner surface. Figure 4.4 shows the experimental
set-up of the pulsatile bioreactor system. Cell seeded scaffolds were cultured for 1-8
weeks under pulastile flow in a humidified environment at 37°C in a CO2 incubator.
Medium was changed every 3 days.
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Cell type

Description of experiment

SMCs

Cell suspension pipetted onto adventitial surface, static culture 4h - 7
days, pulsatile flow 4 weeks

SMCs

Cell suspension pipetted onto adventitial surface, rotation for 1.5 days
followed by pulastile flow for 1, 2 and 4 weeks

SMCs

Cell suspension filled within scaffold lumen, static culture 1 - 4 h,
pulsatile flow 4 weeks

SMCs

Cell suspension filled within scaffold lumen, slow rotation for 48h,
pulsatile flow 4 weeks

SMCs

Cell suspension filled within scaffold lumen, slow rotation for 48h +
static culture 48h, pulsatile flow 4 weeks

SMCs

Vacuum suction of cells, pulsatile flow 4 weeks

SMC/Fibroblasts

Vacuum suction of cells, static culture 48h, pulsatile flow 4 weeks

SMC/Fibroblasts

Cell sheet formation by addition of ascorbic acid 2-phosphate,
wrapped on adventitial side, static culture 48h, pulsatile flow 4 weeks

Fibroblasts

Encapsulation in collagen and collagen-agarose gel as delivery
mechanism:
loaded within lumen, static culture 2 - 7 days, pulsatile flow 4 weeks
loaded on adventitial side, static culture 0 - 7 days, pulsatile flow 4
weeks

Fibroblasts

Exogenous bFGF added to circulating media, static culture 1 - 7 days,
pulsatile flow 4 weeks
Table 4.1 Details of cell culture experiments for improving cell infiltration in
elastin scaffolds in vitro
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Figure 4.4 Experimental set-up of bioreactor system. (A) Electrical components, (B)
system within incubator, (C) pump drive, (D) pressure unit with polyurethane balloon
and (E) construct chamber

4.2.3.3 Analysis
Many different cell seeding and flow regimen were followed after which the
grafts were removed from the chamber, each split into three groups and analyzed by
DNA assay (as described earlier), LIVE/DEAD assay (live cells appear green and dead
cells red) as described by the manufacturer (Molecular Probes, Eugene, OR) or H&E
staining to visualize cell infiltration.
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4.3 Results and Discussion
4.3.1 Scaffold Characterization
Histological analyses showed complete removal of collagen and cells by CNBr
treatment leaving behind a highly porous, pure elastin scaffold. DNA assay (Figure 4.5)
confirmed the complete removal of cells from porcine carotid arteries (95 % lesser DNA
in elastin scaffolds compared to fresh carotid arteries). H&E staining (Figure 4.6 A, B)
showed complete removal of cells, Masson’s trichrome (Figure 4.6 C, D) showed
complete removal of collagen and VVG staining (Figure 4.6 E, F) showed that the elastin
fibers maintained their integrity and were not degraded.

Figure 4.5 DNA assay of fresh carotid artery and elastin scaffolds showing more than 95
% removal of DNA in elastin scaffolds prepared by cyanogen bromide treatment.
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Figure 4.6 Histological analyses of porcine carotid artery before and after CNBr
treatment. (A) H&E, fresh (B) H&E, CNBr treated (C) Masson’s trichrome, fresh (D)
Masson’s trichrome, CNBr treated (E) VVG, fresh (F) VVG, CNBr treated. In Masson’s
trichrome stain blue represents collagen and pink represents elastin. In VVG stain black
represents elastin and pink represents collagen (Magnification x200).

In vitro biodegradability studies showed that elastin scaffolds degraded
gradually with time, reaching 50% degradation in less than 2 days and complete
degradation by 12 days, indicating that the elastin scaffolds are completely biodegradable
(Figure 4.7).
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Figure 4.7 In vitro enzyme degradation of elastin scaffolds. Values are expressed as
percentage (%) mass remaining after exposure to enzyme.

Uniaxial tensile test data (representative curves in Figure 4.8) showed that fresh
carotid arteries exhibited typical biphasic characteristics with low modulus (150–200
kPa) up to ~50% strains and high modulus (3.5–4MPa) from 100% to 150% strain. The
ultimate stress ranged from 1.76 to 2.64MPa whereas the maximum strain ranged from
110% to 200%. Elastin scaffolds showed perfectly linear stress - strain characteristics
with a modulus ~400 kPa. The ultimate stress ranged between 0.42 and 0.85MPa for
strains between 80% and 140%. These characteristics are very much within the range of
mechanical properties of pure elastin [208]
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Figure 4.8 Tensile testing of 3mm wide rings of fresh and CNBr treated carotid arteries.

On increasing the pressure of water through the elastin scaffolds during burst
pressure measurement, the scaffold underwent pulsations of increasing amplitudes until
~100mmHg beyond which the pressure in the scaffolds did not increase due to leakage
due to the high porosity of the scaffolds. Thus the burst pressure could not be determined.
The inset in Figure 4.9 A shows a representative of the pressure waveform within the
scaffold.
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Figure 4.9 Burst pressure measurement system. (A) Set-up of entire system (inset shows
curve of pulsatile flow through scaffold), (B) EL scaffold before flow is started, (C)
porous scaffold starts leaking at ~80mmHg
4.3.2 Scaffold repopulation
We have created a bioreactor which can simulate physiological small diameter
arterial flow conditions in terms of wall shear rate, pulsatile flow and pressure, all of
which are under the user’s control. This system can support the growth and maturation of
tissue engineered grafts. A number of strategies (detailed in Table 4.1) were employed to
improve cell infiltration into the EL scaffolds. Initial experiments were conducted with
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SMCs cultured statically either on the adventitial or luminal side for 1 day after which
pulsatile flow of different flow rates was established for 1 – 4 weeks. At the end of the
dynamic (flow) culture, no cells were seen on the surface or within the interstices of the
scaffold. We hypothesized that the cells may have detached due to the shear stress on
exposure to flow. Thus, static culture time was increased and experiments were
conducted with 4h – 1 week static culture before flow. When cells were statically
cultured for > 48h, they were able to resist detachment and live cells were seen on the
surface however they did not infiltrate the scaffold at all. Figure 4.10 shows
representative Live Dead assay (A) and H&E staining (B) images after 1 week of culture
under flow and after 4 weeks of flow (C) after 1 week of static culture.

Figure 4.10 (A) Image of live dead analysis after 1 week of bioreactor culture (B) Image
of H&E stain after 1 week of bioreactor culture, (C) Image of live dead analysis after 4
weeks of bioreactor culture.

Due to this lack of cell infiltration, a vacuum suction mechanism (inspired by that
described by Soletti et al. [209] was created where the cell suspension was passed
intraluminally in a small loop while vacuum was applied to the entire chamber. This
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method is meant to allow the medium (liquid phase) to come out of the porous scaffold
while the cells get lodged within the interstices however this method too did not provide
any infiltration although it allowed the establishment of flow within 1 day of vacuum
application without the loss of cells.
In order to improve cell adhesion to scaffolds to improve the chances of
infiltration, we created cell sheets with fibroblasts or SMCs by the addition of ascorbic
acid 2-phosphate to the culture medium. After 1 week of culture, cell sheets were scraped
from the culture plates and these sheets were placed on the adventitial side of the scaffold
and allowed to culture statically for 48h before the start of pulsatile flow. bFGF was also
added to the circulating medium to improve infiltration by chemotaxis. However, despite
all the stimulation, mechanical and chemical, the elastin scaffolds used in this study were
not repopulated by cells even after 8 weeks of culture.

4.4 Conclusions
We successfully designed and used a pulsatile flow bioreactor with controllable
flow properties however, when used for providing mechanical stimulus to encourage cell
infiltration into elastin scaffolds, the system did not help. Cells remained on the surface
of the scaffold irrespective of the culture time, culture conditions eg. addition of
exogenous growth factors, and even mechanical stimulation (physiologically similar
pulsation and shear stress). In previous biocompatibility studies in rats [203], the
scaffolds were completely repopulated by cells. This led us to believe that a multifactorial
environment (with growth factors and enzymes) will enable the repopulation of these
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elastin scaffolds. We thus decided to investigate a novel in vivo repopulation technique
by using the body as a bioreactor. These studies are described in the following chapters.
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CHAPTER 5
IN VIVO CELLULAR REPOPULATION OF TUBULAR ELASTIN SCAFFOLDS
MEDIATED BY BASIC FIBROBLAST GROWTH FACTOR

5.1 Introduction
Cardiovascular diseases are the leading cause of death in the US. More than
500,000 bypass surgeries are performed annually [210]. Typically, autologous saphenous
veins or internal mammary arteries are used for these procedures; however, limited
availability has urged the need for synthetic replacements. In small diameter arterial
replacements (<6mm), synthetic grafts often fail due to thrombosis-related occlusion.
Tissue engineering of small diameter arteries has been the holy grail of research in the
last decade. Since the overall goal is to mimic natural arteries, extracellular matrix
(ECM) materials have been widely researched. Due to its abundance in the ECM,
collagen is the most common matrix component utilized for vascular tissue engineering.
On gelation, soluble collagen assembles into linear filaments which aggregate to form
fibers. This fibrillar form is conducive to cell mediated remodeling and is remodeled over
time as the cells lay down their own matrix [149]. However, these gels have inadequate
mechanical properties to withstand hemodynamic pressures and shear stresses [145].
These collagen-based grafts also lack the elastin required to withstand continual pulsatile
flow.
Other materials being researched for vascular graft tissue engineering are
decellularized arteries (porcine, canine, ovine) containing the native collagen and elastin
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networks [126, 127, 211]. Advantages of using decellularized xenogeneic arteries as
vascular grafts include ready availability, ease of procurement from donors, and the
preservation of the ECM which is important for strength and cell attachment [126].
However, cellular repopulation in decellularized arteries has been shown to be
incomplete [212, 213]. We hypothesized that this lack of cellular infiltration is related to
the lower porosity of tissue due to dense collagen-elastin networks, and that the removal
of collagen from the artery, in addition to cells, would increase the porosity of the
scaffold. In our previous study, small square elastin scaffolds made from porcine aortic
wall showed better in vivo repopulation compared to patches of decellularized aorta when
implanted subdermally in rats [203].
In the present study, we wanted to test if small diameter tubular elastin scaffolds
could be repopulated in vivo, in a rat subdermal implant model, for vascular graft
applications. We also wanted to test if controlled release of bioactive molecules such as
bFGF would enhance cellular infiltration in these scaffolds. The results demonstrated that
the sustained release of bFGF brings about enhanced repopulation of elastin scaffolds
while inhibiting calcification. Such an in vivo repopulation technique could be used as a
minimally invasive method for autologous cell repopulation of elastin scaffolds for
vascular grafts in bypass surgeries. If this approach is successful, it can be easily
translated to clinical needs. We can envision placing tubular scaffolds subdermally in the
same patient who needs vascular replacement surgery. After appropriate time for tissue
remodeling, the cellularized graft can be explanted and used immediately for vascular
replacement.
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5.2 Materials and methods
5.2.1 Tubular scaffold preparation
Porcine carotid arteries (5-7mm diameter) were harvested at a local
slaughterhouse, rinsed in cold phosphate buffered saline (PBS) and transported to the
laboratory on ice. They were then cleaned of adherent tissue and fat and rinsed in cold
PBS. Tissues were subsequently processed for the preparation of tubular elastin scaffolds,
by cyanogen bromide (CNBr) treatment, to remove cells, collagen and other ECM
components except elastic fibers [207]. Briefly, fresh tubular carotid artery samples were
treated with 50 mg/ml CNBr (Acros Organics; Morris Plains, NJ) in 70% formic acid
(Acros Organics; Morris Plains, NJ )(8 ml/cm2) for 19 h at 20° C with gentle stirring,
followed by 1 h at 60° C and boiling for 5 min to inactivate CNBr. The scaffolds were
then stored in 70% ethanol as a disinfectant. This method produced pure elastin scaffolds
(shown in chapter 4). For the subdermal implant study, samples were further washed in
sterile saline.
5.2.2 Preparation of bFGF loaded elastin tubes
Human recombinant basic fibroblast growth factor (bFGF, PeproTech Inc, Rocky
Hill, NJ) was reconstituted in 5mM Tris buffered saline (TBS) (pH = 7.6) and diluted in
the same buffer to a working concentration of 6.6 µg/ml. Agarose (MP Biomedicals;
Solon, OH) solution (2 %) was made in TBS, microwaved for 2 minutes to dissolve the
agarose and maintained at 40°C on a heating plate. This solution was mixed with the
working solution of bFGF in a 1:1 ratio to give a final agarose solution of 1 % containing
3.3 µg/ml bFGF. For the experimental (EL-Gel-FGF group), 300 µl of this solution was
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pipetted into tubular elastin scaffolds. The agarose gel solidified immediately and then
both sides of the scaffold were tied with a suture to keep the gel within the scaffold for
the entire duration of implants. For the control (EL-Gel group), elastin tubes were filled
with 1% agarose gel only. This entire procedure was done under sterile conditions. The
scaffolds (n = 6 per group per time point) were prepared 1-2 hours before use and were
stored in sterile conditions until implanted.
5.2.3 In vitro bFGF release
To evaluate the sustained release of bFGF from agarose gel within the elastin
scaffold, we prepared bFGF loaded tubes in the same way as described above. These
samples were then immersed separately in 1ml TBS (pH 7.6 containing sodium azide) in
centrifuge tubes and gently shaken at 37°C for 28 days. Solutions were replaced at
regular time points with fresh TBS. The quantity of bFGF released in solution was
evaluated using a bFGF ELISA kit (Calbiochem; San Diego, California).
5.2.4 Subdermal implantation of tubular elastin scaffolds
EL-Gel-FGF and EL-Gel samples were implanted subdermally (n = 6 per group
per time point) in adult male Sprague Dawley CD rats weighing 250–300g, placed under
general anesthesia, as described earlier [214]. Briefly, a 1 cm wide skin incision was
made on the back of the rats, and two subcutaneous pouches were created in each rat by
blunt dissection. One scaffold (~20 mm long, containing 300µl gel) was placed into each
pouch and the incision closed with surgical staples. Animals were recovered and
provided with food and water ad libitum. Upon recovery, analgesic (buprenorphine, 0.05
mg/kg, s.c.) was provided. After 7 and 28 days, animals were euthanized by CO2
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asphyxiation and the implants along with surrounding capsules were retrieved for
analysis. The agarose gel was removed from all samples and stored separately.
5.2.5 Histology
Explanted elastin tubes were rinsed with phosphate buffered saline (PBS),
embedded in Tissue Tek OCT compound (Sakura Finetek, U.S.A. Inc., Torrance, CA),
and frozen at -80°C. 6 µm thick sections were cut using a cryostat (Microm HM 505 N,
Mikron Instruments, Inc.) and collected on glass slides. The samples were evaluated
using hematoxylin and eosin (H&E) staining for general morphology and Gomori’s one
step trichrome (Gomori’s) stain for matrix formation. Dahl’s Alizarin stain was used for
identifying calcium deposits. Verhoff-Van Gieson stain (VVG) was used to evaluate the
integrity of elastic fibers. For explant analysis, digital pictures were taken from each
section at 200X magnification and cell infiltration depth was measured using the Spot
Advanced software (Diagnostic Instruments Inc., Sterling Heights, MI). Cells populated
elastin scaffolds from outside in and thus infiltration depths were measured as the
distance (in micrometers) between the innermost cellularized layer and the outer
(abluminal) edge of the scaffold. Six measurements were taken from each slide for each
implant. (n = 3 slides per group; 18 measurements per group)
5.2.6 Immunohistochemistry
Cryosections (n = 3 per group) were immunostained using anti-rat prolyl-4hydroxylase primary antibody (1:500 dilution) for fibroblasts (Sigma, St. Louis, MO),
anti-rat macrophage (1:200 dilution) (Chemicon, Temecula, CA), anti-α-smooth muscle
actin (1:200 dilution) for myofibroblasts (Sigma, St. Louis, MO) and anti-rat smooth
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muscle heavy chain myosin (1:3000 dilution) for smooth muscle cells. Vectastain Elite
ABC Kit for mouse IgG and DAB substrate were used to visualize the specific staining
(Vector Laboratories, Burlingame, CA). To minimize cross reactivity, rat-adsorbed
biotinylated anti-mouse IgG at 5 mg/ml (Vector Laboratories) was used in place of the
biotinylated secondary antibody provided with the staining kit. Negative controls were
included with the omission of the primary antibodies. Sections were counterstained with
hematoxylin.
5.2.7 Protein extraction and analysis
Elastin scaffolds and gels (5 samples each) were separately weighed and
homogenized on ice for two minutes in 300µl of extraction buffer (5mM TBS pH 7.6,
0.05% Triton X-100, 1mM proteinase inhibitor cocktail (Sigma Aldrich)). The
homogenate was left on ice for 2 hrs after which it was ultracentrifuged (10,000 rpm, 20
minutes at 4°C). The supernatant was collected and analyzed for total protein content
using BCA assay, bFGF content using an ELISA kit (Calbiochem) and matrix degrading
enzymes such as MMPs using gelatin zymography.
5.2.8 Mechanical testing
2-3 mm wide rings of fresh porcine carotid arteries, tubular elastin scaffolds
(before implant, after 7 and 28 days of subdermal implantation) (n = 6 each) were
subjected to radial tensile testing at a strain rate of 5 mm/s until failure on an MTS
(Synergie 100) machine. Stress strain characteristics were plotted and the ultimate stress
and engineering strain values were calculated. Young’s modulus was calculated between
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10 and 20% strain on the stress strain curve since this is the maximum strain usually
experienced by arteries.
5.2.9 Calcium assay
Quantitative analysis of calcium content in explanted scaffolds was performed
according to a previously described procedure [215]. Briefly, a section of the capsule-free
scaffold (n = 6 per group) was lyophilized, weighed and digested in 1ml of 6N HCl at 95
°C for 10 h. Digested samples were evaporated under a continuous stream of nitrogen gas
until dry, and the residual material was dissolved in 1ml of 0.01N HCl. Calcium
concentration

was

determined

using an

atomic absorption

spectrophotometer

(PerkinElmer, Norwalk, CT) and expressed as µg Ca/mg dry tissue.
5.2.10 DNA assay
Quantitative DNA analysis for the scaffolds was done using the DNeasy® tissue
kit (Qiagen Inc. Valencia, CA). The protocol for DNA purification from rodent tails was
used as described in the kit since the expected yield was 1 – 4µg DNA/mg wet tissue.
Absorption was measured and the quantity of DNA calculated. Values are expressed as
µg DNA/mg wet sample weight (n=6).
5.2.11 Statistical analysis
Results are expressed as means ± standard error of the mean (SEM). Statistical
analyses of the data were performed using single-factor analysis of variance (ANOVA).
Subsequently, differences between means were determined using the least significant
difference (LSD) with an alpha value of 0.05.
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5.3 Results
The purity of elastin scaffolds prepared by the CNBr treatment, evaluated by
histology, SEM and other assays has been described in detail previously [203]. In the
current study we attempted to repopulate tubular elastin scaffolds with cells by
implanting them in a rat subdermal model. We developed an agarose gel system for the
sustained delivery of bFGF within the scaffolds to improve cell infiltration (Figure 5.1).

Figure 5.1 Schematic of in vivo cell recruitment strategy into tubular elastin scaffolds

5.3.1 Release of bFGF from agarose gels
In vitro release studies of bFGF from 1% agarose gels showed a steady release of
bFGF up to ~92% in 10 days (Figure 5.2 A). Quantification of bFGF extracted from
explanted scaffolds and gels showed that the growth factor was gradually released over
28 days from the agarose gel in the lumen and it moved into the elastin scaffold (Figure
5.2 B). There was a 70% release from the gel in 7 days and a total 80% release in 28
days. Thus, in vivo release of bFGF correlated well with in vitro release.
5.3.2 Cellular infiltration and neo-matrix deposition in subdermal implants
Macroscopically, the explants maintained their tubular structure and were covered by a
very thin capsule that could be removed easily (Figure 5.3 A and 5.3 B). Agarose gels
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placed in the lumen were intact and could be removed easily. H&E staining showed that
at 7 days there was almost no cellular infiltration in the EL-Gel group whereas there was
a little infiltration in the EL-Gel-FGF group (Figure 5.3 C and 5.3 D).

Figure 5.2 Sustained release of bFGF from agarose gels in vitro and in vivo (A) shows
70% release in 7 days. In vivo release of bFGF (shown as triangles), matches well with in
vitro results. The total release in vitro was ~92% in 10 days. (B) shows the gradual
decrease of bFGF in the gel and a corresponding increase in the surrounding scaffold
showing the sustained release through the gel and into the scaffold.
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At 28 days, EL-Gel showed similar infiltration as EL-Gel-FGF at 7 days whereas ELGel-FGF showed dense, organized infiltration halfway into the tissue (Figure 5.3).
Infiltration depth measurements (Table 5.1) showed significantly higher infiltration at 28
days in the EL-Gel-FGF group (45.59% ± 1.98) as compared to all other groups.
Gomori’s trichrome staining (Figure 5.3 F) for collagen showed organized collagen
deposition within spaces between the sheets of the elastin only in the 28d EL-Gel-FGF
scaffolds. There was hardly any collagen deposition in the remaining groups (data not
shown) probably due to little cellular infiltration.
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Figure 5.3 Macroscopic and histological features of explanted EL scaffolds (A) shows
the thin capsule over the explants (B) shows the structural integrity of the explants. 7d
EL-Gel (C), 7d EL-Gel-FGF (D) and 28d EL-Gel-FGF (E) representative images. Host
cells could only infiltrate scaffolds by abluminal side. There is visibly reduced cell
infiltration in EL-Gel group. Gomori’s trichrome staining (F) shows new collagen fibers
between layers of elastin only in the 28d EL-Gel-FGF group. The red lines indicate the
scaffold-capsule interface. H&E stain (cell nuclei are dark blue and matrix is pink),
Gomori’s trichrome stain (cell nuclei are dark blue, collagen is blue – green and elastin is
pink. Original magnifications (C–E), 200 X and (F) 400 X.
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Table 5.1 Depth of cellular infiltration into elastin scaffolds implanted subdermally.
There was significantly more repopulation in the 28d EL-Gel-FGF scaffolds as compared
to EL-Gel scaffolds (p<0.01).

The majority of infiltrating cells in both groups at both time points were
fibroblasts of which some stained positive for smooth muscle α-actin indicating their
myofibroblastic phenotype (Figure 5.4 A and 5.4 B). Significant macrophage infiltration
was observed at 7 days which reduced considerably at 28 days (Figure 5.4 C and 5.4 D).
However, there were no smooth muscle cells as observed by the absence of smooth
muscle heavy chain myosin staining (data not shown).
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Figure 5.4 Immunohistochemical characterization of infiltrating cells in EL-Gel-FGF
scaffold. A) immunostained for fibroblasts at 28 day, B) immunostained for smooth
muscle α-actin at 28 day, C) immunostaining for macrophages at 7 day, D)
immunostaining for macrophages at 28 day. The red lines indicate the scaffold-capsule
interface. Insets show negative stains. Original magnifications 400 X.

Quantification of DNA (Figure 5.5) indicated twice as much DNA in the 28d ELGel-FGF group (300 ± 40 ng/mg wet tissue) as compared to 28d EL-Gel as well as 7d
EL-Gel-FGF (160 ± 50 ng/mg wet tissue). The value for 28d FGF group was statistically
different from all other groups (p< 0.05).
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Figure 5.5 Quantification of DNA within explanted scaffolds. At 28 days EL-Gel-FGF
scaffolds had significantly more DNA (p<0.05)

5.3.3 Changes in mechanical properties
Uniaxial radial tensile testing of rings of fresh porcine carotid arteries, elastin
scaffolds (before implantation) and samples explanted at 7 and 28 days was done up to
failure (Figure 5.6). Fresh carotid arteries showed typical biphasic characteristics with
low modulus (150-200 kPa) up to ~ 50% strains and high modulus (3.5 – 4MPa) from
100 – 150% strain. The ultimate stress ranged from 1.76 – 2.64 MPa whereas the
maximum strain ranged from 110% to 200%. Elastin scaffolds showed perfectly linear
stress strain characteristics with a modulus ~400 kPa. The ultimate stress ranged between
0.42 and 0.85 MPa for strains between 80 – 140%. These characteristics are very much
within the range of mechanical properties of pure elastin. [208]
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Figure 5.6 Uniaxial tensile testing of fresh artery and scaffold rings. By 28 days, EL
scaffolds were stiffer and less elastic.

Table 5.2 Mechanical properties of pre-implant and subdermally implanted elastin
scaffolds. Values are averages of 6 samples ± SEM.

Both the EL-Gel and EL-Gel-FGF groups after 7 day subdermal implantation had
exactly the same characteristics as the unimplanted elastin scaffold. However, after 28
days of implantation, both groups were stiffer with moduli ranging 1.3 – 1.65 MPa and
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had reduced elasticity. EL-Gel-FGF scaffolds could be strained upto ~80% whereas ELGel scaffolds were even less elastic and could only be strained upto ~50% (Table 5.2).
MMP-2 was detected in both groups at both 7 and 28 days whereas MMP-9 was detected
in both groups only at day 7 (Figure 5.7 A). Elastic fiber degradation was also seen on the
outer (abluminal) side of the scaffolds (Figure 5.7 B).

5.3.4 Absence of calcification in subdermal implants
Calcification of implants was evaluated using quantitative calcium assay. None of
the samples calcified in EL-Gel-FGF group (values ranged between 0 and 0.25 ± 0.1
µg/mg dry weight), while 2 out of 6 samples in the 28d EL-Gel group calcified
significantly (8.1 and 15.8 µg/mg dry weight) (Figure 5.8 A). Dahl’s Alizarin staining of
scaffolds did not show calcium deposits in EL-Gel-FGF group (Figure 5.8 B) at both time
points but there were a few spots in the EL-Gel group which was consistent with the
quantitative studies. The value for 28d EL-Gel group was statistically different from the
28d EL-Gel-FGF group (p< 0.05).
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Figure 5.7 Degradation of EL scaffolds in vivo. A) Gel image showing MMPs 2 and 9 in
EL-Gel scaffolds 7day (Lane 1), EL-Gel scaffolds 28day (Lane 2), EL-Gel-FGF scaffolds
7day (Lane 3) and EL-Gel-FGF scaffolds 28day (Lane 4). B) VVG stain for elastic fibers.
Arrows indicate degraded fibers on abluminal side (EL-Gel-FGF) at 28 days.
Degradation was observed in both EL-Gel and EL-Gel-FGF samples at 28 days. Original
magnification, 200 X.
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Figure 5.8 Calcification of implanted elastin scaffolds at 7 and 28 days. (A) None of the
samples calcified at 7 days but at 28 days some samples without bFGF calcified. (B)
Alizarin red staining also shows the absence of calcium deposits (red) in 28 days EL-GelFGF samples.
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5.4 Discussion
Tissue engineering of blood vessels has been focused on the search for the ideal
material that will encourage regeneration to provide both a structural and functional
replacement. The ideal vascular graft should be non-thrombogenic, non-antigenic,
biodegradable and should have mechanical properties similar to the native artery
(collagen for strength and elastin for recoil). Most attempts to engineer small diameter
blood vessels however, have failed clinically due to lack of one of the above
characteristics. To eliminate immunorejection, a number of researchers have utilized the
idea of in vivo tissue engineering of vascular grafts. Over 3 decades ago, Eiken [164],
Schilling et al. [165, 166], and most well known, Sparks, [167, 168] first suggested the
subcutaneous implantation of a mandril to allow a fibrocollagenous capsule to grow
around it in 3-4 weeks. The mandril was removed and the tube that formed around it was
used for vascular replacements. Though this method provided a completely autologous
vessel, a follow up study by Hallin et al., [169] showed that the tubes occluded very
quickly due to thrombus formation mainly due to the exposure of collagen fibers to
blood. More recently, this idea of growing a blood vessel in the body was revived by
Campbell et al.,[170, 171] when they implanted polymer tubing into the peritoneal and
pleural cavities of animals to grow vessels similar to natural arteries. The collagenous
capsule mainly contained myofibroblasts and was covered by a confluent layer of
mesothelial cells. Before implantation as carotid interposition grafts in rabbits, the tubes
were everted so that the mesothelium lined the lumen. This allowed the grafts to remain
patent for at least 4 months. Although all these methods eliminated immunogenic
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problems (and later, thrombogenicity), two main questions arise. First, since the
formation of a capsule is the body’s way of sealing off a foreign body, these
fibrocollagenous tubes that form in vivo are relatively avascular and thus may reduce
exchange between cells and blood when implanted intravascularly. Second, these
“biotubes” are rich only in collagen. Collagen provides tensile strength to arteries
however, in order to sustain continual pulsatile flow and prevent dilatation (aneurysm
formation), elastin is a necessary component [216]. Unfortunately, elastogenesis in tissue
engineered constructs has been very limited [172, 217].
In the present studies we used porous elastin tubes carrying bFGF releasing gel
for in vivo cellular repopulation. The bFGF releasing gel was contained within the lumen
of the tubes by tying both edges of the tubular scaffold. This allowed cellular infiltration
through only the abluminal side. The purpose of these studies was to provide intraluminal
growth factor release to allow quicker abluminal cellular infiltration. On implanting these
repopulated scaffolds into vasculature, elastin would provide the necessary elasticity to
the graft.
The release of bFGF improved cell infiltration significantly. By 28 days, EL-GelFGF scaffolds were densely repopulated with host fibroblasts which synthesized new
collagen within the elastic fiber network. Some of these fibroblasts showed a
myofibroblast marker (smooth muscle α-actin) but were negative for smooth muscle
heavy chain myosin staining (data not shown). These results are similar to those shown
by others, who also showed a majority of myofibroblasts after implantation of 1 month
[170, 171, 199]. These myofibroblastic cells have been shown to express strong smooth
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muscle cell markers under pulsatile flow either in vitro [5] or in vivo [171]. Thus, after
implantation of such tubular scaffolds in the vasculature, myofibroblasts in the scaffolds
may show SMC behavior.
Cellular infiltration within scaffolds in the EL-Gel-FGF group however, was
incomplete and did not reach the intimal side, which could be advantageous for vascular
applications for several reasons. First, adventitial fibroblast infiltration would mimic
native adventitia and collagen deposition would provide adequate mechanical strength to
the scaffold. Second, elastin will be exposed to the blood flow after vascular implantation
which will minimize thrombus related failure. Tieche et al., [193] have shown that elastic
laminae possess anti-thrombotic and anti-inflammatory properties and show significantly
lower leukocyte adhesion when in contact with blood. Carr et al.,[192] have also shown
that elastin exhibits a four fold delay in clotting time when compared to synthetic
biomaterials. Third, the space in the media that is not invaded by myofibroblasts during
subdermal implantation could be infiltrated by smooth muscle cells laterally from the
native artery after vascular implantation thus allowing a seamless interface with the
native tissue.
We also observed microvasculature within the EL-Gel-FGF scaffolds. This
observation is very important as cells need nutrients during neo-tissue development and
many in vitro tissue engineering approaches fail due to inadequate nutrient supply deep
within the scaffolds. Inadequate neovascularization of prosthetic vascular grafts often
leads to infection, one of the most common causes of graft failure [218]. The observed
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microvasculature could be due to the release of bFGF, which is a well documented
angiogenic growth factor [219, 220].
One of the important aspects for vascular tissue engineering is appropriate
mechanical strength of scaffolds prior to vascular implantation. We performed uniaxial
tensile testing of rings of scaffolds after subdermal implantation to ensure that the
scaffolds could still withstand physiological strains (arteries experience 1-4% strain and
in extreme cases, 10% strain). [221]. The ultimate stress for the elastin scaffolds even
before implantation is ~1/3rd that of fresh carotid arteries. This is due to the removal of
collagen which provides tensile strength. After 7 days of subdermal implantation
mechanical properties were comparable to the unimplanted elastin scaffolds This may be
because there was very little cellular infiltration and little degradation of the scaffold.
After 28 days of implantation, scaffolds from both groups became stiffer and less elastic.
Synthesis of new collagen by infiltrating cells may be the cause of the increased stiffness
whereas matrix degrading enzymes responsible for elastin remodeling may have reduced
its elasticity. Moreover, though we tried to remove the fibrous capsule surrounding the
elastin implant before mechanical tests were performed, there may have been some
fibrous tissue remaining, which may account for the increase in stiffness in both EL-Gel
and EL-Gel-FGF groups. EL-Gel scaffolds could be strained between 30 and 50% after
28 days whereas EL-Gel-FGF scaffolds could be strained between 50 and 80% before
failure. Synthetic polymer scaffolds possess much lower ultimate strain even before
implantation. Electrospun scaffolds composed of PLGA-elastin-collagen had a maximum
strain of 40% at failure [222]. For the tissue engineering of blood vessels, burst pressure
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and compliance measurement are more important than static mechanical tests presented
here. Although an extensive study was not performed to evaluate the burst pressure of the
present scaffolds, water was pressurized through one EL-Gel-FGF scaffold after 28 days
of implantation which burst at 300 mmHg. A wide range of burst pressures from
240mmHg [223] to 650 mmHg [149] and in many cases in excess of 1000 mmHg [171,
224] have been measured by different researchers. Native arteries have shown burst
pressures between 2000 and 6000 mmHg depending on the animal and the vessel tested
[225, 226]. Detailed studies of burst pressure of EL scaffolds will be undertaken in the
future.
An additional concern for vascular implants is pathologic calcification. We and
others showed earlier that elastin based scaffolds are prone to calcification [227-229].
Cellular remnants are usually the nodes where calcification begins; however in some
cases, even decellularization does not completely eliminate calcium deposition [230].
Attempts to alleviate elastin calcification have met with limited success even in adult rat
models in which calcification is usually lesser than in juvenile animals[228, 231]. In the
present studies, interestingly, controlled release of bFGF suppressed elastin calcification
(the control scaffolds without bFGF showed some calcification p < 0.05). The role of
bFGF in physiologic calcification is controversial. Some studies, mostly with bone, have
shown that bFGF decreases mineralization by inducing hypophosphatemia [232]. The
addition of bFGF to dentin pulp cultures suppressed the increases in ALPase activity,
SPARC synthesis, and their mRNA levels [233]. However, other studies have shown that
bFGF is associated with osteogenic properties especially when used in combination with
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bone forming proteins such as BMPs [234, 235]. Our present studies, however, are the
first to show suppression of elastin calcification by bFGF at 28 days in subdermal
implantation model; however, whether this holds true for long-term studies and in the
circulatory environment is unknown and needs further study in the future.
We have extensively studied mechanisms of elastin calcification and have shown
that matrix degrading enzymes such as MMPs are involved in elastin calcification [139,
236]. In this study, an initial inflammatory response (macrophage infiltration) seen at 7
days was reduced by 28 days. Macrophages were present in the surrounding capsule even
at 28 days and MMPs were present in the scaffold (as seen by zymography). This led to
some elastic fiber degradation on the outer edges of the scaffolds, but in EL-Gel-FGF
scaffolds such MMP activity did not cause calcification. The mechanisms by which
bFGF prevented elastin calcification in the rat subdermal implantation model would need
further investigation.

5.5 Conclusions
Subdermal implantation of elastin tubes loaded with bFGF releasing agarose gel
provided a sustained release of growth factor which improved cell infiltration while
preventing calcification of elastin. Although comprehensive mechanical testing of the
scaffolds is required before implantation into the vascular system, this method provides a
minimally invasive technique to prepare mechanically sound, autologous grafts that can
be used as vascular replacements.
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CHAPTER 6
IN VIVO VASCULAR TISSUE ENGINEERING: INFLUENCE OF CYTOKINE
AND IMPLANT LOCATION ON TISSUE SPECIFIC CELLULAR
RECRUITMENT

6.1 Introduction
Autologous saphenous vein or internal mammary artery has been the gold
standard for vascular replacements; however, in the event of unavailability, synthetic
grafts or allogeneic cadaveric arteries are used. In the case of small diameter arteries,
synthetic replacements fail due to thrombosis. Tissue engineering approaches have shown
the potential to create biocompatible, strong and compliant grafts that have the capability
to remain viable and patent [58].
In vitro tissue engineering techniques have been extensively studied where porous
scaffolds are seeded with cells in static cell culture, under mechanical stimulation such as
rotary culture, pulsatile flow, and even vacuum seeding of all the vascular cells. Cells
isolated from numerous sources have been used including stem cells differentiated into
the required cell type. In particular, endothelial cell (EC) monolayer formation is what
has been extensively investigated since the presence of a quiescent endothelial monolayer
is thought to be the best approach to reduce early failure of vascular grafts either by
thrombosis or intimal hyperplasia. For in vitro EC seeding onto the graft lumen, various
cell sources such as superficial vein ECs [77], EPCs from bone marrow [237], cord blood
[238] and peripheral blood [239] have been used. The use of these cell sources however,
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is hampered by the need to isolate a pure population of the cells and grow them in culture
into enough numbers to seed the graft completely. Sometimes due to individual
preconditions the isolated cells may not even grow in culture [240]. In situ recruitment of
ECs after vascular graft implantation from the adjacent native tissue [241], circulating
progenitors [195], and transmural migration of vessel wall endothelial progenitor cells
EPCs [242], have been attempted. However, complete and rapid endothelialization has
not been achieved. Although ECs have been given a lot of importance, recruitment of all
three vascular cell types (fibroblasts, SMCs and ECs) is very important to create a
functional and viable graft.
We have focused our research on in vivo cell recruitment strategies where the
body could be used as a bioreactor to prepare viable vascular grafts from pure elastin
scaffolds. Earlier studies (described in Chapter 5) with bFGF loaded gels within elastin
tubes, when implanted in subdermal pouches showed the recruitment of fibroblasts and
some myofibroblasts in 28 days [243] however no smooth muscle or endothelial cells
were recruited into the scaffold. In the current study we investigated the ability of local
release of two different growth factors (stromal derived factor; SDF, which has been
shown to attract endothelil cells, and basic fibroblast growth factor; bFGF, whcich is a
well known angiogenic factor) to recruit the vascular cells into the elastin scaffold when
implanted in adipose tissue in rabbits. We also implanted these elastin tubes with growth
factors in subdermal tissue to compare the differences in cell recruitment. The main
purpose of this study was to identify an optimal cytokine – implant location combination
that would create a blood vessel that was histologically similar to the native artery with
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endothelial cells in the intima, smooth muscle (-like) cells in the media (with collagen
and elastin) and fibroblasts in the adventitia (with collagen).

6.2 Materials and methods
6.2.1 Tubular scaffold preparation
Porcine carotid arteries (5-7mm diameter) were harvested at a local
slaughterhouse, rinsed in cold phosphate buffered saline (PBS) and transported to the
laboratory on ice. They were then cleaned of adherent tissue and fat and rinsed in cold
PBS. Vessels were treated with cyanogen bromide (CNBr) [207] to remove cells,
collagen and other ECM components, leaving behind pure elastin tubes. Briefly, fresh
tubular carotid artery samples were treated with 50 mg/ml CNBr (Acros Organics; Morris
Plains, NJ) in 70% formic acid (Acros Organics; Morris Plains, NJ )(8 ml/cm2) for 19 h at
20° C with gentle stirring, followed by 1 h at 60° C and boiling for 5 min to inactivate
CNBr. The scaffolds were then stored in 70% ethanol as a disinfectant. This method
produced pure elastin scaffold. Prior to implantation, samples were washed extensively in
sterile saline.
6.2.2 Preparation of bFGF and SDF loaded elastin tubes
Human recombinant basic fibroblast growth factor (bFGF, PeproTech Inc, Rocky
Hill, NJ) was reconstituted in 5mM Tris buffered saline (TBS) (pH = 7.6) and diluted in
the same buffer to a working concentration of 6.6 µg/ml. Human recombinant stromal
derived factor 1-α (SDF, PeproTech Inc, Rocky Hill, NJ) was also reconstituted in the
same buffer and diluted to a working concentration of
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3.33 µg/ml. Agarose (MP

Biomedicals; Solon, OH) solution (2%) was made in TBS, microwaved for 2 minutes to
dissolve the agarose and maintained at 40°C on a heating plate. This solution was mixed
with the working solution of bFGF or SDF in a 1:1 ratio to give a final agarose solution
of 1% containing 3.3 µg/ml bFGF or 1.67 µg/ml SDF. One side of the tubular elastin
scaffold was tied with suture and 300 µl of either solution (for every 2 cm long scaffold)
was pipetted into it. The agarose gel solidified immediately and then the other side of the
scaffold was tied with a suture to keep the gel within the scaffold for the entire duration
of implants. This entire procedure was done under sterile conditions. The scaffolds (n = 6
per group per time point) were prepared 1-2 hours before use and were stored in sterile
conditions until implanted.
6.2.3 Subdermal and adipose implantation of tubular elastin scaffolds
bFGF and SDF loaded elastin tubes were implanted in subdermal pouches (SubQFGF and SubQ-SDF respectively) and also in adipose pouches located in the upper back
(Adipose-FGF and Adipose-SDF respectively) (n = 6 per group) of New Zealand White
rabbits weighing ~3.5kg, placed under general anesthesia. Briefly, 1 cm wide skin
incisions were made on the back of the rabbits, and either four subcutaneous pouches or
four adipose pouches were created in each rabbit by blunt dissection. One sample (~20
mm long, containing 300µl gel) was placed into each pouch and the incision closed with
surgical staples (i.e. three rabbits had two samples each of SubQ-FGF and SubQ-SDF
and three separate rabbits had two samples each of Adipose-FGF and Adipose-SDF
providing a total of six samples per group). Three of the six SubQ-FGF samples were 50
mm long and were used for burst pressure analysis after explantation. Animals were
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recovered and provided with food and water ad libitum. Upon recovery, analgesic
(buprenorphine, 0.05 mg/kg, s.c.) was provided. After 28 days, animals were euthanized
by intravenous administration of sodium pentobarbital with bilateral pneumothorax and
the implants along with surrounding capsules were retrieved for analysis.
6.2.4 Histology
Explanted elastin tubes were rinsed with phosphate buffered saline (PBS), the gel
was removed from the lumen and tubes were embedded in Tissue Tek OCT compound
(Sakura Finetek, U.S.A. Inc., Torrance, CA), and frozen at -80°C. 6 µm thick sections
were cut using a cryostat (Microm HM 505 N, Mikron Instruments, Inc.) and collected on
glass slides. The samples were evaluated using hematoxylin and eosin (H&E) staining for
general morphology and Van Gieson stain for new collagen formation. Oil Red O
staining was used to evaluate if fat cells were recruited by either Adipose-FGF or
Adipose-SDF samples. Verhoff-Van Gieson stain (VVG) was used to evaluate the
integrity of elastic fibers. For explant analysis, digital pictures were taken from each
section at 200X magnification and 1000X for collagen fiber evaluation and analyzed
using the Spot Advanced software (Diagnostic Instruments Inc., Sterling Heights, MI).
6.2.5 Immunohistochemistry
Cryosections (n = 3 per group) were immunostained using monoclonal antivimentin antibody (1:200) for fibroblasts (Sigma, St. Louis, MO), anti-CD146 (1:100) for
endothelial cells (Millipore), anti-α-smooth muscle actin (1:500) for myofibroblasts
(Sigma, St. Louis, MO) and anti-caldesmon (1:500) for smooth muscle cells (Sigma, St.
Louis, MO). Vectastain Elite ABC Kit for mouse IgG and DAB substrate were used to
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visualize the specific staining (Vector Laboratories, Burlingame, CA). Negative controls
were included with the omission of the primary antibodies. Sections were counterstained
with hematoxylin.
6.2.6 Burst pressure measurement
Burst testing of the scaffolds was performed by the delivery of distilled water
through a peristaltic pump. The maximum (burst) pressure of the scaffold was determined
using a pressure transducer connected to a data acquisition program on a laptop. Thirtymillimeter long scaffolds were attached via tapered adapters directly onto the transducer
on one side and the pressurized water on the other. The system was progressively
pressurized until vessel failure.
6.2.7 Calcium assay
Quantitative analysis of calcium content in explanted scaffolds was performed
according to a previously described procedure [215]. Briefly, a section of the capsule-free
scaffold (n = 6 per group) was lyophilized, weighed and digested in 1ml of 6N HCl at 95
°C for 10 h. Digested samples were evaporated under a continuous stream of nitrogen gas
until dry, and the residual material was dissolved in 1ml of 0.01N HCl. Calcium
concentration

was

determined

using an

atomic absorption

spectrophotometer

(PerkinElmer, Norwalk, CT) and expressed as µg Ca/mg dry tissue.
6.2.8 Hydroxyproline assay
The collagen content in the samples was estimated using a hydroxyproline assay.
20 µl aliquots of the reconstituted sample from the acid hydrolysed samples (described
above for calcium assay) were assayed for hydroxyproline content as described earlier
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[244]. Since elastin is known to also contain hydroxyproline (~1.2%) [245, 246] the
values of hydroxyproline obtained for the explanted samples were corrected for this
elastin-hydroxyproline content by subtracting the value obtained for unimplanted elastin
scaffolds.
6.2.9 Statistical analysis
Results are expressed as means ± standard error of the mean (SEM). Statistical
analyses of the data were performed using single-factor analysis of variance (ANOVA).
Subsequently, differences between means were determined using the least significant
difference (LSD) with an alpha value of 0.05.

6.3 Results
6. 3.1 Cellular infiltration and neo-matrix deposition
In the subdermal implants (controls), cell infiltration was different for the two
cytokines. In the bFGF group, cells remained close to the outer edge of elastin implant
(~22.41 ± 6.78 % infiltration depth) whereas in the SDF group, there was more scattered
and deeper cellular infiltration (53.85 ± 3.41 %) (Figure 6.1 and Table 6.1).
Immunostaining indicated that the majority infiltrating cells in both groups were
fibroblasts (Figure 6.2 A, B). In the SubQ-FGF group there were cells that stained
positive for smooth muscle α-actin (Figure 6.2 C) but none in the SDF group. Also, no
other cell types were seen (caldesmon positive smooth muscle or EC) in either group.
The amount of new collagen laid down by the cells was also quite similar (3.92 ± and
4.69 ± µg/mg dry tissue for bFGF and SDF respectively) (Figure 6.3).
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Figure 6.1 Histological features of subdermally implanted elastin scaffolds (A) H&E
staining of SubQ-SDF (B) H&E staining of SubQ-FGF (C) Van Gieson staining of
SubQ-SDF and (D) Van Gieson staining of SubQ-FGF. The yellow lines indicate the
scaffold-capsule interface. C and D are magnified images (1000 X) of the region
indicated by a black square in A and B respectively. H&E stain (cell nuclei are dark blue
and matrix is pink), Van Gieson stain (cell nuclei are dark blue, collagen is pink). Arrows
indicate collagen within scaffold. Original magnifications, A, B 200 X, and C, D 1000 X.
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Figure 6.2 Immunohistochemical characterization of infiltrating cells in subdermally
implanted elastin scaffold. (A) SubQ-SDF immunostaining for fibroblasts, (B) SubQFGF immunostaining for fibroblasts, (C) SubQ-FGF immunostaining for smooth muscle
α-actin. The red lines indicate the scaffold-capsule interface. Original magnifications
400X.
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Table 6.1 Depth of cellular infiltration into elastin scaffolds implanted in adipose
and subdermal tissue. There was significantly more repopulation in the Adipose-SDF
samples as compared to the other groups (p < 0.01).

Figure 6.3 Hydroxyproline analysis of explanted elastin scaffolds showing significantly
more collagen in Adipose–FGF samples compared to subdermally implanted scaffolds (p
< 0.05).
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In contrast, implantation of elastin tubes in the adipose tissue led to deeper and
denser cell infiltration (Table 6.1 and Figure 6.4) with SDF group showing more
infiltration as compared to the bFGF group. Collagen deposition on the other hand was
slightly more in the bFGF group as indicated by hydroxyproline assay values of 9.78 ±
2.11 ug/mg dry tissue for bFGF as compared to 7.59 ± 0.19 ug/mg dry tissue for SDF
group. This was further confirmed by Van Gieson staining (Figure 6.4 C, D). The higher
amount of collagen deposition in Adipose-FGF group despite lesser cell infiltration can
be attributed to the types of cells that infiltrated the scaffold. A large proportion of the
infiltrating cells in the Adipose-FGF group were fibroblasts (Figure 6.5 B). The SDF
group had fewer vimentin positive cells (fibroblasts), which were mainly restricted to the
capsule surrounding the elastin scaffold (Figure 6.5 A). Quite a few of the infiltrating
cells in Adipose-FGF were also positive for smooth muscle α-actin (Figure 6.5 D).
Microvasculature containing caldesmon positive smooth muscle cells and endothelial
cells were also seen in the collagen rich capsule only around the Adipose-FGF samples
(Figure 6.6 B, 6.6 C). On the other hand, in the Adipose-SDF samples, no smooth muscle
cells were recruited but a large number of ECs were seen within the scaffold interstices
(Figure 6.6 A). No fat cells were seen in either of the adipose implant groups (data not
shown).
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Figure 6.4 Histological features of adipose implanted elastin scaffolds (A) H&E staining
of Adipose-SDF (B) H&E staining of Adipose-FGF (C) Van Gieson staining of AdiposeSDF and (D) Van Gieson staining of Adipose-FGF. The yellow lines indicate the
scaffold-capsule interface. C and D are magnified images (1000X) of the region indicated
by a black square in A and B respectively. H&E stain (cell nuclei are dark blue and
matrix is pink), Van Gieson stain (cell nuclei are dark blue, collagen is pink). Arrows
indicate collagen within scaffold. Original magnifications, A, B 200 X and C, D 1000 X.
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Figure 6.5 Immunohistochemical characterization of infiltrating cells in adipose
implanted elastin scaffold. (A) Adipose-SDF immunostaining for fibroblasts, (B)
Adipose-FGF immunostaining for fibroblasts, (C) Adipose-SDF immunostaining for
smooth muscle α-actin, and (D) Adipose-FGF immunostaining for smooth muscle αactin. The red lines indicate the scaffold-capsule interface. Original magnifications 400X.
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Figure 6.6 Immunohistochemical characterization of infiltrating cells in adipose
implanted elastin scaffold. (A) Adipose-SDF immunostaining for endothelial cells, (B)
Adipose-FGF immunostaining for endothelial cells, and (C) Adipose-FGF
immunostaining for smooth muscle cells (caldesmon). The red lines indicate the scaffoldcapsule interface. Arrows indicate endothelial cells. Original magnifications 400X.

6.3.2 Burst pressure analysis
The burst pressure of elastin scaffolds (pre-implant) could not be determined
since they started to leak at ~100mmHg and thus did not burst. However, they could
sustain this pressure for an infinite amount of time. Burst pressures of three SubQ-FGF
samples (after 28 days of implantation) were determined using the same procedure. They
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burst at 308, 282 and 305mm Hg respectively showing significant improvement in the
properties due to ECM deposition.
6.3.3 Absence of calcification in implants
Calcification of implants was evaluated using quantitative calcium assay. None of
the samples in any group (implant location or growth factor) calcified (values less than
1µg/mg dry tissue).

6.4 Discussion
Autologous cell recruitment strategies have involved the isolation of cells
(progenitors or mature cells) from the source (bone marrow, fat deposits or blood), and
their in vitro culture under stimulatory conditions to obtain the required numbers for
seeding onto the graft. This seeding procedure is then usually followed by an in vitro
culture period wherein the tissue engineered artery is cultured to create a living vessel
replacement. Although this technique is widely used and provides sufficient number of
pure cell types, it has its drawbacks. Firstly, the time required to create a fully engineered
graft is very long (anywhere between 8-12 weeks) [247]. In addition, the process of
isolating the cells, seeding and culture engineering the graft are prone to contamination
problems associated with regular cell culture systems and the possibility of change in
cellular phenotype.
In vivo tissue engineering techniques have also been explored as a means to create
autologous vascular replacements. Most strategies have utilized the idea of implanting
inert materials in various locations to allow the formation of a tubular capsule that is used
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as the replacement tissue [171, 199]. These tissue capsules are mainly composed of
collagen, which provides adequate tensile strength to the grafts; however, in order to
sustain continual pulsatile flow and prevent dilatation, elastin is a necessary component
[216]. Unfortunately, elastin regeneration in tissue engineered constructs has been very
limited [161, 172]. We have pursued a novel in vivo method to recruit vascular cells into
tubular elastin scaffolds. On implanting these repopulated scaffolds as vascular grafts, we
hypothesize that the elastin would provide the necessary elasticity to the graft.
In earlier studies with bFGF loaded elastin tubes implanted in subdermal pouches
in rats, we observed significant increase in cellular colonization due to the local release of
growth factor [243]. The scaffold was repopulated in 28 days by fibroblasts and some
smooth muscle α-actin positive myofibroblasts. There were no other vascular cell types
observed. In the present studies we investigated the possibility of the release of another
factor (SDF-1α) from our agarose gel delivery system and also the implantation in
adipose tissue to encourage smooth muscle and endothelial cell recruitment into the
elastin scaffold.
Like marrow, adipose tissue is derived from the embryonic mesoderm [248] and
consists of a heterogeneous cell population including smooth muscle cells, fibroblasts,
adipocytes, mast-cells and endothelial cells [249]. Adipose tissue also contains a pool of
stem and progenitor cells with unique regenerative capacity that is thought to go beyond
traditional mesenchymal lineages [250]. Many groups working independently have
shown that adult stem cells from adipose tissues can differentiate along multiple
pathways in vitro, including the adipocyte, chondrocyte, endothelial, epithelial,
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hepatocyte, neuronal, myogenic, and osteoblast lineages [251-255]. Subcutaneous
adipose depots are accessible and abundant (in most animals and humans) providing a
potential adult stem cell reservoir. Thus, adipose-derived cells exhibit potential
advantages for tissue engineering applications.
Stromal cell-derived factor-1 (SDF-1) is a chemotactic cytokine that enhances the
homing of mobilized progenitor cells by promoting cell migration and proliferation [256].
SDF-1 has been shown to be produced by bone marrow stromal cells [257], activated
platelets [258], and even adipose capillary endothelial cells [259] and is a potent
chemoattractant to various cell types signaling via the CXCR4 receptor [260-262].
Platelet derived SDF-1 has also been shown to promote differentiation of human CD34+
cells into mature endothelial cells [263].
As adipose tissue contains pool of multipotent stem and vascular cells, we
evaluated the ability to recruit all the vascular cells into the elastin scaffold by our novel
agarose gel release system to release SDF-1 (which has the ability to attract and
differentiate endothelial progenitors) or bFGF (an angiogenic growth factor) in New
Zealand White rabbits. We used the subdermal location as a control for this adipose
implant study.
Immunohistochemical analysis revealed clear differences in the types of cells
recruited in the different groups. Fibroblasts were the only vascular cells recruited in the
subdermal tissue (SubQ-SDF and SubQ-FGF groups) however, a majority of these cells
in the bFGF group were positive for SM-α actin (as was seen in the earlier rat study)
which was not the case in the SDF group. In the adipose tissue, SDF was able to recruit
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SM-α actin positive fibroblasts and even endothelial cells but no smooth muscle cells. On
the other hand, bFGF in the adipose tissue was also able to recruit SM-α actin positive
fibroblasts and even caldesmon positive smooth muscle cells and a very small number of
endothelial cells. The infiltrating cells synthesized collagen in an orderly manner on the
adventitial side making the matrix similar to arterial tissue. Hydroxyproline analysis
revealed significantly more collagen synthesis in the Adipose-FGF group than the other
three factor-location combinations. Although there was more cell infiltration in the
Adipose-SDF group, the higher amount of collagen in Adipose-FGF can be attributed to
the fact that the majority of infiltrating cells were fibroblasts and a few of the other
vascular cells. bFGF is known to be a potent angiogenic factor [219, 220].
Microvasculature composed of smooth muscle cells and ECs was seen in the outermost
layers of the Adipose-FGF group. ECs were not seen anywhere else within the scaffolds
in this group. bFGF in the adipose tissue seems capable of attracting all the vascular cells
and bringing about repopulation of the elastin scaffolds in an organized, hierarchical
manner as in vascular tissue with a vascularized, collagenous outermost layer containing
fibroblasts (adventitia), and smooth muscle cell and α-actin positive myofibroblasts
(which have been shown to express strong smooth muscle cell markers under pulsatile
flow either in vitro [5] or in vivo [171]) in the elastic medial layer. Thus, after
implantation of such tubular scaffolds in the vasculature, myofibroblasts in the scaffolds
may show SMC behavior. Since stromal cells secrete SDF, which is capable of attracting
ECs, ECs should have been infiltrated elastin scaffold in the absence of SDF-releasing
gels. However, we did not see any ECs attracted into the interstices of the scaffold in the
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Adipose-FGF group (which we saw in the Adipose-SDF group). Although the reason for
this is not known, we hypothesize that it may be due to the action of bFGF on SDF.
Nakayama et al. evaluated the effect of fibroblast growth factor 2 on bone marrow
stromal cell expression of stromal cell-derived factor 1 (SDF-1) and showed that FGF-2
reduced SDF-1 mRNA expression and secretion in stromal cells [264]. This may also be
occurring in adipose derived stromal cells thus inhibiting the release of SDF and hence
the attraction of ECs into the tissue. Thus, the creation of a dual factor release system
may be necessary in which both SDF and bFGF are loaded in order to attract all the three
cell types into the scaffold since SDF-Adipose showed a large number of endothelial
cells within the scaffold’s interstices but could not attract SMCs.
One of the important aspects for vascular tissue engineering is appropriate
mechanical strength of scaffolds prior to vascular implantation. Burst pressure
measurement of tubular scaffolds by pressurizing water or saline through it until failure is
a common procedure to evaluate mechanical properties such as strength as well as
compliance. The burst pressure of elastin scaffolds (pre-implant) could not be determined
since they started to leak at ~100mmHg and thus did not burst. However after 28 days
subcutaneous implantation (SubQ-FGF group), the burst pressure of the repopulated
scaffolds were ~300 mm Hg. A wide range of burst pressures from 240 mm Hg [223] to
650 mm Hg [149] and in many cases in excess of 1000 mm Hg [171, 224] have been
documented by different researchers for various natural and synthetic scaffold materials.
Native arteries have burst pressures between 2000 and 6000 mm Hg depending on the
animal and the vessel tested [226].

Although the burst values obtained with our
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cellularized elastin scaffolds are not as high as those achieved with other materials in the
literature, they are high enough to sustain normal arterial pressures and are definitely an
improvement over the pre-implant elastin scaffolds. Also, all the grafts investigated in the
literature that have high burst pressures ( > 1000 mmHg) have very high tensile strength
but are not necessarily elastic and hence may cause compliance mismatch at the
anastomosis when implanted into the vascular system, which is thought to be one of the
main reasons for small diameter graft failure [265, 266]. The elastin scaffold however,
may be able to overcome this problem due to its’ elastic nature. Moreover, before burst
pressure testing of explanted scaffolds, we removed the outermost capsule, which may
have negatively affected the burst pressure values. In practice, these capsules can be kept
intact during vascular grafting thus they can combine with other perivascular tissue
present in the area and that would further improve mechanical properties of elastin
scaffolds. Burst pressures of elastin scaffolds implanted in adipose tissue were not
evaluated due to the small length (2 cm) of the scaffold. However, due to higher cellular
infiltration and significantly higher collagen deposition within Adipose-FGF samples,
burst pressures of these samples may be greater than ~300 mm Hg obtained in subQ-FGF
samples in this study.
An additional concern for vascular implants is calcification. Elastin based
implants are prone to calcification [227, 229]. Attempts to alleviate elastin calcification
have met with limited success even in adult rat models in which calcification is usually
lesser than in juvenile animals [230, 231]. In the current studies almost no elastin
calcification was seen in any group. This was due to combination of effects of ethanol
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pretreatment of elastin tubes prior to implantation and growth factor release during
implantation. Singla et al. also showed that the calcification rate of their collagen-elastin
matrices pretreated with ethanol was significantly lower than that of the untreated control
[194]. Our earlier studies without growth factor release but with ethanol pre-treatment
gave calcium levels of ~15 µg Ca/mg dry tissue (lower than that seen without either
growth factor or ethanol) [203] In the current study when growth factors were
incorporated in these ethanol-pretreated elastin tubes calcification was lower than 1
µg/mg of dry tissue in all groups. It is unclear at this time as to how growth factors
prevent elastin calcification and further mechanistic study is needed.

6.5 Conclusions
Adult autologous stem cells represent an important source of cells for vascular
tissue engineering. Their usefulness is directly related to the availability of the cells in
patient populations with vascular diseases as well as their ability to differentiate
efficiently into vascular cells. The presence of vascular and stem cells within adipose
tissue provides a useful source of adult stem cells that can be utilized for in vivo
repopulation of scaffolds to create autologous grafts. In this study subdermal and adipose
tissue implantation of elastin tubes loaded with bFGF/SDF releasing agarose gel provided
a sustained release of growth factor which improved cell infiltration into the scaffold.
Endothelial cells were recruited in large numbers by SDF in the adipose tissue whereas
smooth muscle cells were found only in the Adipose-FGF group along with a few
endothelial cells. The Adipose-FGF group looked most like a native artery (without the
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luminal EC lining) with a vascularized fibroblastic adventitia, a medial layer with
collagen (synthesized by infiltrating cells) and elastin (scaffold) with organized smooth
muscle-like cells (myofibroblasts) and some endothelial cells. Although the cellular
infiltration into the scaffold was not complete in any group and finer aspects such as
dosage of cytokines and duration of implant needs optimization, this study provides
preliminary results in the use of specific cytokines and locations as a means for tissue
specific autologous cell recruitment. The study also emphasizes the use of an agarose gel
release system, which is easy to use, inexpensive and performs a dual function – provides
structural support to the tubular scaffold to maintain its shape when implanted
subdermally in addition to being a delivery vehicle.

117

CHAPTER 7
DEVELOPMENT OF ELASTIN-HEPARIN MATRICES FOR VASCULAR
TISSUE ENGINEERING: CHARACTERIZATION AND IN VITRO BLOOD
COMPATIBILITY TESTING

7.1 Introduction
Diseased blood vessels can be replaced by vascular grafts to restore regular blood
flow and hence maintain homeostasis. Synthetic vascular grafts, made of Dacron or
expanded PTFE, are widely used to replace occluded or aneurysmal arteries. When used
in large-diameter applications, these synthetic vascular grafts show satisfactory patency
rates; however, in small-diameter replacements (internal diameter < 6 mm), they usually
occlude due to thrombus formation [41].
Surface modification of polymers to produce blood-compatible materials which
can prevent thrombus formation and intimal hyperplasia while encouraging endothelial
cell growth has been of great interest. Heparin is a common molecule used for such
modifications [267-269]. Heparin is a naturally-occurring anticoagulant produced by
basophils and mast cells. It is known to reduce platelet aggregation and inhibit
coagulation by enhancing the action of anti-thrombin on coagulation factors (such as
thrombin and factor Xa) [270]. When antithrombin (AT) combines with thrombin, an
inactive thrombin-antithrombin complex is formed. Heparin can bind AT at a specific
pentasaccharide sequence inducing a conformational change that results in a 1000 fold
increase in the formation of a complex between AT and coagulation proteases [176]. The
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first attempt to immobilize heparin onto biomaterials was carried out in 1963 [71]. These
researchers used electrostatic binding of heparin to the biomaterial through its anionic
groups. Due to the weak binding, the heparin was lost very quickly on establishment of
flow. Thus covalent binding of heparin to biomaterials was initiated which has been
shown to be more effective in long-term retention of heparin [271-273].
Due to the low success rates with synthetic materials in small-caliber vascular grafts,
attempts have also been made at using biologic materials for vascular prostheses. For this
purpose, we have developed tubular elastin scaffolds from porcine carotid arteries [243].
Reconstituted elastin has been shown to be less thrombogenic compared to other
materials (synthetic and natural) [192]; however, we observed a significant amount of
platelet adhesion on our purified elastin scaffolds in an in vitro static adhesion assay as
shown in Figure 7.1.

Figure 7.1 Preliminary platelet adhesion studies showing attachment on EL scaffold
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In order to alleviate this platelet adhesion, we immobilized heparin on the elastin
scaffolds using EDC and NHS, to create EL-Hep scaffolds. Different molar ratios of
NHS:EDC were evaluated to determine the optimal combination that would provide the
maximum bound heparin while maintaining mechanical properties as well as in vitro
biodegradability similar to original elastin scaffolds. Increasing concentrations of heparin
were then immobilized to determine whether heparin immobilization improved the blood
compatibility of the elastin scaffolds, by evaluating clot formation, thrombin inhibition
and deposition of blood platelets in vitro. To our knowledge, this is the first study in
which heparin was covalently linked to elastin scaffolds for vascular graft applications.

7.2 Materials and Methods
7.2.1 Elastin scaffold preparation
Porcine descending aortas were harvested at a local slaughterhouse, rinsed in cold
phosphate buffered saline (PBS) and transported to the laboratory on ice. They were then
cleaned of adherent tissue and fat and rinsed in cold PBS. Tissues were subsequently
processed for the preparation of elastin scaffolds, by cyanogen bromide (CNBr)
treatment, to remove cells, collagen and other ECM components except elastic fibers
[207]. Briefly, fresh aorta samples were treated with 50 mg/ml CNBr (Acros Organics;
Morris Plains, NJ) in 70% formic acid (Acros Organics; Morris Plains, NJ ) (8 ml/cm2)
for 19 h at 20 °C with gentle stirring, followed by 1 h at 60 °C and boiling for 5 min to
inactivate CNBr. The scaffolds were then stored in 70 % ethanol as a disinfectant. This
method produced pure elastin scaffolds (shown in previous publication [203]).
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7.2.2 Heparin immobilization
Elastin scaffolds were equilibrated with MES-buffer (0.05 M, pH 5.6) for 30 min.
Carboxylic acid groups of heparin were activated by adding NHS and EDC in various
molar ratios. Heparin (Acros Organics; Morris Plains, NJ) was pre-activated for 10 min.
Immobilization of heparin was investigated as a function of EDC (varying concentrations
of heparin with constant EDC concentration) and NHS (molar ratio of NHS to EDC of
0.1 to 1.0). 10 mg of elastin scaffold (circular disc of 5 mm diameter) was added to 2 mL
of EDC/NHS activated heparin solution. After 4 h of reaction at 37 °C, the heparinized
elastin scaffolds were washed with 0.1 M Na2HPO4 (2 h), 4 M NaCl (4 times for 24 h)
and distilled water (4-5 times for 24 h) [267].
7.2.3 Characterization of EL-Hep matrices
7.2.3.1 Determination of immobilized heparin – Toluidine Blue assay
The amount of immobilized heparin was determined colorimetrically using
toluidine blue as described by Smith et al. [274]. The heparinized scaffolds (varying
NHS:EDC molar ratios and varying EDC:Hep ratios, n = 3/ molar ratio) were
homogenized in 2.5 mL 0.2% NaCl solution. Toluidine Blue solution (0.005%) was then
added to each tube to bring it up to 5 mL and then mixed with a vortex mixer for 30 s.
The same was done with varying amounts of a standard heparin solution to give a
standard curve for 10 µg -70 µg heparin. Hexane (5 mL) was then added to each of the
tubes and the tubes were then shaken vigorously for 1 min. After centrifugation (1000
rpm, 3 min), the aqueous layer was diluted 1:10 with 100 % ethanol and the absorbance
at 631 nm was measured within 30 min.
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7.2.3.2 Localization of heparin – Alcian blue staining
Alcian Blue staining was used for the localization of immobilized heparin in ELHep scaffolds. Briefly, cryosections were fixed with 95 % ethanol for 1 min, incubated in
acetic acid (3 % v/v, pH 2.5) for 3 min and then stained for 30 min using a solution of
Alcian Blue (2 % w/v) in 3 % acetic acid solution.
7.2.3.3 Mechanical testing
Strips of elastin scaffolds and different NHS:EDC combinations of EL-Hep
scaffolds (n = 4 each) were subjected to uniaxial tensile testing at a strain rate of 5
mm/sec until failure on an MTS (Synergie 100) machine. Stress strain characteristics
were plotted and the ultimate stress and engineering strain values were calculated.
Young’s modulus was calculated between 10 and 20 % strain on the stress strain curve
since this is the maximum strain usually experienced by arteries.
7.2.3.4 In vitro enzyme degradation
Pieces of lyophilized pure elastin scaffolds (~10 mg each. n = 3) were suspended
in 1 mL of 1 U/mL ultrapure elastase solutions prepared in 100 mM Tris buffer, 1 mM
CaCl2, 0.02 % NaN3, pH 7.8 and incubated at 37 °C for 9 h with shaking at 600 rpm.
Samples were removed at 3 h and 9h, centrifuged 3 times for 3 min at 10,000 rpm, rinsed
in Tris buffer, lyophilized, weighed and percentage of elastin degradation calculated from
dry weights before and after exposure to elastase.
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7.2.4 In vitro thrombogenicity testing
7.2.4.1 Platelet adhesion assay
Platelet adhesion tests were performed under static conditions. Human whole
blood was obtained in sodium citrate from Innovative Research Inc. and centrifuged at
300 g for 10 min to obtain platelet rich plasma (PRP). The PRP was re-centrifuged at 700
g for 15 min to obtain the platelet poor plasma (PPP) and a pellet which was resuspended in a suspension buffer composed of 145 mM NaCl, 5 mM KCl, 10 mM Hepes,
0.5 mM Na2HPO4, and 6 mM dextrose, (pH 7.4). The platelet concentration was
determined by using a Coulter particle counter and the density adjusted to 10 x 106
platelets / mL. 100 µL of this suspension (with 1 mM CaCl2 and 1mM MgSO4) was
added to wells carrying the EL and EL-Hep scaffolds of varying heparin concentrations
(n = 3 / group; samples of 5 mm diameter). The platelet concentration and volume of
suspension was kept low in order to allow more sensitive determination of changes in
platelet adhesion to the different surfaces. After an hour of incubation at 37 °C, the
suspension was removed (and collected), samples washed 3x with 100 µL PBS (wash
liquid) and the number of platelets in the suspension and wash liquid counted. The
number of adherent platelets was calculated by a method described by Yang et al. [275]
# of adhered platelets = no - nt
where no is the number of platelets seeded and nt is the number in the suspension
+ wash liquid
Samples from each group were fixed for SEM in Karnovsky’s fixative (2.5 %
glutaraldehyde and 2 % formaldehyde in 100 mM cacodylic acid buffer, pH 7.4),
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dehydrated in a series of graded (50 – 100 %) ethanol followed by soaking in
hexamethylene disilazane (HMDS) and letting it evaporate overnight in a chemical hood.
The samples were then coated with platinum and scanned to evaluate the morphology of
the attached platelets.
7.2.4.2 Thrombin inactivation assay
The anticoagulant activity of immobilized heparin was determined using a
thrombin inhibition assay, based on a method described by Chandler [276]. The ability of
immobilized heparin to mediate the inactivation of thrombin by ATIII was measured
using a chromogenic substrate for thrombin (Benzoyl-Phe-Val-Arg-pNA). Briefly, 150 µl
of substrate solution (containing the chromogenic substrate and human ATIII in Tris
buffer) was added to the samples and the assay was started by adding 50 µl of a human
thrombin solution. The Tris buffer consisted of 50 mM Tris (pH 8.40) containing 1 g/l
PEO 6000, 1 g/l BSA (Sigma) and 150 mM NaCl. The reaction was followed for 20 min
to obtain a time course evaluation of thrombin inactivation. At 5 minute intervals (n = 3
per group per time point) after incubation at 37°C on an orbital shaker, the reaction was
stopped by adding 50 µL of 40% acetic acid. 250 µL of the supernatant was transferred to
a 96 well plate and the absorbance at 405 nm was measured.
7.2.4.3 Plasma recalcification time study
Platelet-poor plasma (PPP) obtained from centrifuging whole human blood was
used to evaluate the clotting time of recalcified plasma (PRT). 100 µL of the PPP was
introduced onto the samples and incubated at 37°C for 1 min. Then 100 µL of 0.025 M
CaCl2 solution was added to it. This solution was monitored for clotting by manually
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dipping a stainless-steel wire hook coated with silicone into the solution to detect fibrin
threads. The clotting time was recorded at the first sign of fibrin formation on the hook
[139]. The clotting time reported is a mean value of three separate experiments carried
out for each sample.
7.2.5 Statistical analysis
Results are expressed as means ± standard error of the mean (SEM). Statistical
analyses of the data were performed using single-factor analysis of variance (ANOVA).
Subsequently, differences between means were determined using the least significant
difference (LSD) with an alpha value of 0.05.

7.3 Results
7.3.1 Characterization of EL-Hep scaffolds
7.3.1.1 Localization of heparin
Microscopic images of Alcian Blue stained sections of EL-Hep scaffolds (varying
NHS:EDC combinations as well as varying heparin concentrations) showed
homogeneous staining through the entire thickness of the specimen. In contrast, the
native elastin scaffold as well as samples without NHS:EDC in the reaction showed no
staining (Figure 7.2). This indicates that heparin is immobilized homogeneously
throughout the thickness of the scaffolds and not just on the surface.

125

Figure 7.2 Alcian blue staining (blue indicates polysaccharides). (A) EL scaffold, (B)
EL-Hep scaffold showing heparin bound to elastin fibres throughout the thickness of the
scaffold, (C) EL-Hep scaffold without EDC/NHS in the reaction showing heparin was
covalently bound to elastin.

7.3.1.2 Effect of heparin immobilization on scaffold properties
The use of EDC to covalently immobilize heparin increased the stiffness of the elastin
scaffolds slightly irrespective of the amount of different NHS:EDC used (Young’s
moduli in the range of 279 - 305kPa). Pure elastin scaffold had a modulus of 219 ± 35kPa
with the stiffness increasing with increasing NHS:EDC molar ratio (Table 7.1).

Table 7.1 Crosslinker concentration in EL-Hep scaffold preparation and mechanical
properties of elastin and EL-Hep scaffolds.
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At 3 h all the different NHS:EDC combinations degraded lesser than pure elastin
scaffolds (7 - 15 % compared with 25 %) however at 9 h the EL-Hep 10-10 scaffolds
degraded significantly more than all the others (~ 59 %) while pure elastin and EL-Hep
5-30 and EL-Hep 9-15 degraded ~ 30 – 35 % (Figure 7.3).

Figure 7.3 In vitro enzyme degradation of pure elastin and EL-Hep scaffolds with
different NHS:EDC combinations. Values are expressed as percentage (%) degraded after
exposure to enzyme. EL-Hep 10-10 degraded significantly more in 9h than the other
NHS:EDC combinations (p < 0.05)
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7.3.1.3 Heparin immobilization (quantification)
After a number of optimizations, the following conditions were chosen for the
heparin immobilization reaction: buffer pH 5.6, 4 h reaction time, 10 min heparin preactivation, and 2mL reaction volume per sample (10 mg dry wt). Different NHS:EDC
combinations (molar ratios 0.1 - 1) were evaluated with 0.2 % heparin in the reaction.
The amount of heparin immobilized increased with increasing NHS:EDC molar ratio and
was maximum when 10.4 mM NHS and EDC (molar ratio of 1) was used as shown in
Figure 7.4.

Figure 7.4 Toluidine Blue assay for quantification of immobilized heparin in EL-Hep
scaffolds with different NHS:EDC combinations. EL-Hep 10-10 had significantly more
heparin immobilized than EL-Hep 5-30 (p <0.05)
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With the same molar ratio but with higher concentration of EDC and NHS, the
amount of heparin immobilized decreased for all three molar ratios (data not shown).
Thus, using this optimal combination (referred to as EL-Hep 10-10), increasing
concentrations of heparin (0.1 – 2 % w/v) were used in the reaction to create scaffolds
with maximal heparin activity and hence increased blood compatibility. Scaffolds thus
prepared showed correspondingly increasing immobilized heparin (1.25 – 1.9 µg/mg dry
tissue) upto 0.5 % w/v (Figure 7.5) after which there was a plateau in the amount of
heparin immobilized.

Figure 7.5 Toluidine Blue assay for quantification of immobilized heparin in EL-Hep
scaffolds with 10.4 mM NHS and EDC, and increasing amounts of heparin in the reaction
mixture. The total heparin immobilized after 4 h plateaued after 0.5 % w/v in the
reaction.
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7.3.2 In vitro blood compatibility testing
7.3.2.1 Platelet adhesion assay
Figure 7.6 and 7.7 (higher magnification) show the SEM images of platelets adhered on
pure EL, EL-Hep 0.1 %, EL-Hep 0.5 % and EL-Hep 2 %. SEM images of EL-Hep 0.2 %
looked similar to 0.1 % and 1 % looked similar to 2% (0.1% and 1% data not shown).
There was visible platelet attachment on EL, EL-Hep 0.1 %, EL-Hep 0.2 %, and EL-Hep
0.5 % whereas EL-Hep 1 % and EL-Hep 2 % had hardly any platelets in spite of similar
quantities of total immobilized heparin. In order to verify if this may be due to higher
amount of surface bound heparin leading to increased activity in the 1 % and 2 %
samples, we performed elemental analysis (XPS) on the EL-Hep 0.5 % and EL-Hep 2 %
samples. The results confirmed that there was in fact 2.5 X more sulfur (indicative of
heparin) on the surface of the EL-Hep 2 % scaffolds as compared to EL-Hep 0.5 %
despite equal amounts of total heparin (spectra given in Appendix). The adhered platelets
were not spread on any of the surfaces including pure EL scaffolds (comparison with
ePTFE shown in Figure 7.8). When quantified, only the EL-Hep 2 % group showed
significantly less platelet adhesion (Figure 7.9).
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Figure 7.6 SEM images of adhered platelets. (A) EL scaffold, (B) EL-Hep 0.1 %, (C)
EL-Hep 0.5 % and (D) EL-Hep 2 %. Arrows point out some of the platelets.
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Figure 7.7 Higfh magnification SEM images of adhered platelets. (A) EL scaffold, (B)
EL-Hep 0.1 %, (C) EL-Hep 0.5 % and (D) EL-Hep 2 %. Arrows point out some of the
platelets
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Figure 7.8 Comparison of adhered platelets on ePTFE and EL scaffolds. (A) and (C)
ePTFE, (B) and (D) EL scaffold. White arrows point out some of the platelets, yellow
arrows show spread out, activated platelets on ePTFE. Platelets on ePTFE were mostly
spread whereas those on EL were all rounded despite higher number of attached platelets.
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Figure 7.9 Quantification of platelets attached in static platelet adhesion assay. EL-Hep
2% scaffolds had significantly fewer platelets compared to all other groups (p < 0.05).

7.3.2.2 Clotting time of recalcified plasma
Figure 7.10 shows the PRT for the EL and EL-Hep surfaces compared to glass.
PRT for glass was 253 ± 28 s. Clotting times for all scaffold surfaces were higher than
glass. EL-Hep 0.1 % (495 ± 25 s) and EL-Hep 0.2 % (382 ± 38 s) were slightly lower
than EL (617 ± 56 s) and EL-Hep 0.5 % (625 ± 104 s) was equal to EL. EL-Hep 1 % had
a significantly enhanced PRT of 989 ± 115 s and EL-Hep 2 % samples did not cause clot
formation in the test period of 1200 s.
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Figure 7.10 PRT of glass, elastin scaffold and heparin immobilized elastin scaffolds. ELHep 1 % had a significantly higher PRT than all other groups (p < 0.05). EL-Hep 2 %
scaffolds did not clot during the 20 min test period.

7.3.2.3 Thrombin inactivation
Heparin acts like a catalyst in the thrombin-antithrombin complex formation
reaction by binding ATIII and thus increasing its affinity for thrombin 1000 fold.
Increasing the amount of heparin in the crosslinking reaction caused higher amounts of
thrombin inactivation (Figure 7.11). Over the reaction time of 20 mins, there was a
significantly higher thrombin inhibition by the 2 % heparin group as compared with pure
elastin scaffolds.
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Figure 7.11 Thrombin inactivation by heparinized elastin scaffolds in the presence of
human AT, over a 20 min time period. At 20 minutes only the EL-Hep 2 % scaffolds
show significantly more thrombin inhibition (p < 0.05)

7.4 Discussion
Exposure of blood to foreign materials, as in the case of all cardiovascular devices
such as vascular grafts, stents, heart valves, etc., initiates interaction with various blood
components which triggers the coagulation cascade eventually leading to the formation of
a fibrin clot. Although necessary for normal hemostasis, blood clot formation is also
responsible for several cardiovascular diseases and for the failure of several artificial
devices. It is thus pertinent to prevent blood clot (thrombus) formation to maintain the
integrity of the tissue or device. Although the exact order of initiation of the coagulation
cascade on implantation of prosthetic devices is still not understood, three factors are
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thought to be involved – adhesion of plasma proteins on the surface and activation of the
contact activation system, formation of thrombin, or adhesion and activation of platelets
[277, 278]. In this study, our aim was to evaluate the blood compatibility of elastin based
scaffolds for use as potential small diameter vascular grafts by investigating all three of
these factors by evaluating platelet adhesion, thrombin inactivation as well as clotting
time.
Elastin has been thought to be inherently non-thrombogenic [279], showing
reduced platelet adhesion and activation and even lower clotting times than other
biomaterials; however, we saw attachment of platelets to our elastin scaffolds in static
platelet adhesion tests. Other researchers have also shown some amount of platelet
adhesion onto isolated elastin [280] and even exposed microfibrils of elastic laminae
[281, 282] although not as much as on collagen scaffolds. Thus our main goal was to
reduce platelet adhesion onto the elastin scaffolds and to do this we immobilized heparin
onto the elastin scaffolds. In addition to reducing platelet adhesion, we also wanted to
evaluate the ability of the immobilized heparin to inactivate thrombin and reduce clotting
of recalcified plasma. Heparin is a naturally-occurring anticoagulant known to control
coagulation in various ways - by reducing platelet aggregation and enhancing the action
of anti-thrombin on coagulation factors (such as thrombin and factor Xa) [270].
Heparin was linked covalently to the surface of elastin scaffolds using EDC/NHS
chemistry to create EL-Hep scaffolds by forming peptide bonds between carboxylic
groups of heparin and the free amine groups on elastin. When creating these EL-Hep
scaffolds, we wanted to retain the native elastin scaffold’s properties - especially the
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mechanical and degradation characteristics. We thus created EL-Hep scaffolds using
three different NHS:EDC combinations to find the optimal combination that would
provide the most amount of bound heparin without changing the properties of the elastin
scaffold significantly.
With increasing NHS:EDC molar ratios, the amount of heparin immobilized
increased with the maximum heparin immobilized in the 10-10 group (10.4 mM NHS and
10.4 mM EDC). This may be due to increased NHS in the reaction which acts to stabilize
the reactive intermediate formed by the action of EDC on carboxyl groups on heparin
thus preventing its hydrolysis and in turn increasing its chances for reacting with amine
groups on elastin. The maximum amount of heparin immobilized was 1.9 µg / mg dry
elastin which is much lower than the quantities of GAGs immobilized on collagen
scaffolds by a number of researchers using the same crosslinking chemistry [267, 283].
This may be attributed to the low primary amine groups in our scaffold. Elastin in its
natural state is a highly crosslinked protein without any free amine groups. While
processing the porcine carotid artery (removing collagen and cells) to create elastin
scaffolds, we may have broken some crosslinks within elastin thus exposing a few free
amines to allow the immobilization of heparin. This was also corroborated by the
mechanical testing data. As expected, the EL-Hep scaffolds (with all the different
NHS:EDC combinations) were slightly stiffer than the elastin scaffold with the modulus
increasing with increasing concentration of EDC in the reaction; however, this difference
was not significant in any of the groups (highest modulus was 0.305 ± 0.009 MPa
compared to 0.219 ± 0.026 MPa of pure elastin). The in vitro biodegradability studies
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also showed little difference between all the groups with all the heparin crosslinked
scaffolds degrading only slightly lesser than the pure elastin scaffold in 3 h. Even at 9 h,
the EL-Hep 5-30 and EL-Hep 9-15 samples degraded just as much as pure elastin
scaffolds (30 – 35%) but the EL-Hep 10-10 samples degraded significantly more. This
can be attributed to the fact that the EL-Hep 10-10 group has significantly more
immobilized heparin (Figure 7.2). GAGs are known to readily bind and absorb water.
Due to a higher amount of heparin in the 10-10 group, more water may have been
absorbed leading to accelerated hydrolysis/degradation (at 9h compared with other
groups) in the presence of elastase.
Once the optimal NHS:EDC concentration (1:1 molar ratio, 10.4 mM each) was
determined, EL-Hep scaffolds with increasing amounts of heparin in the crosslinking
reaction (0.1 – 2 % w/v) were created to find the lowest amount of heparin required to
reduce thrombogenicity of elastin scaffolds. Amount of total heparin immobilized (as
shown by toluidine blue assay) increased with increasing heparin in the reaction, up to
0.5 % w/v, after which the value remained the same.
EL-Hep scaffolds with varying amounts of immobilized heparin were used for
blood compatibility tests. Various molecules and factors are involved in the formation of
a blood clot and we chose three separate methods to evaluate the bioactivity of the
immobilized heparin. Although the amount of total heparin immobilized did not increase
after 0.5 % w/v heparin in the reaction solution, we observed significant differences in
the blood compatibility results with EL-Hep 2 % scaffolds. The heparin quantification
assay evaluates the total heparin immobilized throughout the scaffold and not just on the
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surface. XPS analysis showed that there was 2.5 % more heparin on the surface of the
EL-Hep 2 % scaffolds compared to the EL-Hep 0.5 % samples confirming that the
significant improvement in blood compatibility with the 2% scaffolds was infact due to a
higher amount of heparin on the surface compared with the other groups although the
total amount immobilized may not be much greater.
It has been suggested that platelet adhesion to biomaterial surfaces depends on
surface topography, charge, surface tension and even wettability [284]. On contact with
blood, plasma proteins adsorb onto the surface of the material and may change any or all
of the above properties thus changing the platelet adhesion and activation. Fibrinogen is
thought to be the most influential plasma protein for platelet adhesion onto biomaterial
surfaces [285] because it adsorbs and undergoes conformational changes to interact with
unactivated platelets to promote their adhesion and even activation and secretion of
chemical factors [286, 287]. There have been contrasting reports on platelet adhesion on
biomaterials with immobilized heparin. Some researchers have shown reduced adhesion
and activation [139, 288] while some have reported no change in platelet adhesion with
heparin immobilization [289].
In our static platelet adhesion tests, as seen by scanning electron microscopy
(Figure 7.5), there were very few platelets on the 1 % and 2 % EL-Hep scaffolds. All
other EL-Hep scaffolds had similar number of adherent platelets as those on elastin
scaffolds. When quantified, there were 30 % fewer platelets on 2 % EL-Hep scaffolds
compared with all the other groups (data not shown). There was no platelet aggregation
on any of the groups. Platelet adhesion seems to depend on the type and conformation of
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plasma protein that adsorbs to the material surface thus changing the surface
characteristics affecting platelet adhesion and activation. Also, conformational changes of
the adsorbed proteins may expose receptors for platelet adhesion and activation. It is
therefore reasonable to assume that above a certain threshold, heparin immobilized onto
elastin scaffolds may have changed the surface properties in such a way as to affect the
amount or conformation of adsorbed proteins and thus reduced platelet adhesion.
Platelets contain heparin binding sites [290] which may mediate binding of platelets to
immobilized heparin at lower concentrations when other properties may not be affected
as much. Other researchers have shown that a minimum amount of surface heparin is
needed for significantly higher activity [291, 292]. Although the exact concentration of
heparin on the surface cannot be quantified, the drastic differences in platelet adhesion
can be attributed to more of the heparin being on the surface in the 2 % EL-Hep
scaffolds.
When anti-thrombin (AT) combines with thrombin, an inactive thrombinantithrombin complex is formed preventing clot formation. Heparin can bind AT at a
specific pentasaccharide sequence inducing a conformational change that results in a
more than 1000 fold increase in the formation of a complex between AT and coagulation
proteases [176]. In order to identify if heparin immobilized on elastin scaffolds could
inhibit thrombin (the most important factor in the coagulation cascade) by binding
antithrombin, a time course evaluation of thrombin inhibition in the presence of
antithrombin was performed. As anticipated, increasing amounts of heparin caused
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increasing inhibition of thrombin with a significantly increased inhibition with EL-Hep 2
% samples (Figure 7.7).
It has been shown that this AT binding sequence on heparin influences, almost
immediately on contact with plasma, the inhibition of factor FXII (FXII) [293, 294]. This
prevents the activation of any other enzymes further in the contact activation system.
Although the amount of FXII inhibition was not quantified in this study, the clotting
process was monitored by adding recalcified plasma to elastin and EL-Hep scaffolds of
the same area and monitoring the formation of fibrin fibres over a 20 min period since the
contact activation process is known to be completed within 12 mins [295]. Glass is
known to be a strong activator of the contact system and hence was used a control to
compare the clotting times to it. Accordingly, it did show the fastest clotting of
recalcified plasma completing the clotting process in 4-5 minutes while elastin scaffolds
formed clots in 10-11 mins. EL-Hep 0.1 % and EL-Hep 0.2 % scaffolds showed reduced
clotting times and EL-Hep 0.5 % did not show an increase in clotting time when
compared with elastin scaffolds. This correlates with the platelet adhesion results and
may be due to inaccessibility of AT binding sites on heparin at these low concentrations
either due to lower concentration of sites or due to the conformation of adsorbed plasma
proteins. With increasing heparin concentrations, (EL-Hep 1 % and 2 %), clotting times
increased significantly with EL-Hep 2 % scaffolds not clotting in the test period of 20
mins indicating their non-thrombogenicity.
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7.5 Conclusions
Heparin was immobilized onto elastin scaffolds using EDC and NHS. Using
increasing amounts of EDC: Heparin ratios, increasing amounts of heparin were
immobilized up to 0.5 % w/v. Although the amount of total bound heparin plateaued after
0.5%, surface bound heparin was 2.5 X higher in 2% EL-Hep samples compared to 0.5 %
EL-Hep leading to significantly improved blood compatibility. Platelet adhesion was
much lower, plasma clotting time was increased and thrombin inactivation was also
significantly higher. Improved blood compatibility may improve overall biocompatibility
of these elastin based scaffolds by reducing inflammatory reactions which are also
initiated by the interaction of plasma proteins and blood cells with the material surface.
These results encourage the use of these novel elastin-heparin scaffolds as vascular
grafts.
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CHAPTER 8
ENDOTHELIAL CELLS SEEDED ON ELASTIN-HEPARIN MATRICES
EXPRESS NORMAL EC MARKERS AND RESIST DETACHMENT ON
EXPOSURE TO SHEAR STRESS

8.1 Introduction
Small-diameter vascular grafts rapidly fail as a result of platelet deposition and
thrombus formation eventually leading to occlusion [296, 297]. Normal blood vessels are
lined by a quiescent endothelial monolayer on the luminal side that maintains a delicate
balance of anti-thrombotic and fibrinolytic properties. The success of autologous
saphenous veins as small diameter vascular replacements is thought to be mainly due to
the presence of this endothelial layer [298, 299]. Thus endothelialization of the luminal
surface seems to be the most logical step toward achieving a non-adhesive, nonthrombogenic, and anti-proliferative blood contacting surface [300]. However, two major
problems remain. First, the cells do not attach to the graft surface very well and hence
detach easily on application of flow. Also, the underlying matrix greatly affects the
function of the seeded cells giving rise to an activated phenotype which in fact may
aggravate thrombosis.
A quiescent endothelium is characterized by the expression of several cell surface
markers as well as secreted factors. Typically, thrombomodulin (TM) expression is high,
while tissue factor (TF) expression, prostacyclin (PGI2) secretion, nitric oxide (NO)
secretion is low to negligible. Furthermore, von Willebrand factor (vWF) is present
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within the quiescent endothelial cell (EC) but not secreted, and the number of cell
adhesion molecules expressed on the EC surface is also low [301, 302]. Activation of
ECs causes a reversal of this profile. All materials that are clinically used today as
vascular replacements are inherently thrombogenic and need to be modified to prevent
failure especially in small caliber vessels. A number of researchers have investigated the
ability of ECs to attach to various synthetic graft materials [303-305] and have shown
improved cell adhesion to traditional materials by coating with extracellular matrix
components such as fibronectin [306, 307], vitronectin [308], and collagen [309].
In our lab, we have created heparin coated pure elastin scaffolds (EL-Hep) as
potential tissue engineered grafts (Chapter 7). Heparan sulfate which is found on the
surface of endothelial cells and within the basement membrane is known anticoagulant
[310, 311]. Thus the modification of the graft surface with heparin before EC seeding
may provide the advantage of providing an anti-thrombogenic surface where ECs may
not be present or may detach on exposure to flow thus improving overall anti-thrombotic
properties. However, studies have shown that EC adhesion and proliferation is poor on
heparan sulfate [312]. Good EC adhesion, proliferation, their resistance to detachment on
exposure to shear and the expression of the correct molecules are important factors for
functionalized materials to succeed as small diameter vascular grafts.
Therefore, in this study, we investigated the attachment and viability of rat
vascular ECs cultured on EL-Hep scaffolds for 1 and 7 days. We also tested the retention
of the cells on exposure to orbital shear stress (~12 dynes/cm2) comparing it to cells on
TCPS. In order to determine the functional properties of the ECs seeded on these EL-Hep
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scaffolds, we evaluated the expression of three cell surface molecules – PECAM-1,
thrombomodulin (TM) and ICAM-1. Immunohistochemical analysis was performed to
compare it with normal rat aortic endothelial cell expressions and quantitation was
preformed by cellular ELISA to compare the values to those of expression on TCPS.

8.2 Materials and methods
8.2.1 Elastin scaffold preparation
Porcine descending aortas were harvested at a local slaughterhouse, rinsed in cold
phosphate buffered saline (PBS) and transported to the laboratory on ice. They were then
cleaned of adherent tissue and fat and rinsed in cold PBS. Tissues were subsequently
processed for the preparation of elastin scaffolds, by cyanogen bromide (CNBr)
treatment, to remove cells, collagen and other ECM components except elastic fibers
[207]. Briefly, fresh aorta samples were treated with 50 mg/ml CNBr (Acros Organics;
Morris Plains, NJ) in 70% formic acid (Acros Organics; Morris Plains, NJ ) (8 ml/cm2)
for 19 h at 20°C with gentle stirring, followed by 1 h at 60°C and boiling for 5 min to
inactivate CNBr. The scaffolds were then stored in 70% ethanol as a disinfectant. This
method produced pure elastin scaffolds (shown in previous publication [203]).
8.2.2 Heparin immobilization
Elastin scaffolds were equilibrated with MES-buffer (0.05 M, pH 5.6) for 30 min.
Carboxylic acid groups of heparin (Hep-COOH) were activated by adding NHS and EDC
in 1:1 molar ratio (10.4mM each) and 2% w/v heparin. Heparin was pre-activated for 10
min. For every 10mg of dry elastin scaffold, 2mL EDC/NHS activated heparin solution
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was added. After 4h of reaction at 37°C, the heparinized elastin scaffolds were washed
with 0.1 M Na2HPO4 (2 h), 4 M NaCl (4 times for 24 h) and distilled water (4-5 times for
24 h) [267]
8.2.3 Endothelial cell culture
Rat aortic endothelial cells (RAEC) were obtained from VEC Technologies, Inc
(Rensselaer, NY) and cultured in MCDB-131 complete medium (VEC Technologies,
Inc). Cells in passage 4–8 were used in this study. Scaffolds (6 mm diameter for
functional studies and 22 mm diameter for shear studies) were pre-incubated in medium
for 1 h and placed on non treated culture dishes. A highly concentrated cell suspension
(~5 x 106/mL) was used to cover the complete surface of the scaffold to allow maximal
cell adhesion for 1 h after which samples were transferred to well plates (96 well plate for
functional studies and 12 well plates for shear studies). Cells were also seeded in wells
(TCPS control) of respective plates. Well plates with cells and cell-seeded scaffolds were
placed in a humidified incubator at 37 °C, with 5% CO2. Medium was changed every
other day.
8.2.4 Shear stress application
After 1 and 7 days, 12 well plates with seeded EL-Hep scaffolds attached to the
bottom of the wells with non-cytotoxic cyanoacrylate (tested for cytotoxicity – data not
shown) and control plates with cells on TCPS were either kept as static (n = 6 each)
controls or exposed to shear stress (n = 6 each) using an orbital shaker as described by
several researchers [313-315]. A rotational frequency greater than 200 rpm has been
reported to correspond to arterial magnitudes (11.5 dynes/cm2) of shear stress [316, 317].
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Briefly, shear stress was applied to the plates using an orbital shaker (VWR Signature
Model DS-500; VWR International, West Chester, Pa) placed inside the incubator. The
approximate maximum shear stress at the bottom of the well can be calculated as
Τmax = a √ ηρ (2πf)3
Where a is the radius of gyration of the shaker (cm), ρ is the density of the
medium (g/mL), η is the viscosity of the medium at 37°C (poise), and f is the frequency
of rotation (rotations per second). Using this equation, under the conditions of our
experiments, we calculated a maximal shear stress of 12.7 dynes/cm2 at a frequency of
250 rpm.
Laminar shear (20 dynes/cm2) was applied using a custom designed flow chamber
only to EL-Hep samples after 1 day of static seeding to evaluate cell loss and
morphological differences.
The samples were then either evaluated qualitatively by LIVE/DEAD assay (live
cells appear green and dead cells red, n=3) as described by the manufacturer (Molecular
Probes, Eugene, OR) or quantitatively (only day 1) using crystal violet (n=3). For the
crystal violet assay, cells or scaffolds were rinsed with warm PBS before fixing with
methanol/acetone (1:1) at -20°C for 10 min. They were then again washed with PBS and
stained for 30 min with 0.005 % crystal violet (Sigma-Aldrich) in deionized water. Wells
were then extensively washed with deionized water and allowed to air-dry. The crystal
violet that absorbed onto the nucleus was solubilized with 1% Triton X-100 (SigmaAldrich) for 3 days and then transferred into new 96-well plates and the absorption was
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measured at 590 nm. Cell numbers were calculated from crystal violet absorbance values
using a standard curve plotted with known numbers of endothelial cells.
8.2.5 Functional (molecular) studies
8.2.5.1 Immunohistochemistry
EL-Hep samples (7d static and after shear; n = 3 per group) were either embedded
in Tissue Tek OCT compound (Sakura Finetek, U.S.A. Inc., Torrance, CA), and frozen at
-80 °C or fixed in 10 % neutral buffered formalin at room temperature for 24 h, processed
with an automatic tissue processor (Tissue TEK VIP, Miles Inc., Mishawaka, IN) and
embedded in paraffin. After either procedure, 6 µm thick sections were cut and collected
on glass slides.
Sections (n = 3 per group) were immunostained using monoclonal mouse anti-rat
CD31 (1:10; frozen section) (GeneTex Inc., SanAntonio, TX), monoclonal mouse anti-rat
CD54 (1:200; frozen section) (AbD Serotec, Raleigh, NC) and mouse antithrombomodulin (1:100; paraffin section) (gift from Covance Inc., CA). Vectastain Elite
ABC Kit for mouse IgG and DAB substrate (Vector Laboratories, Burlingame, CA) were
used to visualize the specific staining. Negative controls were included with the omission
of the primary antibodies. Sections were counterstained with hematoxylin.
8.2.5.2 Quantification of ICAM and TM expression (cellular ELISA)
The expression of the surface-bound adhesion molecule ICAM-1 and TM was
quantified using a method described by Lehle et al. [318]. EC function was verified by
the determination of spontaneous and TNF-α induced (treatment for 20 h) cell surface
expression of ICAM-1 on RVECs seeded on TCPS (control) and EL-Hep scaffolds. To
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activate the cells, 5µL of TNF-α reconstituted and diluted in PBS (10 µg; Calbiochem,
Gibbstown, NJ) was added to the wells (n = 3 per group) and treated for 20 h as the
expression of ICAM-1 is thought to peak 20h after activation with TNF- α.
The adherent cells were then washed once with warm PBS, fixed with a cold
mixture of 1:1 methanol/acetone for 10 min, then washed twice with PBS containing 0.2
% bovine serum albumin (BSA; Sigma-Aldrich, St. Louis, MO), and incubated for 1 h at
37 °C with 50 µL of the primary antibody (mouse anti-rat ICAM or mouse anti-TM)
diluted 1:200 or 1:100 respectively with PBS containing 0.02 % BSA. Samples were then
washed twice, incubated with a biotinylated goat anti-mouse IgG (50 µL/well, 1:200,
Vector Laboratories, Burlingame, CA) for 30 min at 37 °C, followed by repeated
washing and further incubation for 30 min with alkaline phosphatase streptavidin (50
µL/well, 1:1000, Vector Labs). The substrate p-nitrophenylphosphate (1 mg/mL, SigmaAldrich) in 0.1M diethanolamine (Sigma-Aldrich) pH 10.3 was then added, and after 15
min the absorption was measured at 405 nm with a spectrophotometer.
To control for loss of cells during fixation and washing procedures, crystal violet
staining was used (as described above). ICAM-1 expression was normalized to cell
numbers and calculated as a percentage of the expression by cells on TCPS stimulated by
TNF. For the determination of TM expression, only the basal values (without TNF
stimulation) were calculated and are expressed as a percentage of values of cells on
TCPS.
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8.2.6 Statistical analysis
Results are expressed as means ± standard error of the mean (SEM). Statistical
analyses of the data were performed using single-factor analysis of variance (ANOVA).
Subsequently, differences between means were determined using the least significant
difference (LSD) with an alpha value of 0.05.

8.3 Results
8.3.1 Effect of shear stress on EC retention
Cells were seeded on TCPS (control) and EL-Hep scaffolds in 12 well plates and
cultured for either 1 day or 7 days (n = 12 / group / time point). The shear group (n = 6 /
group / time point) was exposed to 4 h of orbital shear (250 rpm setting) after the 1d or
7d static culture period after which 1d samples were evaluated either by L/D assay shown
or quantification of cell retention by crystal violet (n = 3 / group / time point). The 7d
samples were only evaluated by L/D assay. Some 1 day seeded EL-Hep samples were
exposed to laminar flow (n = 3) and evaluated by L/D assay.
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Figure 8.1 Live Dead assay images. (A) 1d static culture on TCPS, (B) 1d static on
TCPS followed by 4h orbital shear, (C) 1d static culture on EL-Hep scaffold, (D) 1d
static on EL-Hep followed by 4h orbital shear. Green = live and red = dead cells.
Direction of flow is clockwise. Maximum shear was 12.7 dynes/cm2

ECs exposed to static conditions were randomly aligned and uniformly polygonal
both on TCPS as well as EL-Hep (Figure 8.1 A and C respectively). Cells were lost from
EL-Hep scaffolds on establishment of flow (both orbital, Figure 8.1 D and laminar,
Figure 8.2 B) as seen by empty spots without cells as well as dead (red) cells. Cell loss
was dramatic on TCPS after 1d static culture (Figure 8.1 B) where hardly any cells
survived the shear; however, after 7d static culture cells were able to withstand the shear
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even on TCPS (Figure 8.3 B). ECs on EL-Hep exposed to laminar shear stress after 1d
static culture as well as orbital shear after 7 day static culture, aligned in the direction of
flow (Figure 8.2 B and 3D).

Figure 8.2 Live Dead assay images. (A) 1d static culture on EL-Hep scaffold, (B) 1d
static on EL-Hep followed by 4h laminar shear (20 dynes/cm2). Green = live and red =
dead cells. Arrow indicates direction of flow.
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Figure 8.3 Live Dead assay images. (A) 7d static culture on TCPS, (B) 7d static on
TCPS followed by 4h orbital shear, (C) 7d static culture on EL-Hep scaffold, (D) 7d
static on EL-Hep followed by 4h orbital shear showing alignment of cells in the direction
of flow (clockwise). Green = live and red = dead cells. Maximum shear was 12.7
dynes/cm2

Quantification of cells using crystal violet (Figure 8.4) showed that after 1d
culture there were ~2.81 x 105 cells/cm2 on TCPS (control) static samples, ~ 2.39 x 105
cells/cm2 on EL-Hep static and ~ 1.8 x 105 cells/cm2 (75 % of static) on EL-Hep samples
exposed to shear. There were such few cells on TCPS samples exposed to shear that they
could not be quantified exactly. Exposure of 1d seeded EL-Hep scaffolds exposed to
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laminar flow (20 dynes/cm2) gave similar results with 75 – 80 % cells remaining on the
scaffold surface after 4 h of physiological levels of shear stress (data not shown).

Figure 8.4 Quantification of cells on TCPS after 1 day static culture, EL-Hep after 1 day
static culture and EL-Hep after 1 day static culture followed by 4h orbital shear. Hardly
any cells were present on TCPS after 1 day static culture followed by 4h orbital shear
whereas 75 % of cells remained on EL-Hep after exposure to orbital shear.

8.3.2 Expression of cell surface molecules
8.3.2.1 Effect of underlying matrix on surface molecule expression
To evaluate whether endothelial cell markers were conserved or whether the cells
were activated when seeded on the EL-Hep scaffolds, staining for three cell surface
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molecules was performed after 7 days of seeding. Rat aorta was used as a positive control
for all IHC evaluation of the molecules. Preservation of the monolayer integrity was
assessed

by

labeling

intercellular

molecules

localized

at

cell-cell

junctions

(CD31/PECAM-1), the labeling of which shows the confluence of the endothelium
(Figure 8.5).

Figure 8.5 Immunohistochemical staining for PECAM-1. (A) 7d static culture on ELHep scaffold, (B) 7d static on EL-Hep followed by 4h orbital shear, (C) Rat aorta. Insets
show negative controls. Original magnifications 1000X.

The intense staining of thrombomodulin on RVECs seeded on EL-Hep scaffolds
(Figure 8.6) indicated that a large number of the cells maintained this antithrombogenic
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protein on their surface. When quantified, TM expression on cells seeded on EL-Hep
scaffolds (static) was 90.2 ± 6.3 % compared to 100% expression on TCPS (data not
shown).

Figure 8.6 Immunohistochemical staining for thrombomodulin. (A) 7d static culture on
EL-Hep scaffold, (B) 7d static on EL-Hep followed by 4h orbital shear, (C) Rat aorta.
Insets show negative controls. Original magnifications 1000X.

ICAM-1 expression on the EL-Hep scaffolds was lower than that seen on rat aorta
(Figure 8.7 A, C) however when stimulated by TNF-α, the cells responded and ICAM-1
expression was visibly increased (Figure 8.7 D). In order to quantify this ICAM
expression, basal and stimulated expression levels of cells seeded on TCPS and EL-Hep
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were compared by cellular ELISA (Figure 8.8). When compared to cells seeded on
TCPS, the basal expression of ICAM-1 of cells on EL-Hep was slightly higher (45.3 ±
7.4 % vs. 28.2 ± 1.8 % of activated expression level) but this difference was not
significant. Also, when simulated by the inflammatory cytokine TNF-α, the cells on ELHep responded showing a significantly increased ICAM-1 expression (70.3 ± 11.7 %).

Figure 8.7 Immunohistochemical staining for ICAM-1. (A) 7d static culture on EL-Hep
scaffold, (B) 7d static on EL-Hep followed by 4h orbital shear, (C) Rat aorta, (D) 7d
static culture on EL-Hep activated by TNFα. Insets show negative control. Original
magnifications 1000 X.
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Figure 8.8 Expression of ICAM-1 on RVECs cultured on TCPS and EL-Hep scaffolds
activated by TNF-α for 20h. White bars set in front represent basal (unactivated) levels.
Dashed line represents basal level of cells on TCPS. Values were calculated as a
percentage of TNF activated cells on TCPS (considered as 100% shown by dash-dot
line). Basal levels were significantly lower than activated ICAM-1 levels (p < 0.01).

8.3.2.2 Effect of shear stress on surface molecule expression
Although not quantified, the expression of both PECAM-1 (CD31) (Figure 8.5 B)
and thrombomodulin (Figure 8.6 B) remained high and ICAM-1 (Figure 8.7 B) seemed
slightly higher than that that of static culture when RVECs seeded on EL-Hep scaffolds
were exposed to physiological levels of orbital shear stress ( ~12 dynes/cm2).
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8.4 Discussion
Blood compatibility of vascular prostheses is very important for their success. The
most common cause of failure of small diameter vascular prostheses is occlusion due to
thrombosis. Thrombosis involves the activation of three interconnected regulatory
systems, the coagulation cascade, the complement cascade and the cellular components
of the blood such as leukocytes and platelets which when activated, lead to the formation
of a clot within the blood vessel thereby obstructing blood flow. Endothelial cell (EC)
seeding of the blood contacting surface has been proposed as a method to reduce this
thrombosis progression and hence prevent graft failure [77, 319]. However, there are two
main problems associated with this technique. First, the seeded cells do not adhere well
enough to the biomaterial so that on establishment of flow they detach leaving behind
vacant, exposed, pro-thrombotic spots of the underlying material [320, 321]. The other
major problem is that ECs get activated just by mere culture on graft materials [304,
322].
The role that graft surface properties play in EC adhesion and growth, and the
effects of surface properties on seeded EC behavior have been studied by several
researchers [323-325]. In order to avoid thrombosis related failure, we have created novel
elastin-heparin scaffolds that have very good in vitro blood compatibility with almost no
platelet adhesion, highly increased plasma clotting time and high thrombin inactivation
(data submitted for publication). In the present study, we wanted to test the ability of ECs
to adhere to these natural, extracellular matrix based scaffolds and provide a normal,
quiescent lining of ECs hence preventing failure of these small diameter grafts by both
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thrombosis as well as hyperplasia. Normal, un-activated, confluent endothelium provides
a natural anti-thrombogenic surface by balancing the cell surface expression and
secretion of various molecules. Although the interplay of several different molecules
determines the health of the endothelium, we decided to evaluate the expression of three
molecules – PECAM-1, thrombomodulin and ICAM-1 on ECs seeded on the elastinheparin scaffolds. In addition to functional studies, we also quantified the retention of
cells after exposure to high levels (~ 12 dynes/cm2) of shear stress.
We have shown in earlier studies that elastin scaffolds support EC growth [203]
however the ability of the elastin-heparin scaffolds to form tight bonds with cells that
enable them to resist detachment on establishment of fluid flow had not been tested. A
number of researchers have shown the loss of in vitro seeded cells on the establishment
of flow. Rosenman et al. [87] showed that in a canine vascular graft model there was a
rapid loss of seeded cells (70.2 % of those seeded) in the first 30 minutes of establishing
flow. Even with the coating of extracellular matrix elements such as fibronectin on the
surface of synthetic polymer grafts to improve cell adhesion and retention on exposure to
flow, most studies have shown only ~ 60% cells remaining on the graft surface [326,
327].
In this study, the seeding density selected for shear studies was such that the cells
were confluent 24 h after seeding. This was done to allow the application of shear as soon
as possible after seeding. The 24 h attachment period used in this study is much longer
that that available clinically and future studies will involve shear exposure after 2 h
seeding to evaluate the feasibility of single stage EC seeding on EL-Hep scaffolds.
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After static seeding for 1 day, similar number of cells attached to TCPS as well as
EL-Hep scaffolds however on exposure to 4 h shear, majority of the cells came off the
TCPS and were dead (Figure 8.1 B) whereas 75 % (compared with static EL-Hep) of the
cells on the biomaterial scaffold remained attached (Figure 8.1 D and Figure 8.4). The
relative amount of cells retained (75%) is similar to that seen with other synthetic
polymers [176, 320]. After 7 days of static culture however, there was hardly any cell
loss on either TCPS or EL-Hep (Figure 8.3) (quantification not performed) on exposure
to shear. There was also alignment of cells in the direction of flow (tangential to well
wall) only on the EL-Hep (Figure 8.3 D) but not on TCPS even after just 4h of flow
similar to that seen with laminar flow (Figure 8.2 B).
EC attachment to synthetic polymer grafts has been shown to be minimal and
adhesion has been improved by coating the graft surfaces with natural, basement
membrane components such as FN [324, 328], collagen [329, 330] laminin [95, 331] etc.
which carry specific sites recognized by integrins on the cells that help bind the cells to
the matrix. Our natural material scaffold provided the right base for EC attachment and
did not need any coating to improve adhesion. Other researchers using natural materials
to create tissue engineered grafts have appreciated the fact that since the architecture of
the underlying matrix decides the status and adhesion of ECs, a natural ECM protein
scaffold may promote endothelial cell attachment without pretreatment with adhesive
proteins [332]. The effect of heparin immobilization on EC growth and proliferation is
quite contradictory. Some investigators have shown an inhibitory effect of heparin on EC
adhesion [333] however most have shown tendency of heparin to promote EC adhesion
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and growth [334, 335]. Although cells grow well and adhere on EL-Hep there is some
amount of cell loss (25%) on exposure to high shear as seen with all materials (natural
and synthetic) and these spots of exposed scaffold can be initiation points for thrombus
formation. The heparin immobilization on the elastin scaffolds should act to prevent
thrombus formation in the event of EC detachment hence maintaining the antithrombogenic properties of the graft.
Not only must ECs attach and grow well on the graft surface but they must remain
functional by exhibiting normal EC molecules. The behavior of ECs is known to be
influenced by the underlying matrix [336] and hence this behavior must be evaluated to
prove the efficiency of this method of thrombus prevention. In the present study the
expression of three EC molecules – PECAM-1, ICAM-1 and thrombomodulin was tested
on cells after static cultured on the EL-Hep scaffolds for 7 days to allow the maturation
and exhibition of true phenotype and compared to expression on normal rat aorta
(control). For quantification of expression, cells were similarly cultured on TCPS. The
phenotype of the ECs was checked by PECAM-1 expression, anticoagulant property by
TM expression and activation by basal ICAM-1 expression. The response of seeded cells
to stimulation by the cytokine TNF-α was also evaluated by quantifying increase in
ICAM-1 expression.
PECAM-1 occurs on the EC membrane and regulates EC adhesion to other ECs
and to leucocytes. A reduction in PECAM expression has been associated with EC
damage [337]. Our studies showed a high amount of PECAM expression (Figure 8.5)
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indicating the presence of a normal endothelium on the material surface. Even on
exposure to high shear stress PECAM-1 expression remained high.
To evaluate the expression of TM and ICAM-1, in addition to IHC comparing
their expression on normal aorta, we performed an in situ functional characterization
technique (cellular ELISA) comparing the expression to cells seeded on TCPS. ICAM-1
is constitutively expressed at low levels on the surface of several cells (including ECs)
[338] and is upregulated on activation by inflammatory cytokines such as interleukins,
TNFa, interferons [339, 340]. Qualitatively the expression of both TM and ICAM-1 on
statically cultured EL-Hep scaffolds was similar to that seen on normal aorta. On
exposure to shear, TM expression remained high (Figure 8.6 B) whereas ICAM-1
expression seemed slightly elevated on the seeded EL-Hep scaffolds (Figure 8.7 B).
Quantification of ICAM-1 expression (Figure 8.8) was performed for four
situations: RVECs on TCPS (control) and EL-Hep in resting conditions, and RVECs on
TCPS and EL-Hep under TNF-α stimulation. The presence of graft material (EL-Hep)
does not seem to affect ICAM-1 expression much – it was slightly higher than that on
TCPS (45.3 ± 7.4 % vs. 28.2 ± 1.8 %). This demonstrates that the EL-Hep scaffolds do
not activate, in vitro, the proteins involved in the adhesion between leucocytes and
endothelium. These values are similar to the expression on several other polymers where
up to 25 % higher expression was observed [318, 341, 342]. On the other hand, other
researchers have shown no significant change in the expression of ICAM-1 after 24 h
culture on PET grafts [343, 344]. Upon cytokine stimulation ICAM-1 expression
increased significantly (70.3 ± 11.7 % of expression of stimulated cells on TCPS)
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indicating that the higher basal levels seen on EL-Hep were not an activated phenotype.
TM expression was also seen to be stable at 7 days (90.2 ± 6.3 % of that on TCPS)
suggesting the conservation of the anticoagulant properties of ECs.

8.5 Conclusions
Our results show that the novel elastin-heparin scaffolds created in our lab
promote a quiescent endothelial lining on the luminal surface which is capable of
responding to cytokine stimulation. We believe that the availability of binding sites on
the matrix surface and the familiar natural architecture promotes strong adhesion of the
cells such that they are able to resist detachment on application of physiological range of
shear stress.
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CHAPTER 9
CONCLUSIONS AND RECOMMENDATIONS

8.1 Conclusions
Tissue engineering techniques provide novel approaches to the fabrication of ideal
blood vessel replacements – that are biocompatible, porous to allow nutrient exchange,
non-thrombogenic and mechanically similar to host tissue. Several materials, synthetic
and natural as well as different cell sources have been investigated. Based on the work
presented here to create an ideal tissue engineered small diameter blood vessel, the
following conclusions can be drawn:
• Cyanogen bromide treatment of porcine carotid arteries completely removes
cells and collagen, leaving behind tubular pure elastin scaffolds which are
porous, highly elastic, biocompatible and biodegradable.
• In vitro repopulation of the scaffolds with vascular cells in static and dynamic
(pulsatile flow bioreactor) culture was not achieved
• A novel in vivo cell recruitment technique with the use of a growth factor
delivering agarose gel was investigated in a subdermal pouch model. This
technique was extended to compare effect of two different growth factors
(bFGF and SDF-1α) and two different implant locations (subdermal and
adipose). The sustained release of bFGF in adipose tissue recruited several
smooth muscle α-actin cells (myofibroblasts), smooth muscle cells and some
endothelial cells.
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• Thrombogenicity of the elastin scaffolds was significantly reduced by
covalent binding of heparin. EL-Hep 2 % showed very few adhered platelets,
elevated thrombin inactivation and highly elongated plasma clotting time ( >
20 mins).
• Endothelial cells cultured on EL-Hep scaffolds were viable and able to resist
detachment on exposure to laminar flow ( 20 dynes/cm2) and orbital flow ( 12
dynes/cm2). These cells formed a confluent monolayer that was quiescent –
expressing high amounts of PECAM-1 and thrombomodulin (TM) and low
ICAM-1.

8.2 Recommendations
The studies listed below are recommended for future work in the use of elastin
based scaffolds as small diameter tissue engineered grafts.
• The in vivo cell recruitment capability of EL-Hep scaffolds needs to be tested.
In addition to being an anticoagulant, heparin is known to have binding
domains for angiogenic growth factors such as bFGF and VEGF. This could
improve cell recruitment in the in vivo models.
• The delivery of more than one growth factor in vivo needs to be explored. In
our studies, endothelial cells were recruited in large numbers by SDF in the
adipose tissue whereas smooth muscle cells were found only in the AdiposeFGF group whereas myofibroblasts were recruited in both groups. The delivery
of both factors may help recruit large numbers of all three vascular cells.
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• The use of adipose derived endothelial cells can be explored as a means of
endothelialization of the cellularized graft just before vascular grafting. The
cells can be isolated and grown in culture while the in vivo cell recruitment is
underway. On explanting the cellularized tube, these cells can be seeded onto
the luminal surface before vascular grafting.
• Endothelial cells seeded on the scaffolds need to be tested for retention after
only 1 -2 hours of static seeding to evaluate the adhesion capacity for single
stage seeding (clinically relevant application)
• The long term functionality of the graft needs to be tested in a suitable animal
model (eg. dog). Although the in vitro blood compatibility was very good, the
true test of a vascular graft is in situ.

168

APPENDICES

169

Appendix A
XPS spectra for sulfur in EL-Hep scaffolds

Spectrum for S 2p (0.5 % EL-Hep scaffolds)
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Spectrum for S 2p (2 % EL-Hep scaffolds)
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Appendix B
ISO10993: Biological evaluation of medical devices - Part 6: Tests for local effects
after implantation
This part specifies test methods for the assessment of the local effects after implantation
of biomaterials intended for use in medical devices. Evaluation should be undertaken by
comparing the tissue reaction to that of a similar specimen/material of which the clinical
acceptability and biocompatibility characteristics have been established.
1. Test methods, general aspects
• For short-term testing, animals such as rodents or rabbits are commonly used. For
long-term testing, animals such as rodents, rabbits, dogs, sheep, goats, pigs, and
other animals with a relatively long life expectancy are suitable.
• For biodegradable materials a pilot study in rodents should be undertaken to
determine the expected rate of degradation before embarking on studies on larger
animals. For degradable/resorbable materials the test period should be related to
the estimated degradation time of the test product.
• The specimens of test and control materials should be implanted under the same
conditions in animals of the same species and of the same age, sex, and strain in
corresponding anatomical sites. The number and size of implants inserted in an
animal depends on the size of the species and the anatomical location.
• Whenever possible, the reference control and the test specimens should be
implanted into the same animal.
• The test period should be determined by the likely clinical exposure time or be
continued until or beyond a steady state has been reached with respect to the
biological response.
• For non-degradable and non-resorbable materials the short-term responses are
normally assessed from 1 week up to 4 weeks and the long-term responses in tests
exceeding 12 weeks. The local biological response to implanted materials
depends both on the properties of the materials and on the response to the
associated trauma of surgery. The tissue configuration in the vicinity of an
implant changes with the time elapsed after surgery. During the first two weeks
after implantation the reaction due to the surgical procedure itself may be difficult
to distinguish from the tissue reaction evoked by the implant. In muscle and
connective tissue, depending on the species, and the severity of the surgical
trauma, a steady state is seen in the cell population after 9 weeks to 12 weeks.
Implantation in bone tissue may need longer observation periods before a steady
state is reached. In general, it is expected that experiments that go up to or beyond
the point of absorption are needed for the evaluation of degradable materials.
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2. Evaluation
2.1 General
The biological response should be evaluated by documenting the macroscopic and
histopathological responses as a function of time. The responses to the test sample should
be compared to the responses obtained at the control sample or sham operated sites.
For each of the endpoints samples should be obtained from at least 3 different animals.
2.2 Macroscopic assessment
Each implant site should be examined for alterations of the normal structure. Recordings
of the nature and extent of any tissue reaction observed, such as hematoma, edema,
encapsulation, and/or additional gross findings should be made. The presence, form, and
location of implant including possible remnants of degradable materials should also be
recorded. Macro photography should be used for documentation.
In addition to the inspection of the implant site, whenever an animal has shown signs of
ill health or reactions to the implant, a gross necropsy as appropriate should be
conducted.
2.3 Implant retrieval and tissue sample collection
After the animal has been humanely killed, the implant together with sufficient
unaffected surrounding tissue should be excised to enable evaluation of the local
histopathological response. If the candidate material is not evident at the site examined
(degradable/resorbable materials), the explantation site should be extended to include
several millimeters of normal tissue on all sides of the expected implant site. For nondegradable implants, draining lymph nodes should be collected as indicated by the gross
pathology. For degradable implants, draining lymph nodes should be collected, when
feasible, as evaluation of draining lymph nodes is of importance to demonstrate migration
of degradable materials.
2.4 Microscopic assessment
The scoring system used for the histological evaluation should take into account the
extent of the area affected, either quantitatively (e.g. in micrometers) or semiquantitatively. The implant orientation in relation to the implant dimensions, number of
sections, and cutting geometry should be recorded.
The biological response parameters, which should be assessed and recorded, include:
• the extent of fibrosis/fibrous capsule (layer in micrometers) and inflammation;
• the degeneration as determined by changes in tissue morphology;
• the number and distribution as a function of distance from the material/tissue
interface of the inflammatory cell types, namely polymorphonuclear leucocytes
(neutrophils), lymphocytes, plasma cells, eosinophils, macrophages, and
multinucleated cells; the presence, extent, and type of necrosis;
• other tissue alterations such as vascularization, fatty infiltration, granuloma
formation, and bone formation;
• the material parameters such as fragmentation and/or debris presence, form and
location of remnants of degraded material;
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•

the quality and quantity of tissue ingrowth, for porous and degradable implant
materials.

Adverse histological responses shall be documented by photomicrograph and the test
sample should be evaluated as compared to the negative control sample based on a
scoring system:
• non-irritant (0.0 up to 2.9)
• slight irritant (3.0 up to 8.9)
• moderate irritant (9.0 up to 15.0)
• severe irritant (> 15)
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